179324-69-7 | Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$7.00	$5.00
10mg	98%powder	in stock	$42.00	$30.00
250mg	98%	in stock	$78.00	$55.00
1g	98%	in stock	$233.00	$163.00

Description

• Catalog Number: AB02092
• Chemical Name: Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-
• CAS Number: 179324-69-7
• Molecular Formula: C19H25BN4O4
• Molecular Weight: 384.2372
• MDL Number: MFCD09056737
• SMILES: CC(C[C@@H](B(O)O)NC(=O)[C@@H](NC(=O)c1cnccn1)Cc1ccccc1)C
• NSC Number: 681239

Computed Properties

• Complexity: 500
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 2
• Heavy Atom Count: 28
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 9

Literature

• Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome.

  eLife 20180101

• Curcumin Inhibits 5-Fluorouracil-induced Up-regulation of CXCL1 and CXCL2 of the Colon Associated with Attenuation of Diarrhoea Development.

  Basic & clinical pharmacology & toxicology 20161201

• ON 01910.Na inhibits growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 complex.

  Translational research : the journal of laboratory and clinical medicine 20160901

• Mantle Cell Lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20160410

• Increased hepatic receptor interacting protein kinase 3 expression due to impaired proteasomal functions contributes to alcohol-induced steatosis and liver injury.

  Oncotarget 20160405

• Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study.

  Turkish journal of haematology : official journal of Turkish Society of Haematology 20150901

• Muscle Segment Homeobox Genes Direct Embryonic Diapause by Limiting Inflammation in the Uterus.

  The Journal of biological chemistry 20150612

• Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.

  Toxicological sciences : an official journal of the Society of Toxicology 20150601

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• Chronic Deletion and Acute Knockdown of Parkin Have Differential Responses to Acetaminophen-induced Mitophagy and Liver Injury in Mice.

  The Journal of biological chemistry 20150424

• Preferential cytotoxicity of bortezomib toward highly malignant human liposarcoma cells via suppression of MDR1 expression and function.

  Toxicology and applied pharmacology 20150215

• Suppression of BRCA1 sensitizes cells to proteasome inhibitors.

  Cell death & disease 20141201

• Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.

  Leukemia 20141001

• Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.

  European journal of haematology 20140901

• Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.

  European journal of medicinal chemistry 20140818

• Activation of the ubiquitin-proteasome system against arsenic trioxide cardiotoxicity involves ubiquitin ligase Parkin for mitochondrial homeostasis.

  Toxicology 20140801

• Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.

  International journal of hematology 20140801

• A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity.

  Nature chemical biology 20140801

• Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.

  The Journal of biological chemistry 20140502

• Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.

  Bone 20140401

• Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage.

  Carcinogenesis 20140301

• The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo.

  Toxicology letters 20140130

• Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.

  Annals of hematology 20140101

• Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.

  BMJ case reports 20140101

• Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor.

  Scientific reports 20140101

• Induction of steroid sulfatase expression in PC-3 human prostate cancer cells by insulin-like growth factor II.

  Toxicology letters 20131125

• Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib.

  Leukemia 20131001

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.

  Journal of medicinal chemistry 20130509

• Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20130501

• Tolerance to nitroglycerin through proteasomal down-regulation of aldehyde dehydrogenase-2 in a genetic mouse model of ascorbate deficiency.

  British journal of pharmacology 20130401

• Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.

  Experimental hematology 20130201

• Inhibition of HIV-1 replication by a tricyclic coumarin GUT-70 in acutely and chronically infected cells.

  Bioorganic & medicinal chemistry letters 20130201

• Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma.

  PloS one 20130101

• Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells.

  PloS one 20130101

• Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models.

  Journal of ovarian research 20130101

• A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology.

  PloS one 20130101

• Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells.

  Asian Pacific journal of cancer prevention : APJCP 20130101

• Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-κB pathways.

  Cancer letters 20121230

• Molecular crosstalk between the proteasome, aggresomes and autophagy: translational potential and clinical implications.

  Cancer letters 20121228

• Molecular mechanisms of acquired proteasome inhibitor resistance.

  Journal of medicinal chemistry 20121213

• Impact of bortezomib on bone health in myeloma: a review of current evidence.

  Cancer treatment reviews 20121201

• High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy.

  Leukemia & lymphoma 20121201

• Bortezomib and dexamethasone as first-line therapy for a patient with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes syndrome complicated by renal failure.

  Leukemia & lymphoma 20121201

• Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells.

  Leukemia & lymphoma 20121201

• Simultaneous mitochondrial Ca(2+) overload and proteasomal inhibition are responsible for the induction of paraptosis in malignant breast cancer cells.

  Cancer letters 20121128

• Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma.

  Cancer 20121115

• Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib.

  Annals of hematology 20121101

• Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20121101

• (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.

  Annals of hematology 20121101

• Bortezomib alleviates experimental pulmonary arterial hypertension.

  American journal of respiratory cell and molecular biology 20121101

• Sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide in multiple myeloma cells via stress-mediated pathways.

  Oncology reports 20121101

• Involvement of the Nrf2-proteasome pathway in the endoplasmic reticulum stress response in pancreatic β-cells.

  Toxicology and applied pharmacology 20121101

• Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange.

  European journal of haematology 20121101

• Bortezomib inhibits the angiogenesis mediated by mesenchymal stem cells.

  Cancer investigation 20121101

• Identification of a glutathione peroxidase inhibitor that reverses resistance to anticancer drugs in human B-cell lymphoma cell lines.

  Bioorganic & medicinal chemistry letters 20121101

• Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20121101

• Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20121101

• Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

  Blood 20121018

• Brazilin induces apoptosis and G2/M arrest via inactivation of histone deacetylase in multiple myeloma U266 cells.

  Journal of agricultural and food chemistry 20121003

• Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20121001

• Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib.

  Leukemia 20121001

• The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib.

  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20121001

• Cellular signal transduction can be induced by TRAIL conjugated to microcapsules.

  Journal of biomedical materials research. Part A 20121001

• Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis.

  Annals of the rheumatic diseases 20121001

• Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20121001

• Treatment with bortezomib in multiple myeloma is associated with only a transient and brief increase of bone specific alkaline phosphatase.

  Leukemia research 20121001

• Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer.

  Biomaterials 20121001

• Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells.

  Molecular oncology 20121001

• PKCδ regulates death receptor 5 expression induced by PS-341 through ATF4-ATF3/CHOP axis in human lung cancer cells.

  Molecular cancer therapeutics 20121001

• Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production.

  British journal of haematology 20121001

• Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells.

  Mini reviews in medicinal chemistry 20121001

• Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.

  International journal of hematology 20121001

• Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma.

  Clinical lymphoma, myeloma & leukemia 20121001

• An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

  Clinical lymphoma, myeloma & leukemia 20121001

• Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.

  Clinical lymphoma, myeloma & leukemia 20121001

• Expression of vascular endothelial growth factor receptors VEGFR1 in cultured multiple myeloma cells: correlation with immunophenotype and drug resistance.

  Bulletin of experimental biology and medicine 20121001

• [Inhibitory effect of histone deacetylase inhibitor LBH589 on multiple myeloma MM1R cells in vitro].

  Zhongguo shi yan xue ye xue za zhi 20121001

• Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.

  Blood 20120927

• How I treat plasma cell leukemia.

  Blood 20120920

• Fatalities resulting from accidental intrathecal administration of bortezomib: strategies for prevention.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120920

• Combination treatment with bortezomib and thiostrepton is effective against tumor formation in mouse models of DEN/PB-induced liver carcinogenesis.

  Cell cycle (Georgetown, Tex.) 20120915

• Immune mechanism of the antitumor effects generated by bortezomib.

  Journal of immunology (Baltimore, Md. : 1950) 20120915

• A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.

  Cancer cell 20120911

• Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120910

• Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.

  Hematological oncology 20120901

• Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.

  Leukemia & lymphoma 20120901

• Renal Fanconi syndrome as a cause of chronic kidney disease in patients with monoclonal gammopathy of undetermined significance: partially reversed renal function by high-dose dexamethasone with bortezomib.

  Leukemia & lymphoma 20120901

• The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation.

  Haematologica 20120901

• Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells.

  Leukemia research 20120901

• In vivo imaging of proteasome inhibition using a proteasome-sensitive fluorescent reporter.

  Cancer science 20120901

• Bortezomib for acute antibody-mediated rejection in liver transplantation.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20120901

• NFκB pathway is down-regulated by 1α,25(OH)(2)-vitamin D(3) in endothelial cells transformed by Kaposi sarcoma-associated herpes virus G protein coupled receptor.

  Steroids 20120901

• Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.

  International journal of oncology 20120901

• Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype.

  Cancer gene therapy 20120901

• Deaths reported from the accidental intrathecal administration of bortezomib.

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20120901

• Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.

  British journal of haematology 20120901

• Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120901

• Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity.

  British journal of haematology 20120901

• An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.

  British journal of haematology 20120901

• Multiple myeloma: improved outcomes with new therapeutic approaches.

  Current opinion in supportive and palliative care 20120901

• Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120901

• Biological therapy doublets: pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphoma.

  Current hematologic malignancy reports 20120901

• Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity.

  Asian journal of andrology 20120901

• Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective.

  Advances in chronic kidney disease 20120901

• Myeloma kidney: improving clinical outcomes?

  Advances in chronic kidney disease 20120901

• How to select among available options for the treatment of multiple myeloma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120901

• Bortezomib: 3 deaths following intrathecal injection.

  Prescrire international 20120901

• Emerging agents for the treatment of mantle cell lymphoma.

  Expert review of anticancer therapy 20120901

• Tumor cells can evade dependence on autophagy through adaptation.

  Biochemical and biophysical research communications 20120831

• Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.

  Angewandte Chemie (International ed. in English) 20120827

• Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients.

  Transplantation 20120827

• Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.

  Blood 20120823

• Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

  Blood 20120823

• Complete and partial responses of the TEMPI syndrome to bortezomib.

  The New England journal of medicine 20120823

• Transplantation for myeloma: work in progress.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120820

• Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120820

• The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.

  Biochemical pharmacology 20120815

• Proteasome inhibitors in multiple myeloma: 10 years later.

  Blood 20120802

• Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.

  Blood 20120802

• In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors.

  Investigational new drugs 20120801

• Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma.

  Leukemia & lymphoma 20120801

• Protection against titanium particle-induced inflammatory osteolysis by the proteasome inhibitor bortezomib in vivo.

  Inflammation 20120801

• Inhibition of titanium particle-induced inflammation by the proteasome inhibitor bortezomib in murine macrophage-like RAW 264.7 cells.

  Inflammation 20120801

• Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis.

  Experimental and molecular pathology 20120801

• Light chain deposition disease: novel biological insights and treatment advances.

  International journal of laboratory hematology 20120801

• The use of a reversible proteasome inhibitor in a model of Reduced-Size Orthotopic Liver transplantation in rats.

  Experimental and molecular pathology 20120801

• Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.

  Journal of cancer research and clinical oncology 20120801

• Bortezomib-induced severe autonomic neuropathy.

  Clinical autonomic research : official journal of the Clinical Autonomic Research Society 20120801

• The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: an analysis of the Singapore multiple myeloma study group.

  European journal of haematology 20120801

• Bortezomib combined with thalidomide and dexamethasone is effective for patient with crystal-storing histiocytosis associated with monoclonal gammopathy of undermined significance.

  European journal of haematology 20120801

• Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.

  British journal of haematology 20120801

• Effects of brucine on bone metabolism in multiple myeloma.

  Molecular medicine reports 20120801

• Cutaneous lesion induced by a subcutaneous administration of bortezomib.

  Clinical lymphoma, myeloma & leukemia 20120801

• Autologous stem cell transplant for light chain deposition disease: incorporating bortezomib to the induction therapy.

  American journal of hematology 20120801

• Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.

  Journal of inorganic biochemistry 20120801

• Combination therapy with VELCADE and tissue plasminogen activator is neuroprotective in aged rats after stroke and targets microRNA-146a and the toll-like receptor signaling pathway.

  Arteriosclerosis, thrombosis, and vascular biology 20120801

• Effective therapy for acute antibody-mediated rejection with mild chronic changes: case report and review of the literature.

  Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 20120801

• Bortezomib partially protects the rat diaphragm from ventilator-induced diaphragm dysfunction.

  Critical care medicine 20120801

• Proteasome inhibition and ventilator-induced diaphragmatic dysfunction: is the glass half full or half empty?

  Critical care medicine 20120801

• Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.

  Cell death & disease 20120801

• Once- versus twice-weekly Bortezomib induction therapy with dexamethasone in newly diagnosed multiple myeloma.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20120801

• [A case of adult primitive neuroectodermal tumor(PNET)with multiple lung metastases effectively treated with ADM, IFM(AI)regimen].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120801

• [Early onset of paralytic ileus caused by simultaneous administration of bortezomib and azole antifungals in multiple myeloma patients].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20120801

• Role of carfilzomib in the treatment of multiple myeloma.

  Expert review of hematology 20120801

• Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.

  Blood 20120726

• Preliminary experience with personalized and targeted therapy for pediatric brain tumors.

  Pediatric blood & cancer 20120715

• Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies.

  International journal of radiation oncology, biology, physics 20120715

• A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.

  Cancer 20120715

• Anti-myeloma effects of the novel anthracycline derivative INNO-206.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120715

• Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.

  Blood 20120712

• Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.

  Blood 20120712

• Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120710

• Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120710

• [Modern times: back to past, back to future].

  Medicina clinica 20120707

• Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.

  Blood 20120705

• Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma.

  Haematologica 20120701

• The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.

  Haematologica 20120701

• A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.

  Annals of hematology 20120701

• CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.

  Oral oncology 20120701

• A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.

  Leukemia 20120701

• Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.

  European journal of haematology 20120701

• Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy.

  Stem cells (Dayton, Ohio) 20120701

• Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma.

  British journal of haematology 20120701

• Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1.

  International journal of oncology 20120701

• The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.

  Leukemia research 20120701

• Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.

  British journal of haematology 20120701

• Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantation.

  International journal of hematology 20120701

• Bortezomib-induced pneumonitis during bortezomib retreatment in multiple myeloma.

  Japanese journal of clinical oncology 20120701

• Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib.

  Genes to cells : devoted to molecular & cellular mechanisms 20120701

• An historic perspective of proteasome inhibition.

  Seminars in hematology 20120701

• Discovery and development of second-generation proteasome inhibitors.

  Seminars in hematology 20120701

• Bortezomib combination therapy in multiple myeloma.

  Seminars in hematology 20120701

• General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.

  Seminars in hematology 20120701

• Proteasome inhibition for antibody-mediated allograft rejection.

  Seminars in hematology 20120701

• Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience.

  Seminars in hematology 20120701

• Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.

  Anticancer research 20120701

• Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.

  Cell death & disease 20120701

• Anti-inflammatory effect of the proteasome inhibitor bortezomib on endotoxin-induced uveitis in rats.

  Investigative ophthalmology & visual science 20120626

• Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma.

  Oncogene 20120621

• Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.

  Blood 20120621

• Bortezomib induces heme oxygenase-1 expression in multiple myeloma.

  Cell cycle (Georgetown, Tex.) 20120615

• Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.

  Blood 20120614

• An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

  Blood 20120614

• Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure.

  Medical oncology (Northwood, London, England) 20120601

• Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.

  Hematological oncology 20120601

• Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib.

  Bone marrow transplantation 20120601

• Proteasome inhibition prevents development of experimental dermal fibrosis.

  Inflammation 20120601

• Radioresistance of prostate cancer cells with low proteasome activity.

  The Prostate 20120601

• Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma.

  Cardiovascular toxicology 20120601

• Therapeutic potential of the proteasome inhibitor Bortezomib on titanium particle-induced inflammation in a murine model.

  Inflammation 20120601

• Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120601

• Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120601

• Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.

  Human pathology 20120601

• Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma.

  Leukemia & lymphoma 20120601

• Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines.

  International journal of laboratory hematology 20120601

• The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.

  Annals of hematology 20120601

• Ischemia-reperfusion injury in rat steatotic liver is dependent on NFκB P65 activation.

  Transplant immunology 20120601

• Incorporating monoclonal antibodies into the therapy of multiple myeloma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120601

• Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120601

• Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.

  International journal of urology : official journal of the Japanese Urological Association 20120601

• Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation.

  Transplant immunology 20120601

• Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.

  European journal of haematology 20120601

• ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.

  The Journal of pharmacology and experimental therapeutics 20120601

• Diltiazem enhances the apoptotic effects of proteasome inhibitors to induce prostate cancer cell death.

  The Journal of pharmacology and experimental therapeutics 20120601

• Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale.

  Transplant international : official journal of the European Society for Organ Transplantation 20120601

• Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.

  European journal of haematology 20120601

• Low-dose cyclosporine mediates donor hyporesponsiveness in a fully mismatched rat kidney transplant model.

  Transplant immunology 20120601

• Successful use of cyclophosphamide, bortezomib, and dexamethasone to treat a case of relapsed POEMS.

  European journal of haematology 20120601

• In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells.

  British journal of haematology 20120601

• Bortezomib and panobinostat combination is effective against PTCL.

  Leukemia research 20120601

• Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.

  British journal of haematology 20120601

• Bortezomib-associated fatal liver failure in a haemodialysis patient with multiple myeloma.

  Clinical toxicology (Philadelphia, Pa.) 20120601

• High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy.

  American journal of hematology 20120601

• SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.

  Annals of hematology 20120601

• AAV-mediated gene targeting is significantly enhanced by transient inhibition of nonhomologous end joining or the proteasome in vivo.

  Human gene therapy 20120601

• Why is management of cancer pain still a problem?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120601

• Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition.

  Arteriosclerosis, thrombosis, and vascular biology 20120601

• Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.

  Molecular cancer therapeutics 20120601

• Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120601

• Characterization of the protein ubiquitination response induced by Doxorubicin.

  The FEBS journal 20120601

• First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib.

  Clinical nuclear medicine 20120601

• An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20120601

• Proteasome inhibitors in mantle cell lymphoma.

  Best practice & research. Clinical haematology 20120601

• Jejunal amyloidosis: a rare cause of severe gastrointestinal bleeding.

  Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20120601

• [Effect of bortezomib and low concentration cytarabine on apoptosis in U937 cell line].

  Zhongguo shi yan xue ye xue za zhi 20120601

• [Clinical study of bortezomib for treating multiple myeloma with renal impairment].

  Zhongguo shi yan xue ye xue za zhi 20120601

• Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma.

  Journal of chemotherapy (Florence, Italy) 20120601

• Integrated protein quality-control pathways regulate free α-globin in murine β-thalassemia.

  Blood 20120531

• Do not super-excess me!

  Blood 20120531

• Proteasomal insensitivity of apoptin in tumor cells.

  Biochemical and biophysical research communications 20120525

• Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120515

• Serendipity in discovery of proteasome inhibitors.

  Bioorganic & medicinal chemistry letters 20120515

• Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.

  Blood 20120510

• Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.

  Blood 20120510

• Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

  Blood 20120510

• Bortezomib to treat the TEMPI syndrome.

  The New England journal of medicine 20120510

• Survivin is a therapeutic target in Merkel cell carcinoma.

  Science translational medicine 20120509

• Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.

  Molecular pharmaceutics 20120507

• Novel molecular targeted therapies for refractory thyroid cancer.

  Head & neck 20120501

• A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.

  Cancer 20120501

• Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.

  Cancer chemotherapy and pharmacology 20120501

• Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.

  International journal of oncology 20120501

• Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen.

  Experimental hematology 20120501

• Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.

  British journal of haematology 20120501

• The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.

  European journal of haematology 20120501

• The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: a rare disease with new clinical insights.

  European journal of haematology 20120501

• Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.

  International journal of hematology 20120501

• Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone.

  British journal of haematology 20120501

• Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes.

  Cell cycle (Georgetown, Tex.) 20120501

• Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.

  Expert opinion on drug metabolism & toxicology 20120501

• Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside.

  The oncologist 20120501

• European perspective on multiple myeloma treatment strategies: update following recent congresses.

  The oncologist 20120501

• [Once-weekly bortezomib plus dexamethasone therapy induced complete response, reducing severe gastrointestinal adverse events for a patient with relapsed multiple myeloma - a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120501

• Successful use of combined high cut-off haemodialysis and bortezomib for acute kidney injury associated with myeloma cast nephropathy.

  Irish medical journal 20120501

• Proteasome inhibition can impair caspase-8 activation upon submaximal stimulation of apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL) signaling.

  The Journal of biological chemistry 20120427

• [Improved prognosis in light chain nephropathy due to multiple myeloma].

  Ugeskrift for laeger 20120423

• Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120415

• [AL amyloidosis].

  Orvosi hetilap 20120415

• Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma.

  Biochemical and biophysical research communications 20120413

• A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response.

  Investigational new drugs 20120401

• In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.

  Investigational new drugs 20120401

• Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120401

• Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.

  BJU international 20120401

• Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.

  Leukemia 20120401

• Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma.

  Leukemia & lymphoma 20120401

• Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A.

  Cancer letters 20120401

• The state of therapy for removal of alloantibody producing plasma cells in transplantation.

  Seminars in immunology 20120401

• Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20120401

• Management of treatment-emergent peripheral neuropathy in multiple myeloma.

  Leukemia 20120401

• Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells.

  International journal of oncology 20120401

• Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.

  The Journal of pharmacology and experimental therapeutics 20120401

• Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.

  Molecular cancer therapeutics 20120401

• [Unusual skin alterations in a 72-year-old patient with multiple myeloma].

  Der Internist 20120401

• Opposing effects of bortezomib-induced nuclear factor-κB inhibition on chemical lung carcinogenesis.

  Carcinogenesis 20120401

• Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.

  Urology 20120401

• Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor.

  Cancer biology & therapy 20120401

• HSPA2 overexpression protects V79 fibroblasts against bortezomib-induced apoptosis.

  Biochemistry and cell biology = Biochimie et biologie cellulaire 20120401

• Multiple myeloma: treatment evolution.

  Hematology (Amsterdam, Netherlands) 20120401

• New developments in the field of diffuse large cell lymphoma.

  Hematology (Amsterdam, Netherlands) 20120401

• Frontline treatment of multiple myeloma.

  Hematology (Amsterdam, Netherlands) 20120401

• Myeloma: diagnosis complications and supportive care.

  Hematology (Amsterdam, Netherlands) 20120401

• Stem cell transplantation for multiple myeloma: current and future status.

  Hematology (Amsterdam, Netherlands) 20120401

• Targeted therapy of multiple myeloma.

  Hematology (Amsterdam, Netherlands) 20120401

• Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.

  Future oncology (London, England) 20120401

• [Effects of triptolide on bortezomib-induced apoptosis in multiple myeloma cells].

  Zhongguo shi yan xue ye xue za zhi 20120401

• Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.

  Clinical advances in hematology & oncology : H&O 20120401

• [Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20120401

• Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody.

  Transplantation 20120327

• Durability of antibody removal following proteasome inhibitor-based therapy.

  Transplantation 20120327

• [Clinical analysis of multiple myeloma with extramedullary plasmacytomas].

  Zhonghua yi xue za zhi 20120327

• Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells.

  The Journal of biological chemistry 20120323

• Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.

  Journal of surgical oncology 20120315

• Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

  Blood 20120315

• Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.

  Blood 20120315

• Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.

  Cancer research 20120315

• Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120315

• Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors.

  Journal of medicinal chemistry 20120308

• Microscale functional cytomics for studying hematologic cancers.

  Blood 20120308

• Mutation of Glu521 or Glu535 in cytoplasmic loop 5 causes differential misfolding in multiple domains of multidrug and organic anion transporter MRP1 (ABCC1).

  The Journal of biological chemistry 20120302

• Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy.

  American journal of therapeutics 20120301

• Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120301

• Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.

  Leukemia research 20120301

• A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer.

  Oncology reports 20120301

• [Renal tolerance of targeted therapies].

  Bulletin du cancer 20120301

• Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120301

• The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.

  British journal of haematology 20120301

• [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].

  Presse medicale (Paris, France : 1983) 20120301

• Using transcriptome sequencing to identify mechanisms of drug action and resistance.

  Nature chemical biology 20120301

• Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.

  APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 20120301

• Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.

  Clinical nephrology 20120301

• Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.

  The oncologist 20120301

• Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.

  Anticancer research 20120301

• Bortezomib is effective to treat acute humoral rejection after liver transplantation.

  Transplantation proceedings 20120301

• [Current perspectives in the treatment of multiple myeloma - news and views].

  Deutsche medizinische Wochenschrift (1946) 20120301

• Vincristine and bortezomib cause axon outgrowth and behavioral defects in larval zebrafish.

  Journal of the peripheral nervous system : JPNS 20120301

• Shoulder X-ray--a clue to multiple myeloma.

  The Journal of the Association of Physicians of India 20120301

• Dephosphorylation-induced ubiquitination and degradation of FMRP in dendrites: a role in immediate early mGluR-stimulated translation.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20120222

• Latest advances and current challenges in the treatment of multiple myeloma.

  Nature reviews. Clinical oncology 20120221

• [Current treatment of acute myeloid leukaemia in adults].

  Orvosi hetilap 20120219

• Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.

  International journal of cancer 20120215

• Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients.

  Transplantation 20120215

• KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.

  Blood 20120209

• An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.

  Investigational new drugs 20120201

• Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.

  Investigational new drugs 20120201

• Toxicity burden score: a novel approach to summarize multiple toxic effects.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120201

• Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120201

• [EGFR/HER1: a target life].

  Bulletin du cancer 20120201

• Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.

  Annals of hematology 20120201

• Bortezomib (Velcade), rituximab, cyclophosphamide, and dexamethasone combination regimen is active as front-line therapy of low-grade non-Hodgkin lymphoma.

  Clinical lymphoma, myeloma & leukemia 20120201

• Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.

  Annals of hematology 20120201

• A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.

  Leukemia & lymphoma 20120201

• Genomic stratification of multiple myeloma treated with novel agents.

  Leukemia & lymphoma 20120201

• Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.

  Leukemia & lymphoma 20120201

• A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20120201

• Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement.

  Leukemia & lymphoma 20120201

• Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.

  Arthritis and rheumatism 20120201

• Managing light chain deposition disease.

  Leukemia & lymphoma 20120201

• Proteasomal inhibition after injury prevents fibrosis by modulating TGF-β(1) signalling.

  Thorax 20120201

• Knockdown of ubiquitin ligases in glioblastoma cancer stem cells leads to cell death and differentiation.

  Journal of biomolecular screening 20120201

• Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.

  Journal of cellular biochemistry 20120201

• Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.

  Leukemia research 20120201

• Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia.

  International journal of oncology 20120201

• Changes in the ratio of free NEDD8 to ubiquitin triggers NEDDylation by ubiquitin enzymes.

  The Biochemical journal 20120201

• Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells.

  Cancer science 20120201

• Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma.

  Experimental hematology 20120201

• Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.

  Chemical communications (Cambridge, England) 20120201

• Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.

  Neuro-oncology 20120201

• Proteasome inhibitor bortezomib (PS-341) enhances RANKL-induced MDA-MB-231 breast cancer cell migration.

  Molecular medicine reports 20120201

• A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.

  British journal of haematology 20120201

• Management of myeloma-associated renal dysfunction in the era of novel therapies.

  Expert review of hematology 20120201

• Bortezomib-induced peripheral neuropathy in patients with multiple myeloma.

  Clinical journal of oncology nursing 20120201

• Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton.

  Cancer biology & therapy 20120201

• Effects of arsenic trioxide combined with bortezomib on apoptosis of multiple myeloma cell line KM3 and its mechanisms.

  Zhongguo shi yan xue ye xue za zhi 20120201

• [Multiple myeloma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20120201

• Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials.

  Oncology (Williston Park, N.Y.) 20120201

• The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.

  Die Pharmazie 20120201

• [Effects of secoisolariciresinol diglucoside combined with bortezomib on induction of apoptosis in lung cancer cell line A549].

  Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials 20120201

• Proteasome inhibitors: an expanding army attacking a unique target.

  Chemistry & biology 20120127

• Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.

  Blood 20120126

• Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition.

  Blood 20120119

• Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment.

  British journal of cancer 20120117

• Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.

  Biochemical pharmacology 20120115

• Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.

  Cell cycle (Georgetown, Tex.) 20120115

• Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.

  Bone marrow transplantation 20120101

• Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.

  Annals of hematology 20120101

• Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells.

  Journal of molecular medicine (Berlin, Germany) 20120101

• Methylseleninic acid antagonizes the cytotoxic effect of bortezomib in mantle cell lymphoma cell lines through modulation of Bcl-2 family proteins.

  British journal of haematology 20120101

• An autophagy inhibitor enhances the inhibition of cell proliferation induced by a proteasome inhibitor in MCF-7 cells.

  Molecular medicine reports 20120101

• Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation.

  Cancer letters 20120101

• Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.

  Haematologica 20120101

• Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.

  International journal of molecular medicine 20120101

• Molecular pathways: targeting proteasomal protein degradation in cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120101

• Fluorescence-based proteasome activity profiling.

  Methods in molecular biology (Clifton, N.J.) 20120101

• Myelin structure is unaltered in chemotherapy-induced peripheral neuropathy.

  Neurotoxicology 20120101

• [Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20120101

• Inhibition of intraerythrocytic proteasome retards the generation of hemorphins.

  Peptides 20120101

• Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma.

  Pharmaceutical biology 20120101

• Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.

  The Annals of pharmacotherapy 20120101

• Long-term bortezomib treatment reduces allergen-specific IgE but fails to ameliorate chronic asthma in mice.

  International archives of allergy and immunology 20120101

• Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients.

  The journal of supportive oncology 20120101

• Emerging therapies in hematopoietic stem cell transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120101

• The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture.

  Nephron. Experimental nephrology 20120101

• HHV-8-associated multicentric Castleman's disease in HIV-negative patient: a novel therapy for an orphan disease.

  The oncologist 20120101

• Abrogation of antibodies improves outcome of renal transplantation.

  Transplantation proceedings 20120101

• Synergistic effects of combination treatment with bortezomib and doxorubicin in human neuroblastoma cell lines.

  Chemotherapy 20120101

• [Comparative plasma proteomic analysis of patients with multiple myeloma treated with bortezomib-based regimens].

  Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20120101

• Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies.

  Methods in molecular biology (Clifton, N.J.) 20120101

• Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC).

  PloS one 20120101

• [Successful treatment with bortezomib for a patient with plasma cell leukemia accompanied by severe hyperbilirubinemia].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20120101

• Future trends in organ transplant recipients--important issues for dermatologists.

  Current problems in dermatology 20120101

• Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells.

  PloS one 20120101

• Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91.

  PloS one 20120101

• Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastoma.

  BMC cancer 20120101

• Proteasome inhibitor bortezomib ameliorates intestinal injury in mice.

  PloS one 20120101

• [A rare cause of hyperamylasemia].

  Annales de biologie clinique 20120101

• Curative resection of double primary lung cancer after 15-month bortezomib administration.

  Onkologie 20120101

• Involvement of the ubiquitin-proteasome system in the formation of experimental postsurgical peritoneal adhesions.

  Mediators of inflammation 20120101

• Proteasome inhibition is partially effective in attenuating pre-existing immunity against recombinant adeno-associated viral vectors.

  PloS one 20120101

• [Prognostic significance of morphology in multiple myeloma].

  Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20120101

• CIP2A is a target of bortezomib in human triple negative breast cancer cells.

  Breast cancer research : BCR 20120101

• Effective response with bortezomib retreatment in relapsed multiple myeloma--a multicentre retrospective survey in Switzerland.

  Swiss medical weekly 20120101

• Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.

  BMC cancer 20120101

• Bortezomib and bilateral herpes zoster.

  Acta dermatovenerologica Alpina, Pannonica, et Adriatica 20120101

• Curcumin enhances cytotoxic effects of bortezomib in human multiple myeloma H929 cells: potential roles of NF-κB/JNK.

  International journal of molecular sciences 20120101

• Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib.

  BMC cancer 20120101

• Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD.

  Journal of hematology & oncology 20120101

• Response to low-dose bortezomib in plasma cell leukemia patients with malignant pleural effusion and ascites: a case report and a review of the literature.

  Internal medicine (Tokyo, Japan) 20120101

• Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro.

  BMC cancer 20120101

• Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy : case report.

  Journal of clinical and experimental hematopathology : JCEH 20120101

• Proteasome inhibitors.

  Progress in molecular biology and translational science 20120101

• Bortezomib-induced thrombotic thrombocytopaenic purpura.

  BMJ case reports 20120101

• Polyubiquitin is required for growth, development and pathogenicity in the rice blast fungus Magnaporthe oryzae.

  PloS one 20120101

• [Velcade for multiple myeloma. A new method of administration].

  Perspective infirmiere : revue officielle de l'Ordre des infirmieres et infirmiers du Quebec 20120101

• Inhibition of fatty acid metabolism reduces human myeloma cells proliferation.

  PloS one 20120101

• [Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma].

  Terapevticheskii arkhiv 20120101

• Toxicity of autologous hematopoietic cell transplantation in patients with multiple myeloma - comparison between two different induction regimens.

  Clinical transplantation 20120101

• PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells.

  PloS one 20120101

• Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway.

  Journal of medicinal chemistry 20111222

• AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors.

  Blood 20111215

• Drugs: More shots on target.

  Nature 20111214

• Orthopaedics: Structural support.

  Nature 20111214

• p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis.

  Biochemical and biophysical research communications 20111209

• A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.

  Blood 20111208

• Bortezomib-induced 'BRCAness' sensitizes multiple myeloma cells to PARP inhibitors.

  Blood 20111208

• From the observation DAC: romidepsin revisited.

  Blood 20111208

• Innovation in myeloma treatments PARP excellence!

  Blood 20111208

• A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.

  Investigational new drugs 20111201

• Stability of unused reconstituted bortezomib in original manufacturer vials.

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20111201

• Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors.

  American journal of clinical oncology 20111201

• Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.

  Annals of hematology 20111201

• Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.

  Annals of hematology 20111201

• Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.

  Cancer chemotherapy and pharmacology 20111201

• Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma.

  Journal of neuro-oncology 20111201

• Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-κB activity.

  Leukemia & lymphoma 20111201

• Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.

  International journal of oncology 20111201

• The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.

  Leukemia 20111201

• Multiple myeloma associated IgA pemphigus: treatment with bortezomib- and lenalidomide-based regimen.

  Clinical lymphoma, myeloma & leukemia 20111201

• Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study.

  Haematologica 20111201

• Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111201

• Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen.

  Experimental hematology 20111201

• A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients.

  British journal of haematology 20111201

• Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells.

  British journal of haematology 20111201

• Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma.

  Cellular oncology (Dordrecht) 20111201

• Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.

  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20111201

• Differential action of 3-hydroxyanthranilic acid on viability and activation of stimulated lymphocytes.

  International immunopharmacology 20111201

• Acquired STAT4 deficiency as a consequence of cancer chemotherapy.

  Blood 20111201

• Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma.

  Clinical pharmacokinetics 20111201

• Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.

  Leukemia & lymphoma 20111201

• The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20111201

• [Effect of BAFF/APRIL mRNA expression induced by glucocorticoid and bortezomib in multiple myeloma cells in vitro].

  Zhongguo shi yan xue ye xue za zhi 20111201

• [Mechanism associated to enhancing the sensitivity of myeloma cells U266 to bortezomib by 2-methoxyestradiol].

  Zhongguo shi yan xue ye xue za zhi 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Advances in the understanding of mechanisms and therapeutic use of bortezomib.

  Discovery medicine 20111201

• [Thrombotic complications following the treatment of multiple myeloma with new agents].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20111201

• [Lung injury associated with bortezomib therapy in Japan].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20111201

• Timing of the high-dose therapy in the area of new drugs.

  Srpski arhiv za celokupno lekarstvo 20111201

• Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts.

  Cancer letters 20111128

• Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.

  Blood 20111124

• Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.

  Blood 20111124

• Rapid in vivo testing of drug response in multiple myeloma made possible by xenograft to turkey embryos.

  British journal of cancer 20111122

• Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A.

  ACS chemical biology 20111118

• Proteasome inhibitors improve the function of mutant lysosomal α-glucosidase in fibroblasts from Pompe disease patient carrying c.546G>T mutation.

  Biochemical and biophysical research communications 20111118

• Amyloidosis.

  BMJ (Clinical research ed.) 20111116

• Proteasome inhibitors suppress expression of NPM and ARF proteins.

  Cell cycle (Georgetown, Tex.) 20111115

• Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111110

• Inhibition of proteasome deubiquitinating activity as a new cancer therapy.

  Nature medicine 20111106

• Antagonists of anaphase-promoting complex (APC)-2-cell cycle and apoptosis regulatory protein (CARP)-1 interaction are novel regulators of cell growth and apoptosis.

  The Journal of biological chemistry 20111104

• Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

  Blood 20111103

• Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.

  International journal of cancer 20111101

• Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea.

  Cancer chemotherapy and pharmacology 20111101

• Modulation of the tumor cell death pathway by androgen receptor in response to cytotoxic stimuli.

  Journal of cellular physiology 20111101

• [Current treatment of AL amyloidosis].

  Nephrologie & therapeutique 20111101

• [New insights in the treatment of myeloma with renal failure].

  Nephrologie & therapeutique 20111101

• Curcumin suppresses growth of mesothelioma cells in vitro and in vivo, in part, by stimulating apoptosis.

  Molecular and cellular biochemistry 20111101

• Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.

  QJM : monthly journal of the Association of Physicians 20111101

• Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients.

  Haematologica 20111101

• Response to bortezomib of a patient with scleromyxedema refractory to other therapies.

  Leukemia research 20111101

• The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma.

  The American journal of pathology 20111101

• [Pneumonia and Rothia dentocariosa].

  Medecine et maladies infectieuses 20111101

• Clinical and investigational use of proteasome inhibitors for transplant rejection.

  Expert opinion on investigational drugs 20111101

• Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia.

  Current cancer drug targets 20111101

• Bortezomib for previously untreated multiple myeloma.

  Expert opinion on pharmacotherapy 20111101

• Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.

  Molecular cancer therapeutics 20111101

• Varicella-zoster virus prophylaxis with the traditional Chinese medicine Radix isatidis (Banlangen) in patients with multiple myeloma treated with bortezomib.

  Journal of alternative and complementary medicine (New York, N.Y.) 20111101

• Intramural delivery of bortezomib inhibits restenosis following arterial injury.

  VASA. Zeitschrift fur Gefasskrankheiten 20111101

• Antitumor effect of non-steroid glucocorticoid receptor ligand CpdA on leukemia cell lines CEM and K562.

  Biochemistry. Biokhimiia 20111101

• The proteasome as a target for prevention of restenosis following vascular injury.

  VASA. Zeitschrift fur Gefasskrankheiten 20111101

• [Autologous hematopoietic stem cell transplantation following bortezomib-based chemotherapy for one case with POEMS syndrome].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20111101

• Bioassay-guided isolation of constituents of Piper sarmentosum using a mitochondrial transmembrane potential assay.

  Journal of natural products 20111028

• Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.

  Blood 20111027

• Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111015

• Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.

  Annals of hematology 20111001

• Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8.

  Cell death and differentiation 20111001

• Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens.

  Leukemia research 20111001

• Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20111001

• Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation.

  Leukemia & lymphoma 20111001

• Heavy-chain amyloidosis in TGFBI-negative and gelsolin-negative atypical lattice corneal dystrophy.

  Cornea 20111001

• The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.

  Experimental hematology 20111001

• VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.

  British journal of haematology 20111001

• Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.

  Molecular cancer therapeutics 20111001

• Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease.

  Japanese journal of clinical oncology 20111001

• [POEMS syndrome. An interdisciplinary clinical challenge].

  Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20111001

• Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies.

  Expert review of hematology 20111001

• FoxM1 knockdown sensitizes human cancer cells to proteasome inhibitor-induced apoptosis but not to autophagy.

  Cell cycle (Georgetown, Tex.) 20111001

• Renal crescentic alpha heavy chain deposition disease: a report of 3 cases and review of the literature.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20111001

• Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.

  Cancer control : journal of the Moffitt Cancer Center 20111001

• Scleromyxedema and dermato–neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib.

  American journal of hematology 20111001

• Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.

  Chinese medical journal 20111001

• [Effect of proteasome inhibitor on migration ability and hepatocyte growth factor expression of bone marrow mesenchymal stem cells in multiple myeloma patients].

  Zhongguo shi yan xue ye xue za zhi 20111001

• [Bortezomib combined with autologous peripheral blood hematopoietic stem cell transplantation for therapy of patients with multiple myeloma].

  Zhongguo shi yan xue ye xue za zhi 20111001

• [Treatment of myeloma when high dose therapy is not possible. New drugs--alternatives for elderly patients].

  Lakartidningen 20111001

• [Clinical analysis of bortezomib combined with chemotherapy for one case of refractory acute lymphocytic leukemia].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20111001

• Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

  Blood 20110929

• Degradation-linked ubiquitin signal and proteasome are integral components of DNA double strand break repair: New perspectives for anti-cancer therapy.

  FEBS letters 20110916

• Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.

  Blood 20110915

• Renal improvement in myeloma with plasma exchange.

  The New England journal of medicine 20110915

• Renal improvement in myeloma with plasma exchange.

  The New England journal of medicine 20110915

• A third-generation IMiD for MM.

  Blood 20110915

• An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma.

  Cancer cell 20110913

• Complete heart block secondary to bortezomib use in multiple myeloma.

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20110901

• Bortezomib: friend or foe of hemolytic anemia?

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20110901

• Successful treatment with bortezomib and thalidomide for POEMS syndrome.

  Annals of hematology 20110901

• Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.

  Annals of hematology 20110901

• Development of a brain metastatic canine prostate cancer cell line.

  The Prostate 20110901

• Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression.

  Leukemia & lymphoma 20110901

• Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.

  Leukemia & lymphoma 20110901

• Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients.

  The journal of pain : official journal of the American Pain Society 20110901

• The micros in harmony: microRNA and microenvironment.

  Leukemia & lymphoma 20110901

• Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110901

• Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir.

  Current cancer drug targets 20110901

• Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: oncolytic strategies.

  Current opinion in oncology 20110901

• Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110901

• Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110901

• Proteasomal inhibition promotes ATP-binding cassette transporter A1 (ABCA1) and ABCG1 expression and cholesterol efflux from macrophages in vitro and in vivo.

  Arteriosclerosis, thrombosis, and vascular biology 20110901

• Complementary cell-based high-throughput screens identify novel modulators of the unfolded protein response.

  Journal of biomolecular screening 20110901

• Successful bone reconstruction after bortezomib therapy in a myeloma patient.

  International journal of hematology 20110901

• Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B.

  Cancer research 20110901

• Modulation of cisplatin cytotoxicity due to its combination with bortezomib and the nature of its administration.

  Anticancer research 20110901

• Proteasome inhibitor therapy for antibody-mediated rejection.

  Pediatric transplantation 20110901

• Myeloma cast nephropathy: a rare cause of primary renal allograft dysfunction.

  Transplantation proceedings 20110901

• An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation.

  Immunotherapy 20110901

• NICE guidance on bortezomib and thalidomide for first-line treatment of multiple myeloma.

  The Lancet. Oncology 20110901

• Evaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model.

  Journal of the peripheral nervous system : JPNS 20110901

• Influence of proteasome inhibitor bortezomib on the expression of multidrug resistance genes and Akt kinase activity.

  Biochemistry. Biokhimiia 20110901

• [Effect of omega-3 fish oil fat emulsion on the peripheral neuropathy caused by bortezomib].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110901

• Cardiac amyloidosis: a treatable disease, often overlooked.

  Circulation 20110830

• Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression.

  Cancer 20110815

• In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110815

• Catechol polymers for pH-responsive, targeted drug delivery to cancer cells.

  Journal of the American Chemical Society 20110810

• The TEMPI syndrome--a novel multisystem disease.

  The New England journal of medicine 20110804

• A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).

  Cancer 20110801

• Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells.

  Annals of hematology 20110801

• Renal failure caused by plasma cell infiltration in multiple myeloma.

  Clinical and experimental nephrology 20110801

• Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions.

  Cellular signalling 20110801

• [Meningeal plasmacytoma: delayed diagnosis with sequelae].

  RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 20110801

• Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.

  Pancreas 20110801

• Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part I.

  Archivum immunologiae et therapiae experimentalis 20110801

• Targeting the extrinsic apoptosis signaling pathway for cancer therapy.

  Cancer immunology, immunotherapy : CII 20110801

• Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents.

  American journal of hematology 20110801

• Levels of p27 sensitize to dual PI3K/mTOR inhibition.

  Molecular cancer therapeutics 20110801

• Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation.

  Leukemia & lymphoma 20110801

• Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach.

  Molecular cancer therapeutics 20110801

• Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110801

• The challenge of recurrent follicular lymphoma.

  The Lancet. Oncology 20110801

• Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.

  The Lancet. Oncology 20110801

• Apoptotic role of IKK in T-ALL therapeutic response.

  Molecular cancer research : MCR 20110801

• Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.

  Cancer investigation 20110801

• Proteasome inhibitor treatment of antibody-mediated allograft rejection.

  Current opinion in organ transplantation 20110801

• Bortezomib for previously untreated multiple myeloma.

  Expert review of hematology 20110801

• Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.

  Clinical lymphoma, myeloma & leukemia 20110801

• [Comparison of protein expression profiles between bortezomib-resistant JurkatB cells with PSMB5 mutation and their parent cells].

  Zhongguo shi yan xue ye xue za zhi 20110801

• [Proteasome inhibitor bortezomib inducing apoptosis of K562 cells not affected by bone marrow mesenchymal stem cells in vitro].

  Zhongguo shi yan xue ye xue za zhi 20110801

• [Effects of bortezomib alone or combined with arsenic trioxide on the apoptosis of Jurkat cells and expression of livin mRNA].

  Zhongguo shi yan xue ye xue za zhi 20110801

• [Effects of bortezomib combined with methylprednisolone in treatment of 33 cases of relapsed or refractory multiple myeloma].

  Zhongguo shi yan xue ye xue za zhi 20110801

• Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma.

  Cancer discovery 20110801

• [Current treatment strategies with novel agents for multiple myeloma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20110801

• [Present status and perspective of targeted therapy for B-cell lymphoma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20110801

• [Reversal effect of LBH589 alone or in combination with bortezomib on drug-resistance in myeloid leukemia and its mechanism].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110801

• Calibration of prior variance in the Bayesian continual reassessment method.

  Statistics in medicine 20110730

• Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.

  Blood 20110728

• A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia.

  Blood 20110728

• Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.

  Blood 20110721

• Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade.

  Cancer biology & therapy 20110715

• Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma.

  Cancer research 20110715

• Chemical and biological evaluation of dipeptidyl boronic acid proteasome inhibitors for use in prodrugs and pro-soft drugs targeting solid tumors.

  Journal of medicinal chemistry 20110714

• Novel proteasome inhibitors to overcome bortezomib resistance.

  Journal of the National Cancer Institute 20110706

• Acute dyspnea from treatment of AL amyloidisis with bortezomib.

  American journal of therapeutics 20110701

• Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.

  Annals of the rheumatic diseases 20110701

• Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110701

• Cutaneous macroglobulinosis treated with bortezomib and rituximab.

  European journal of haematology 20110701

• Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110701

• Proteasome inhibition improves diaphragm function in an animal model for COPD.

  American journal of physiology. Lung cellular and molecular physiology 20110701

• Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.

  Haematologica 20110701

• Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?

  Blood reviews 20110701

• Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.

  British journal of haematology 20110701

• A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients.

  British journal of haematology 20110701

• Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study.

  Japanese journal of clinical oncology 20110701

• A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.

  American journal of hematology 20110701

• Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.

  American journal of hematology 20110701

• The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia.

  American journal of hematology 20110701

• Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. European Journal of Haematology 2010; 85 (6):484-491.

  European journal of haematology 20110701

• Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial.

  Leukemia & lymphoma 20110701

• Bortezomib in patients with renal impairment.

  Hematology (Amsterdam, Netherlands) 20110701

• Multiple myeloma presenting with hepatosplenomegaly.

  The Journal of the Association of Physicians of India 20110701

• Renal improvement in myeloma with bortezomib plus plasma exchange.

  The New England journal of medicine 20110616

• Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110615

• Cervical amyloidoma successfully treated with bortezomib and dexamethasone.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110610

• Constitutive activation of metalloproteinase ADAM10 in mantle cell lymphoma promotes cell growth and activates the TNFα/NFκB pathway.

  Blood 20110609

• Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma.

  Blood 20110609

• Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.

  Blood 20110609

• MicroCT-based virtual histology evaluation of preclinical medulloblastoma.

  Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 20110601

• Re-transplantation after bortezomib-based therapy.

  British journal of haematology 20110601

• Signal transducer and activator of transcription 3 pathway mediates genipin-induced apoptosis in U266 multiple myeloma cells.

  Journal of cellular biochemistry 20110601

• Treatment of newly diagnosed myeloma in patients not eligible for transplantation.

  Current hematologic malignancy reports 20110601

• Bortezomib attenuates acute graft-vs.-host disease through interfering with host immature dendritic cells.

  Experimental hematology 20110601

• Treatment of newly diagnosed multiple myeloma in transplant-eligible patients.

  Current hematologic malignancy reports 20110601

• Analysis of two commercially available bortezomib products: differences in assay of active agent and impurity profile.

  AAPS PharmSciTech 20110601

• Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.

  Leukemia 20110601

• Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.

  European journal of haematology 20110601

• Delayed treatment with vitamin C and N-acetyl-L-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib.

  International journal of hematology 20110601

• Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.

  British journal of haematology 20110601

• Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma.

  International journal of hematology 20110601

• Desensitization across the HLA barrier in kidney transplantaion.

  Frontiers in bioscience (Scholar edition) 20110601

• New agents in follicular lymphoma.

  Best practice & research. Clinical haematology 20110601

• [Effect of different concentrations of bortezomib on the expression of ERK, JNK and P38 in daunorubicin-resistant K562 cells].

  Zhongguo shi yan xue ye xue za zhi 20110601

• [Effect of curcumin in combination with bortezomib on proliferation and apoptosis of human multiple myeloma cell line H929 and its mechanism].

  Zhongguo shi yan xue ye xue za zhi 20110601

• Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.

  Anticancer research 20110601

• [Effect of bortezomib on the drug sensitivity of imatinib resistant K562/G01 cells].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110601

• A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy.

  Medical physics 20110601

• Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis.

  Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 20110601

• Bortezomib in systemic AL amyloidosis: a single center experience.

  Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 20110601

• Bortezomib (Velcade) treatment of AL amyloidosis: Indiana University experience.

  Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 20110601

• Quick response to bortezomib plus dexamethasone in a patient with AL amyloidosis in first relapse.

  Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 20110601

• Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.

  Chemico-biological interactions 20110530

• Proteasome inhibitor treatment in alcoholic liver disease.

  World journal of gastroenterology 20110528

• Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib.

  Chemistry & biology 20110527

• Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells.

  The Journal of biological chemistry 20110520

• Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110515

• Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110515

• Inhibition of p53 DNA binding function by the MDM2 protein acidic domain.

  The Journal of biological chemistry 20110506

• Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma.

  Bone marrow transplantation 20110501

• Salvage therapy for refractory rejection and persistence of donor-specific antibodies after intestinal transplantation using the proteasome inhibitor bortezomib.

  Transplant international : official journal of the European Society for Organ Transplantation 20110501

• Successful treatment with a modified bortezomib schedule of weekly and longer intervals for patients with refractory/resistance multiple myeloma.

  Leukemia research 20110501

• A promising new regimen for the treatment of advanced extranodal NK/T cell lymphoma.

  Acta oncologica (Stockholm, Sweden) 20110501

• Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.

  Haematologica 20110501

• Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma.

  Leukemia 20110501

• Multiple myeloma: interplay between osteoblastogenesis and adipogenesis.

  European journal of haematology 20110501

• Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.

  Immunology 20110501

• Synergistic efficacy in human ovarian cancer cells by histone deacetylase inhibitor TSA and proteasome inhibitor PS-341.

  Cancer investigation 20110501

• Proteasome inhibition induces a p38 MAPK pathway-dependent antiapoptotic program via Nrf2 in thyroid cancer cells.

  The Journal of clinical endocrinology and metabolism 20110501

• Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110501

• Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.

  European journal of haematology 20110501

• Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A.

  Molecular cancer therapeutics 20110501

• The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110501

• Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

  The Lancet. Oncology 20110501

• Subcutaneous bortezomib: a step towards optimised drug use.

  The Lancet. Oncology 20110501

• The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens.

  Cancer 20110501

• Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma.

  The American journal of pathology 20110501

• Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.

  Danish medical bulletin 20110501

• Carfilzomib: a novel second-generation proteasome inhibitor.

  Future oncology (London, England) 20110501

• Proteotoxic stress targeted therapy (PSTT).

  Oncotarget 20110501

• [Treatment options and prognosis in newly diagnosed multiple myeloma patients].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110501

• Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link.

  Oncotarget 20110501

• Oncogenic B-RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110415

• Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110415

• Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110415

• Out foxing bcr-abl.

  Cancer biology & therapy 20110415

• RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.

  Blood 20110407

• CYT997 causes apoptosis in human multiple myeloma.

  Investigational new drugs 20110401

• Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells.

  Cell biology and toxicology 20110401

• Continual reassessment method with multiple toxicity constraints.

  Biostatistics (Oxford, England) 20110401

• An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib.

  International journal of laboratory hematology 20110401

• Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes.

  Leukemia research 20110401

• Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.

  Cancer science 20110401

• Farnesyl transferase inhibitors, autophagy, and proteasome inhibition: synergy for all the right reasons.

  Autophagy 20110401

• Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cells.

  Journal of thrombosis and haemostasis : JTH 20110401

• Feasibility and efficacy of administration of bortezomib-containing regimens to patients over the age of 70 years.

  British journal of haematology 20110401

• Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20110401

• Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.

  Leukemia & lymphoma 20110401

• Recent advances in myeloma treatment.

  Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 20110401

• Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110401

• Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells.

  Molecular cancer research : MCR 20110401

• Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial.

  British journal of haematology 20110401

• Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.

  British journal of haematology 20110401

• The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.

  PharmacoEconomics 20110401

• Velcade combinations in mantle cell lymphoma: are we learning anything?

  Leukemia & lymphoma 20110401

• Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.

  The oncologist 20110401

• [Malignant lymphoma: individualized treatment according to biological and clinical risk factors].

  Deutsche medizinische Wochenschrift (1946) 20110401

• Antitumor activity and drug interactions of proteasome inhibitor Bortezomib in human high-risk myelodysplastic syndrome cells.

  International journal of hematology 20110401

• Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.

  Seminars in thrombosis and hemostasis 20110401

• Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib.

  Internal medicine journal 20110401

• Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.

  Anticancer research 20110401

• [NB4 cell apoptosis induced by bortezomib combined with As(2)O(3) and its mechanism].

  Zhongguo shi yan xue ye xue za zhi 20110401

• [The significances of 13q14 deletion for development and prognosis of multiple myeloma].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110401

• [Effect of different regimens on bone disease of multiple myeloma].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110401

• [The clinical study on treatment with bortezomib for multiple myeloma].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110401

• [Mechanism of apoptosis induced by bortezomib and As2O3 in APL cell line NB4].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110401

• Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.

  Clinical lymphoma, myeloma & leukemia 20110401

• [The efficacy and safety of bortezomib plus thalidomide in treatment of newly diagnosed multiple myeloma].

  Zhonghua nei ke za zhi 20110401

• Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.

  Neurology 20110329

• Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker.

  Cancer biology & therapy 20110315

• The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo.

  Transplantation 20110315

• Clinical perspective of acute humoral rejection after blood type-compatible liver transplantation.

  Transplantation 20110315

• Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110315

• Treatment options for relapsed and refractory multiple myeloma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110315

• The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.

  Blood 20110310

• Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.

  Lung cancer (Amsterdam, Netherlands) 20110301

• Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).

  Annals of oncology : official journal of the European Society for Medical Oncology 20110301

• Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study.

  Japanese journal of clinical oncology 20110301

• Radiosensitizing properties of bortezomib depend on therapeutic schedule.

  International journal of radiation oncology, biology, physics 20110301

• Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.

  European journal of pharmacology 20110301

• Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.

  International journal of oncology 20110301

• Chemotherapy-induced neuropathic pain.

  Current opinion in supportive and palliative care 20110301

• High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors.

  Cancer research 20110301

• Genetic variation associated with bortezomib-induced peripheral neuropathy.

  Pharmacogenetics and genomics 20110301

• A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110301

• Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma.

  British journal of haematology 20110301

• Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

  Current cancer drug targets 20110301

• Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose cyclophosphamide.

  American journal of hematology 20110301

• Antibody-mediated rejection in kidney transplantation: an update.

  Expert opinion on pharmacotherapy 20110301

• Management of older patients with multiple myeloma.

  Blood reviews 20110301

• A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).

  Leukemia & lymphoma 20110301

• De novo AL amyloidosis in the kidney allograft.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20110301

• Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.

  The Lancet. Oncology 20110301

• A new combination for advanced multiple myeloma.

  The Lancet. Oncology 20110301

• Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.

  Arthritis and rheumatism 20110301

• [A case of aggressive multiple myeloma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110301

• Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.

  Oncotarget 20110301

• [Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20110301

• Role of proteasome inhibition in sensitized transplant candidates.

  Chinese medical journal 20110301

• [Effect of proteasome inhibitor bortezomib on proliferation, apoptosis and XIAP expression in K562 cells].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110301

• Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110220

• Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis.

  Journal of immunology (Baltimore, Md. : 1950) 20110215

• Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1.

  Biochemical and biophysical research communications 20110204

• Bortezomib and donor lymphocyte infusion in multiple myeloma relapsed after allo-SCT does not result in durable remissions.

  Bone marrow transplantation 20110201

• A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.

  Annals of hematology 20110201

• Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis.

  Annals of hematology 20110201

• Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma.

  Leukemia research 20110201

• Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells.

  Gut 20110201

• The impact of bortezomib on the risk of thrombosis in multiple myeloma.

  Leukemia research 20110201

• A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients.

  Haematologica 20110201

• Proteasome inhibitor up regulates liver antioxidative enzymes in rat model of alcoholic liver disease.

  Experimental and molecular pathology 20110201

• The combination of bortezomib and resveratrol may prevent muscle wasting in diabetes.

  Medical hypotheses 20110201

• Decursin chemosensitizes human multiple myeloma cells through inhibition of STAT3 signaling pathway.

  Cancer letters 20110201

• Clinical impact of chromosomal aberrations in multiple myeloma.

  Journal of internal medicine 20110201

• Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.

  Journal of clinical pharmacy and therapeutics 20110201

• Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.

  British journal of haematology 20110201

• Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.

  Molecular cancer research : MCR 20110201

• Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis.

  Journal of the American Society of Nephrology : JASN 20110201

• Clinical and biological features of t(4;14) multiple myeloma: a prospective study.

  Leukemia & lymphoma 20110201

• Bortezomib-induced peripheral neuropathy: facts and genes.

  The Lancet. Oncology 20110201

• Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.

  Expert review of hematology 20110201

• [Screening drugs for regulating tissue factor gene expression].

  Zhongguo shi yan xue ye xue za zhi 20110201

• [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110201

• [Significance of bortezomib and dexamethasone therapy for multiple myeloma showing a serum creatinine level above 2 mg/dl].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20110201

• [Study on mechanism of bortezomib inducing peripheral neuropathy and the reversing effect of reduced glutathione].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110201

• Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.

  Clinical lymphoma, myeloma & leukemia 20110201

• Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.

  Clinical lymphoma, myeloma & leukemia 20110201

• Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia.

  Clinical lymphoma, myeloma & leukemia 20110201

• Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma.

  Blood 20110127

• Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism.

  Blood 20110127

• The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.

  Blood 20110127

• α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells.

  Journal of medicinal chemistry 20110127

• Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.

  Blood 20110113

• Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis.

  Blood 20110113

• [Case report; a case of acute kidney injury due to intravenous zoledronic acid hydrate, improved with bortezomib plus dexamethazone therapy in a patient with multiple myeloma].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20110110

• Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.

  British journal of cancer 20110104

• Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.

  Cancer chemotherapy and pharmacology 20110101

• [Progressive hypertelorism secondary to craniofacial plasmocytoma].

  Acta otorrinolaringologica espanola 20110101

• Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains.

  Leukemia research 20110101

• Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia/lymphoma.

  Annals of hematology 20110101

• NF-κB localization in multiple myeloma plasma cells and mesenchymal cells.

  Leukemia research 20110101

• Inhibition of NF-κB signaling retards eosinophilic dermatitis in SHARPIN-deficient mice.

  The Journal of investigative dermatology 20110101

• Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

  European journal of haematology 20110101

• Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma.

  European journal of haematology 20110101

• The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.

  Haematologica 20110101

• The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.

  Experimental hematology 20110101

• Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma.

  Thrombosis and haemostasis 20110101

• Multiple myeloma.

  Annual review of medicine 20110101

• Chemotherapy: Failure of bevacizumab in early-stage colon cancer.

  Nature reviews. Clinical oncology 20110101

• Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review.

  American journal of hematology 20110101

• Treatment approaches to IgG4-related systemic disease.

  Current opinion in rheumatology 20110101

• Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).

  Leukemia & lymphoma 20110101

• Complete atrioventricular block secondary to bortezomib use in multiple myeloma.

  Yonsei medical journal 20110101

• Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.

  Future oncology (London, England) 20110101

• Hematology: Bortezomib and dexamethasone induction for multiple myeloma.

  Nature reviews. Clinical oncology 20110101

• Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.

  Molecular cancer therapeutics 20110101

• Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.

  Clinical lung cancer 20110101

• Constitutively active FGFR3 with Lys650Glu mutation enhances bortezomib sensitivity in plasma cell malignancy.

  Anticancer research 20110101

• Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy.

  Journal of biomedical optics 20110101

• Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia.

  PloS one 20110101

• Thiazole antibiotic thiostrepton synergize with bortezomib to induce apoptosis in cancer cells.

  PloS one 20110101

• [Immunosuppressive agents in kidney transplantation].

  Nihon Jinzo Gakkai shi 20110101

• [In vitro synergistic effect of bortezomib and pirarubicin on proliferation and apoptosis of T cell lymphoma cell line Hut-78 cells].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110101

• [Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20110101

• Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo.

  BMC cancer 20110101

• Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20110101

• The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.

  Current pharmaceutical design 20110101

• History of multiple myeloma.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20110101

• Novel drugs in myeloma: harnessing tumour biology to treat myeloma.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20110101

• Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20110101

• Therapy of relapsed and refractory multiple myeloma.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20110101

• Allogeneic transplantation in multiple myeloma.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20110101

• p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin.

  PloS one 20110101

• Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid.

  In vivo (Athens, Greece) 20110101

• p21(WAF1/CIP1) upregulation through the stress granule-associated protein CUGBP1 confers resistance to bortezomib-mediated apoptosis.

  PloS one 20110101

• [Regression of an osteolytic lesion in a patient with multiple myeloma treated with clodronate after a successful therapy with bortezomib-based regimen].

  Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20110101

• Small compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma.

  PloS one 20110101

• Identification of genes affecting the toxicity of anti-cancer drug bortezomib by genome-wide screening in S. pombe.

  PloS one 20110101

• Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma.

  PloS one 20110101

• A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence?

  Acta haematologica 20110101

• Ideal vial size for bortezomib: real-world data on waste and cost reduction in treatment of multiple myeloma in Brazil.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20110101

• Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models.

  Pharmacology 20110101

• Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.

  Journal of medical economics 20110101

• Sudden significant total protein concentration change: not an analytical problem.

  Journal of clinical laboratory analysis 20110101

• Successful treatment of immunoglobulin D myeloma by bortezomib and dexamethasone therapy.

  Internal medicine (Tokyo, Japan) 20110101

• Macrocyclic proteasome inhibitors.

  Current medicinal chemistry 20110101

• Relapsed multiple myeloma presenting as an orbital plasmacytoma.

  Ophthalmic plastic and reconstructive surgery 20110101

• The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.

  PloS one 20110101

• Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.

  PloS one 20110101

• Bortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients.

  The Journal of international medical research 20110101

• The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner.

  Journal of hematology & oncology 20110101

• Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.

  Acta clinica Belgica 20110101

• What is the benefit of maintenance therapy with lenalidomide or bortezomib after autologous stem cell transplantation in multiple myeloma and what is the risk of developing a secondary primary malignancy?

  Hematology. American Society of Hematology. Education Program 20110101

• Hyponatremia is not a rare adverse event in bortezomib-treated patients.

  Chemotherapy 20110101

• Molecular mechanisms of bortezomib resistant adenocarcinoma cells.

  PloS one 20110101

• Breathless on bortezomib.

  BMJ case reports 20110101

• High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.

  Clinical transplants 20110101

• The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.

  Clinical transplants 20110101

• MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.

  Cancer letters 20101228

• Protective immunity remains intact after antibody removal by means of proteasome inhibition.

  Transplantation 20101227

• The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation.

  Transplantation 20101227

• Synthesis, in vitro and in vivo biological evaluation, and comprehensive understanding of structure-activity relationships of dipeptidyl boronic acid proteasome inhibitors constructed from β-amino acids.

  Journal of medicinal chemistry 20101223

• A new standard of care in newly diagnosed multiple myeloma.

  Lancet (London, England) 20101218

• Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

  Lancet (London, England) 20101218

• Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells.

  Blood 20101216

• Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.

  Blood 20101209

• Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

  Blood 20101202

• Prophylactic antivirals may be helpful in prevention of varicella-zoster virus reactivation in myeloma, but are they safe?

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20101201

• Bortezomib synergizes TRAIL-induced apoptosis in gastric cancer cells.

  Digestive diseases and sciences 20101201

• Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results.

  European radiology 20101201

• Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts.

  Cardiovascular research 20101201

• Amyloid myopathy: a therapeutic trial for the rare and underdiagnosed myopathy with bortezomib.

  Journal of neurology 20101201

• Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.

  Cancer 20101201

• Rectal bleeding and diarrhea caused by bortezomib-induced colitis.

  Gastroenterologia y hepatologia 20101201

• Potentiation of bortezomib-induced apoptosis by TGF-beta in cultured human Tenon's fibroblasts: contribution of the PI3K/Akt signaling pathway.

  Investigative ophthalmology & visual science 20101201

• Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare®) for chemotherapy-induced peripheral neuropathy.

  Journal of pain and symptom management 20101201

• Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101201

• Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy.

  Glia 20101201

• Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies.

  Experimental neurology 20101201

• The spectrum of kidney involvement in lymphoma: a case report and review of the literature.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20101201

• The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.

  European journal of haematology 20101201

• Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression.

  Angiogenesis 20101201

• Too much of a good thing is bad: proteasome inhibition induces stressed hearts to fail.

  Cardiovascular research 20101201

• Complete remission following treatment with bortezomib, doxorubicin, dexamethasone and autologous stem cell transplant in patient with immunoglobulin E multiple myeloma.

  Leukemia & lymphoma 20101201

• Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathy.

  Leukemia & lymphoma 20101201

• Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101201

• Myeloma: making sense of a complex blood cancer.

  British journal of nursing (Mark Allen Publishing) 20101201

• Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.

  Clinical breast cancer 20101201

• Ten years of improvement in the management of multiple myeloma: 2000-2010.

  Clinical lymphoma, myeloma & leukemia 20101201

• [Effect of bortezomib on MAPK signaling pathway of K562/DNR cells].

  Zhongguo shi yan xue ye xue za zhi 20101201

• [Therapeutic efficacy of bortezomib-based chemotherapy on 40 patients with multiple myeloma].

  Zhongguo shi yan xue ye xue za zhi 20101201

• Bortezomib-induced inflammatory neuropathy.

  Journal of the peripheral nervous system : JPNS 20101201

• Focal adhesion kinase as a therapeutic target of bortezomib.

  Anti-cancer agents in medicinal chemistry 20101201

• Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.

  Blood 20101125

• CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.

  Oncogene 20101125

• Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101120

• Mantle cell lymphoma activation enhances bortezomib sensitivity.

  Blood 20101118

• Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome.

  Bioorganic & medicinal chemistry letters 20101115

• Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.

  Blood 20101111

• Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy.

  British journal of cancer 20101109

• Lupus tumidus induced by bortezomib not requiring discontinuation of the drug.

  Journal of the European Academy of Dermatology and Venereology : JEADV 20101101

• Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20101101

• Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.

  Annals of hematology 20101101

• Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma.

  Leukemia research 20101101

• Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.

  Haematologica 20101101

• Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application.

  Molecular therapy : the journal of the American Society of Gene Therapy 20101101

• The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats.

  Arthritis and rheumatism 20101101

• Bortezomib: a new player in pre- and post-transplant desensitization?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20101101

• Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.

  The Lancet. Oncology 20101101

• The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.

  British journal of haematology 20101101

• Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.

  British journal of haematology 20101101

• The early marginal zone B cell-initiated T-independent type 2 response resists the proteasome inhibitor bortezomib.

  Journal of immunology (Baltimore, Md. : 1950) 20101101

• Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka.

  International journal of hematology 20101101

• Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.

  The Lancet. Oncology 20101101

• Sustained improvement in cardiac function with persistent amyloid deposition in a patient with multiple myeloma-associated cardiac amyloidosis treated with bortezomib.

  International journal of hematology 20101101

• Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.

  International journal of hematology 20101101

• Stroke after treatment with bortezomib and dexamethasone in a Chinese patient with extramedullary relapse of multiple myeloma.

  International journal of clinical pharmacology and therapeutics 20101101

• Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma.

  The Lancet. Oncology 20101101

• Ubiquitin-regulated nuclear-cytoplasmic trafficking of the Nipah virus matrix protein is important for viral budding.

  PLoS pathogens 20101101

• Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.

  Blood reviews 20101101

• [New treatment strategy for Crow-Fukase (POEMS) syndrome].

  Rinsho shinkeigaku = Clinical neurology 20101101

• γ-Tocotrienol but not γ-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents.

  The Journal of biological chemistry 20101022

• Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101020

• Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101020

• Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101020

• [Bortezomib-based regimen for the treatment of 110 multiple myeloma patients].

  Zhonghua yi xue za zhi 20101019

• Pro-inflammatory genes as biomarkers and therapeutic targets in oral squamous cell carcinoma.

  The Journal of biological chemistry 20101015

• A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20101015

• A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20101015

• Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma.

  Cell cycle (Georgetown, Tex.) 20101015

• Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.

  Journal of medicinal chemistry 20101014

• Regulation of human carbonyl reductase 3 (CBR3; SDR21C2) expression by Nrf2 in cultured cancer cells.

  Biochemistry 20101005

• Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.

  Journal of cellular and molecular medicine 20101001

• Functional evaluation of therapeutic response for a mouse model of medulloblastoma.

  Transgenic research 20101001

• Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies.

  International journal of radiation oncology, biology, physics 20101001

• Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.

  Journal of neuro-oncology 20101001

• A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma.

  Annals of hematology 20101001

• Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents.

  Leukemia research 20101001

• First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.

  European journal of haematology 20101001

• Targeting GRP78 to enhance melanoma cell death.

  Pigment cell & melanoma research 20101001

• Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20101001

• Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma.

  Gut 20101001

• Butein suppresses the expression of nuclear factor-kappa B-mediated matrix metalloproteinase-9 and vascular endothelial growth factor in prostate cancer cells.

  Toxicology in vitro : an international journal published in association with BIBRA 20101001

• Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells.

  Cancer science 20101001

• The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma.

  Leukemia 20101001

• Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer.

  Molecular cancer therapeutics 20101001

• An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.

  American journal of hematology 20101001

• Therapeutic options for HIV-associated lymphomas.

  Expert opinion on pharmacotherapy 20101001

• Structure-activity relationship of boronic acid derivatives of tyropeptin: proteasome inhibitors.

  Bioorganic & medicinal chemistry letters 20101001

• Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China.

  Anatomical record (Hoboken, N.J. : 2007) 20101001

• Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.

  British journal of haematology 20101001

• Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.

  The Lancet. Oncology 20101001

• Optimising bortezomib in newly diagnosed multiple myeloma.

  The Lancet. Oncology 20101001

• Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.

  Leukemia 20101001

• A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma.

  International journal of hematology 20101001

• Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway.

  British journal of pharmacology 20101001

• Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience.

  International journal of hematology 20101001

• [Current treatment strategies for multiple myeloma].

  Therapeutische Umschau. Revue therapeutique 20101001

• [Study on natural products for drug development].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20101001

• [Proteasome inhibitors].

  Nihon rinsho. Japanese journal of clinical medicine 20101001

• Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials.

  Clinical lymphoma, myeloma & leukemia 20101001

• Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin.

  Anticancer research 20101001

• Plasma cell leukemia: concepts and management.

  Expert review of hematology 20101001

• [Effects of xbp-1 gene silencing on bortezomib-induced apoptosis in human multiple myeloma cells].

  Zhongguo shi yan xue ye xue za zhi 20101001

• [Bortezomib depresses osteoblast apoptosis induced by mouse myeloma cells].

  Zhongguo shi yan xue ye xue za zhi 20101001

• Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20101001

• Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma.

  Clinical lymphoma, myeloma & leukemia 20101001

• Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.

  The Biochemical journal 20100915

• Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100901

• Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.

  Annals of hematology 20100901

• Hyperlipidemia in a myeloma patient after bortezomib treatment.

  Leukemia research 20100901

• Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells.

  Haematologica 20100901

• Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.

  Leukemia research 20100901

• Targeting X-linked inhibitor of apoptosis protein to increase the efficacy of endoplasmic reticulum stress-induced apoptosis for melanoma therapy.

  The Journal of investigative dermatology 20100901

• Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome.

  Leukemia & lymphoma 20100901

• Individualizing cancer therapy.

  Leukemia & lymphoma 20100901

• Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20100901

• The treatment of traumatic brain injury with velcade.

  Journal of neurotrauma 20100901

• Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.

  American journal of hematology 20100901

• Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen.

  American journal of hematology 20100901

• Lenalidomide for bortezomib-resistant multiple myeloma.

  Nature reviews. Clinical oncology 20100901

• Lenalidomide efficacy in bortezomib-resistant myeloma.

  Nature reviews. Clinical oncology 20100901

• Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice.

  Journal of the National Comprehensive Cancer Network : JNCCN 20100901

• Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas.

  Anticancer research 20100901

• [The efficacy and safety of PAD and VAD regimens for untreated multiple myeloma].

  Zhonghua nei ke za zhi 20100901

• [Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20100901

• [The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20100901

• Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.

  Blood 20100826

• Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100820

• Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100815

• Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

  Blood 20100805

• Regulation of autophagy by ATF4 in response to severe hypoxia.

  Oncogene 20100805

• Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease.

  Annals of hematology 20100801

• Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.

  Cancer chemotherapy and pharmacology 20100801

• The potential effect of proteasome inhibitor PS-341 on severe acute pancreatitis detected by positron emission tomography in ICR mice.

  The Journal of surgical research 20100801

• The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro.

  Cancer chemotherapy and pharmacology 20100801

• Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial.

  Leukemia 20100801

• Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.

  American journal of hematology 20100801

• The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.

  Molecular immunology 20100801

• Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.

  Leukemia 20100801

• Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.

  Pediatric blood & cancer 20100801

• Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.

  British journal of haematology 20100801

• Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors.

  Bioorganic & medicinal chemistry 20100801

• Plasma cell leukaemia and other aggressive plasma cell malignancies.

  British journal of haematology 20100801

• [Effect of bortezomib on lymphoma cell line CA46 and its relative mechanisms].

  Zhongguo shi yan xue ye xue za zhi 20100801

• [Adverse effects of PAD and VAD regimens in multiple myeloma patients].

  Zhongguo shi yan xue ye xue za zhi 20100801

• [Multiple myeloma complicated with disseminated zygomycosis after bortezomib therapy].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20100801

• Proteomics of apoptosis of multiple myeloma cells induced by proteasome inhibitor PS-341.

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20100801

• [Effect of Velcade combined with Dexamethasone on multiple myeloma].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20100801

• First-line treatment of elderly multiple myeloma patients.

  Clinical advances in hematology & oncology : H&O 20100801

• Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients.

  Transplantation 20100727

• Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma.

  Blood 20100722

• Effect of noncompetitive proteasome inhibition on bortezomib resistance.

  Journal of the National Cancer Institute 20100721

• Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma.

  Proceedings of the National Academy of Sciences of the United States of America 20100720

• High-throughput detection of nuclear factor-kappaB activity using a sensitive oligo-based chemiluminescent enzyme-linked immunosorbent assay.

  International journal of cancer 20100715

• Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells.

  International journal of cancer 20100715

• Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100715

• A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.

  Cancer 20100715

• High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study.

  Blood 20100708

• Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma.

  International journal of cancer 20100701

• Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.

  Leukemia research 20100701

• A proteasome inhibitor to treat acute pancreatitis? Maybe..

  The Journal of surgical research 20100701

• Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.

  Leukemia research 20100701

• The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.

  European journal of haematology 20100701

• Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors.

  Cancer immunology, immunotherapy : CII 20100701

• A novel gallium compound synergistically enhances bortezomib-induced apoptosis in mantle cell lymphoma cells.

  Leukemia research 20100701

• Bortezomib for the treatment of refractory Type-1 cryoglobulinaemia.

  British journal of haematology 20100701

• Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib.

  International journal of colorectal disease 20100701

• The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses.

  Journal of leukocyte biology 20100701

• G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.

  Carcinogenesis 20100701

• Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.

  Leukemia & lymphoma 20100701

• Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100701

• Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.

  Leukemia 20100701

• Experiences with bortezomib in multiple myeloma - from Phase II studies to daily practice.

  International journal of clinical pharmacology and therapeutics 20100701

• Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.

  Cancer 20100701

• PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.

  Molecular cancer therapeutics 20100701

• Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial.

  Leukemia & lymphoma 20100701

• Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experience.

  American journal of hematology 20100701

• Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib.

  Pharmacotherapy 20100701

• Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.

  Gut 20100701

• Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.

  Molecular cancer therapeutics 20100701

• Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells.

  Neoplasia (New York, N.Y.) 20100701

• A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.

  Blood 20100624

• Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates.

  Transplantation 20100615

• Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.

  British journal of cancer 20100608

• The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.

  Blood 20100603

• Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells.

  Oncogene 20100603

• New targets of PS-341: BAFF and APRIL.

  Medical oncology (Northwood, London, England) 20100601

• A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20100601

• Future directions in immunomodulatory therapy.

  Medical oncology (Northwood, London, England) 20100601

• New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer.

  The Prostate 20100601

• Bortezomib upregulates [corrected] the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease.

  Leukemia research 20100601

• Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice.

  Experimental neurology 20100601

• Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain.

  British journal of haematology 20100601

• Advances in treatment for relapses and refractory multiple myeloma.

  Medical oncology (Northwood, London, England) 20100601

• Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition.

  Cancer science 20100601

• Detrimental effect of the proteasome inhibitor, bortezomib in bacterial superantigen- and lipopolysaccharide-induced systemic inflammation.

  Molecular therapy : the journal of the American Society of Gene Therapy 20100601

• MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.

  Cancer biology & therapy 20100601

• Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial.

  Leukemia 20100601

• Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma.

  International journal of hematology 20100601

• Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib.

  Cancer research 20100601

• Macroautophagy modulates cellular response to proteasome inhibitors in cancer therapy.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20100601

• Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.

  Cancer genetics and cytogenetics 20100601

• Treatment with bortezomib of a patient having hyper IgG4 disease.

  Clinical lymphoma, myeloma & leukemia 20100601

• Intracranial multifocal dural involvement in multiple myeloma: case report and review of the literature.

  Clinical lymphoma, myeloma & leukemia 20100601

• Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie.

  Mayo Clinic proceedings 20100601

• The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib.

  Molecular cancer therapeutics 20100601

• Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.

  Molecular cancer therapeutics 20100601

• Cardiotoxicity of the anticancer therapeutic agent bortezomib.

  The American journal of pathology 20100601

• PRDM1 is required for mantle cell lymphoma response to bortezomib.

  Molecular cancer research : MCR 20100601

• [Proteasome inhibitor].

  Nihon rinsho. Japanese journal of clinical medicine 20100601

• [Effect of bortezomib on sensitization of HL-60 cells to TRAIL].

  Zhongguo shi yan xue ye xue za zhi 20100601

• [Effect of bortezomib on VEGF gene expression of endothelial cell line HMEC-1 and its possible mechanisms].

  Zhongguo shi yan xue ye xue za zhi 20100601

• [Mechanism of bortezomib in inducing apoptosis and improving chemosensitivity of Ishikawa cells].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20100601

• Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells.

  Anticancer research 20100601

• Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia.

  Anticancer research 20100601

• Bortezomib-associated late hepatitis B reactivation in a case of multiple myeloma.

  The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 20100601

• [Proteasome inhibitors sensitize ovarian cancer cells to cisplatin].

  Zhonghua fu chan ke za zhi 20100601

• Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

  Blood 20100527

• Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.

  The Journal of biological chemistry 20100521

• Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity.

  Blood 20100506

• Bortezomib-induced acute pancreatitis.

  JOP : Journal of the pancreas 20100505

• Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance.

  Journal of cardiovascular medicine (Hagerstown, Md.) 20100501

• A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20100501

• Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.

  Annals of hematology 20100501

• In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.

  Haematologica 20100501

• Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP).

  Annals of hematology 20100501

• Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia.

  Stroke 20100501

• Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide.

  Leukemia & lymphoma 20100501

• Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma.

  Nature reviews. Clinical oncology 20100501

• How best to use new therapies in multiple myeloma.

  Blood reviews 20100501

• [Waldenström's macroglobulinemia].

  La Revue de medecine interne 20100501

• Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100501

• Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient.

  Yonsei medical journal 20100501

• Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy.

  Cancer research 20100501

• ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination.

  Cancer research 20100501

• Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.

  The Journal of thoracic and cardiovascular surgery 20100501

• Bortezomib effectiveness in one patient with acquired von Willebrand syndrome associated to monoclonal gammopathy of undetermined significance.

  American journal of hematology 20100501

• Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.

  Molecular cancer research : MCR 20100501

• Clinical management of myeloma--state of the art.

  Cancer treatment reviews 20100501

• Management of treatment-related adverse events in patients with multiple myeloma.

  Cancer treatment reviews 20100501

• Multiple myeloma - current issues and controversies.

  Cancer treatment reviews 20100501

• Optimising patient outcomes in myeloma.

  Cancer treatment reviews 20100501

• Frontline regimens for multiple myeloma patients.

  Clinical advances in hematology & oncology : H&O 20100501

• IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen.

  Wiener klinische Wochenschrift 20100501

• Retrospective case series of three patients with plasma cell leukemia treated with bortezomib-based regimens.

  Clinical therapeutics 20100501

• Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance.

  Oncotarget 20100501

• Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors.

  Oncotarget 20100501

• Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.

  Blood 20100422

• Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100420

• Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.

  The Tokai journal of experimental and clinical medicine 20100420

• Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).

  Lung cancer (Amsterdam, Netherlands) 20100401

• Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20100401

• Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.

  Leukemia research 20100401

• Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats.

  European journal of pain (London, England) 20100401

• Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis.

  Journal of neuro-oncology 20100401

• Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells.

  Urology 20100401

• Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status.

  Leukemia research 20100401

• Home administration of bortezomib: making a difference to myeloma patients' lives.

  European journal of oncology nursing : the official journal of European Oncology Nursing Society 20100401

• Captivating bortezomib: an active but still mysterious drug.

  Leukemia research 20100401

• First report of a medullar cord compression secondary to osseous plasmacytoma successfully treated with bortezomib and dexamethasone.

  Leukemia research 20100401

• Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100401

• Multiple lipoma with hyperlipidemia in a multiple myeloma patient treated with bortezomib/dexamethazone.

  Leukemia research 20100401

• Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record.

  Leukemia research 20100401

• Bortezomib induces autophagic death in proliferating human endothelial cells.

  Experimental cell research 20100401

• NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.

  The Journal of investigative dermatology 20100401

• Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration.

  European journal of haematology 20100401

• Inhibition of mTORC1 activity by REDD1 induction in myeloma cells resistant to bortezomib cytotoxicity.

  Cancer science 20100401

• Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.

  Leukemia 20100401

• Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia.

  Archives of toxicology 20100401

• Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies.

  The American journal of pathology 20100401

• Novel agents in development for peripheral T-cell lymphoma.

  Seminars in hematology 20100401

• Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.

  Clinical lymphoma, myeloma & leukemia 20100401

• Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib.

  Clinical lymphoma, myeloma & leukemia 20100401

• Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.

  Clinical lymphoma, myeloma & leukemia 20100401

• Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice.

  Clinical lymphoma, myeloma & leukemia 20100401

• Rapid fatal pulmonary complications in a Chinese patient after bortezomib treatment for ALK-negative anaplastic large-cell lymphoma.

  Clinical lymphoma, myeloma & leukemia 20100401

• A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer.

  Clinical colorectal cancer 20100401

• Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).

  Hematology (Amsterdam, Netherlands) 20100401

• [Severe bortezomib-induced peripheral neuropathy in a patient with multiple myeloma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20100401

• [Arsenic trioxide enhances the effects of bortezomib, dexamethasone on multiple myeloma cell line KM3 in vitro.].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20100401

• Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.

  Blood 20100318

• Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.

  Oncogene 20100311

• Synthesis, in vitro and in vivo biological evaluation, docking studies, and structure--activity relationship (SAR) discussion of dipeptidyl boronic acid proteasome inhibitors composed of beta-amino acids.

  Journal of medicinal chemistry 20100311

• Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100310

• The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression.

  The Journal of biological chemistry 20100305

• Bmf is upregulated by PS-341-mediated cell death of glioma cells through JNK phosphorylation.

  Molecular biology reports 20100301

• Severe pulmonary complications after bortezomib treatment in multiple myeloma.

  Hematological oncology 20100301

• High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents.

  Leukemia research 20100301

• DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.

  European journal of haematology 20100301

• Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant.

  Haematologica 20100301

• Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.

  British journal of haematology 20100301

• Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.

  European journal of haematology 20100301

• Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma.

  European journal of haematology 20100301

• Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.

  European journal of haematology 20100301

• Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.

  European journal of haematology 20100301

• Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.

  Leukemia 20100301

• Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.

  Drug discovery today 20100301

• Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20100301

• Effect of proteasome inhibitors with different chemical structures on the ubiquitin-proteasome system in vitro.

  Veterinary pathology 20100301

• Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors.

  International journal of oncology 20100301

• Recurrent capillary leak syndrome following bortezomib therapy in a patient with relapsed myeloma.

  The Annals of pharmacotherapy 20100301

• Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.

  Cancer research 20100301

• The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack.

  Cancer research 20100301

• Allergy for a lifetime?

  Allergology international : official journal of the Japanese Society of Allergology 20100301

• [Analysis of high-risk multiple myeloma patients treated with high-dose chemotherapy].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20100301

• Bortezomib induces apoptosis in human neuroblastoma CHP126 cells.

  Die Pharmazie 20100301

• [Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].

  Vnitrni lekarstvi 20100301

• What should work, may not.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20100301

• Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.

  Journal of the peripheral nervous system : JPNS 20100301

• Drug-mediated and cellular immunotherapy in multiple myeloma.

  Immunotherapy 20100301

• Regulation of endoplasmic reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells.

  The Journal of biological chemistry 20100226

• Studies of the synthesis of all stereoisomers of MG-132 proteasome inhibitors in the tumor targeting approach.

  Journal of medicinal chemistry 20100225

• Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100220

• Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma.

  Talanta 20100215

• Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.

  Transplantation 20100215

• Proteasomal regulation of pulmonary fibrosis.

  Proceedings of the American Thoracic Society 20100215

• Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100210

• The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02.

  International journal of laboratory hematology 20100201

• Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons.

  Neurotoxicity research 20100201

• Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant).

  Annals of hematology 20100201

• Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.

  Leukemia research 20100201

• Bortezomib: a new therapeutic option for POEMS syndrome.

  European journal of haematology 20100201

• Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2.

  Leukemia research 20100201

• Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.

  British journal of haematology 20100201

• The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.

  British journal of haematology 20100201

• Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma.

  Leukemia & lymphoma 20100201

• Cutting edge: bortezomib-treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells.

  Journal of immunology (Baltimore, Md. : 1950) 20100201

• Thalidomide-induced phrenic nerve paralysis.

  Leukemia & lymphoma 20100201

• Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.

  Leukemia & lymphoma 20100201

• Osteoblastogenesis and tumor growth in myeloma.

  Leukemia & lymphoma 20100201

• Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.

  Expert opinion on investigational drugs 20100201

• Drug discovery and assay development in the ubiquitin-proteasome system.

  Biochemical Society transactions 20100201

• The therapeutic potential of deubiquitinating enzyme inhibitors.

  Biochemical Society transactions 20100201

• Bortezomib: a new pro-apoptotic agent in cancer treatment.

  Current cancer drug targets 20100201

• Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.

  Molecular cancer therapeutics 20100201

• Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.

  Haematologica 20100201

• Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.

  Journal of the National Comprehensive Cancer Network : JNCCN 20100201

• Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma.

  Clinical lymphoma, myeloma & leukemia 20100201

• Treatment of human respiratory syncytial virus infected Balb/C mice with the proteasome inhibitor bortezomib (Velcade, PS-341) results in increased inflammation and mortality.

  Toxicology 20100131

• Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B.

  Life sciences 20100130

• Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib.

  Blood 20100128

• Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells.

  Oncogene 20100121

• Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.

  Blood 20100121

• Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors.

  Cardiovascular research 20100115

• Acute humoral rejection in a lung recipient: reversion with bortezomib.

  Transplantation 20100115

• Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100115

• Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100115

• Identification of USP18 as an important regulator of the susceptibility to IFN-alpha and drug-induced apoptosis.

  Cancer research 20100115

• [Molecular-targeted therapy of multiple myeloma].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20100110

• Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma.

  Blood 20100107

• Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

  Blood 20100107

• Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition.

  Leukemia research 20100101

• Proteasome inhibitor bortezomib promotes a rupture-prone plaque phenotype in ApoE-deficient mice.

  Basic research in cardiology 20100101

• The ubiquitin-proteasome system regulates the stability of neuronal nicotinic acetylcholine receptors.

  Journal of molecular neuroscience : MN 20100101

• 'Short course' bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20100101

• Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma.

  Leukemia & lymphoma 20100101

• TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species.

  Leukemia 20100101

• Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma.

  Neoplasma 20100101

• Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.

  Molecular therapy : the journal of the American Society of Gene Therapy 20100101

• Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents.

  Dermatology (Basel, Switzerland) 20100101

• Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.

  Journal of hepatology 20100101

• Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma.

  European journal of cancer (Oxford, England : 1990) 20100101

• Heat stress triggers apoptosis by impairing NF-kappaB survival signaling in malignant B cells.

  Leukemia 20100101

• Salmonella enteritidis necrotising fasciitis in a multiple myeloma patient receiving bortezomib.

  International journal of hematology 20100101

• An unusual case of transient dermatological reaction to bortezomib in AL amyloidosis.

  International journal of hematology 20100101

• A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100101

• Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells.

  Cancer research 20100101

• New treatments for myeloma.

  Joint, bone, spine : revue du rhumatisme 20100101

• Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib.

  Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20100101

• Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70.

  PLoS genetics 20100101

• The AJT report: news and issues that affect organ and tissue transplantation. Wrestling with positive cross-matches. A look at some of the newer desensitization therapies.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20100101

• INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.

  Neoplasia (New York, N.Y.) 20100101

• Bortezomib.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101

• Current multiple myeloma treatment strategies with novel agents: a European perspective.

  The oncologist 20100101

• Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types.

  Journal of experimental & clinical cancer research : CR 20100101

• New developments in the treatment of patients with multiple myeloma.

  The Netherlands journal of medicine 20100101

• Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells.

  Autophagy 20100101

• The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro.

  Anticancer research 20100101

• Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors.

  Anticancer research 20100101

• Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.

  Molecular cancer 20100101

• [Effect of bortezomib and arabinoside on proliferation and apoptosis of K562 cell.].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20100101

• The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide.

  Onkologie 20100101

• Transcriptional regulation of matrix metalloproteinase-1 and collagen 1A2 explains the anti-fibrotic effect exerted by proteasome inhibition in human dermal fibroblasts.

  Arthritis research & therapy 20100101

• Angiotensin I-converting enzyme Gln1069Arg mutation impairs trafficking to the cell surface resulting in selective denaturation of the C-domain.

  PloS one 20100101

• Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.

  Swiss medical weekly 20100101

• Characterization of bortezomib-adapted I-45 mesothelioma cells.

  Molecular cancer 20100101

• Comparison of therapeutic efficacy between bortezomib and combination treatment of prednisolone and mycophenolate mofetil on nephritis in NZB/WF1 mice.

  Clinical and experimental rheumatology 20100101

• Reversible posterior encephalopathy syndrome associated with bortezomib.

  Internal medicine journal 20100101

• Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells.

  Molecular cancer 20100101

• Clinical value of absolute lymphocyte counts before bortezomib-dexamethasone therapy in relapsed multiple myeloma patients.

  Acta haematologica 20100101

• Characterization of side populations in HNSCC: highly invasive, chemoresistant and abnormal Wnt signaling.

  PloS one 20100101

• No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.

  BMC cancer 20100101

• [Bortezomib in multiple myeloma patients after allogeneic stem cell transplantation].

  Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20100101

• [Effectiveness of bortezomib and bortezomib-containing programs for the treatment of recurrent and resistant multiple myeloma].

  Terapevticheskii arkhiv 20100101

• Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death.

  BMC cancer 20100101

• Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.

  PloS one 20100101

• Investigation of the eIF2alpha phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells.

  Molekuliarnaia biologiia 20100101

• Targeted therapy in lymphoma.

  Journal of hematology & oncology 20100101

• Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients.

  Journal of translational medicine 20100101

• The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group.

  PloS one 20100101

• Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.

  Oncology 20100101

• Successful treatment of early relapse of ocular myeloma with bortezomib and steroid after autologous stem cell transplantation.

  Bratislavske lekarske listy 20100101

• Synergistic induction of apoptosis in HeLa cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitor SAHA.

  Molecular medicine reports 20100101

• An update on antibody reduction and rejection reversal following bortezomib use: a report of 52 cases across 10 centers.

  Clinical transplants 20100101

• Bortezomib for desensitization of patients on a waiting list for deceased donor kidney transplant: experience in Mexico City.

  Clinical transplants 20100101

• Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.

  Clinical transplants 20100101

• Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report.

  Clinical transplants 20100101

• Targeting alloantibody production with bortezomib: does it make more sense?

  Clinical transplants 20100101

• 1.7 year follow-up after bortezomib therapy for refractory antibody mediated rejection.

  Clinical transplants 20100101

• Bortezomib alone fails to decrease donor specific anti-HLA antibodies: even after one year post-treatment.

  Clinical transplants 20100101

• Bortezomib as rescue therapy for antibody mediated rejection: a single-center experience.

  Clinical transplants 20100101

• Reduction in proteinuria with bortezomib based therapy for antibody mediated rejection.

  Clinical transplants 20100101

• Bortezomib for acute humoral rejection treatment at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City: an update.

  Clinical transplants 20100101

• Bortezomib use in chronic antibody-mediated allograft dysfunction: updates and additional cases.

  Clinical transplants 20100101

• Rescue therapy for acute antibody mediated rejection with a proteosome inhibitor after kidney transplantation.

  Clinical transplants 20100101

• MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.

  Cancer letters 20091228

• Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates.

  Transplantation 20091227

• VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091220

• Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.

  Blood 20091217

• Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.

  Cancer research 20091215

• The 26 S proteasome: from basic mechanisms to drug targeting.

  The Journal of biological chemistry 20091204

• Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis.

  Investigational new drugs 20091201

• Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells.

  Cancer immunology, immunotherapy : CII 20091201

• Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.

  European journal of haematology 20091201

• Proteasome inhibition for antibody-mediated rejection.

  Current opinion in organ transplantation 20091201

• Successful bortezomib-based treatment in POEMS syndrome.

  European journal of haematology 20091201

• The use of novel agents in the treatment of relapsed and refractory multiple myeloma.

  Leukemia 20091201

• Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.

  Leukemia research 20091201

• Relapse/Refractory myeloma patient: potential treatment guidelines.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091201

• Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091201

• [Update in multiple myeloma: international criteria for treatment response and renal complications].

  La Revue de medecine interne 20091201

• Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications.

  Cell cycle (Georgetown, Tex.) 20091201

• The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models.

  Molecular cancer therapeutics 20091201

• Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091201

• Hematology: first-line bortezomib benefits patients with multiple myeloma.

  Nature reviews. Clinical oncology 20091201

• Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.

  Clinical lymphoma & myeloma 20091201

• Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.

  Transplantation proceedings 20091201

• Potentiation of (-)-epigallocatechin-3-gallate-induced apoptosis by bortezomib in multiple myeloma cells.

  Acta biochimica et biophysica Sinica 20091201

• Treatment of multiple myeloma: 2009 update.

  Prescrire international 20091201

• Combined effects of bortezomib and daunorubicin on multiple myeloma cell KM3 in vitro.

  Zhongguo shi yan xue ye xue za zhi 20091201

• [Retrospective analysis of 71 cases of multiple myeloma].

  Zhongguo shi yan xue ye xue za zhi 20091201

• Cutaneous lymphoid perivascular reaction with atypical CD30+ T cells in a patient with multiple myeloma treated with bortezomib.

  Clinical and experimental dermatology 20091201

• [IgM-lambda multiple myeloma presenting with systemic amyloidosis].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20091201

• [Apoptosis in Jurkat cells induced by bortezomib combined with adriamycin].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20091201

• Multiple myeloma patients experience high response rate with new three-drug combination.

  Cancer biology & therapy 20091201

• [Classification and synthesis of ubiquitin-proteasome inhibitor].

  Yao xue xue bao = Acta pharmaceutica Sinica 20091201

• The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.

  Journal of immunology (Baltimore, Md. : 1950) 20091115

• Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines.

  Chembiochem : a European journal of chemical biology 20091102

• Bortezomib attenuates murine collagen-induced arthritis.

  Annals of the rheumatic diseases 20091101

• Cutaneous involvement in multiple myeloma and bortezomib.

  Annals of hematology 20091101

• DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.

  Annals of hematology 20091101

• Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation.

  Cancer letters 20091101

• Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma.

  Leukemia 20091101

• Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived.

  European journal of haematology 20091101

• Combating endometriosis by blocking proteasome and nuclear factor-kappaB pathways.

  Human reproduction (Oxford, England) 20091101

• TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.

  British journal of haematology 20091101

• Activation of SHIP via a small molecule agonist kills multiple myeloma cells.

  Experimental hematology 20091101

• A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.

  Gynecologic oncology 20091101

• Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.

  British journal of haematology 20091101

• Proteasome inhibition activates the mitochondrial pathway of apoptosis in human CD4+ T cells.

  Journal of cellular biochemistry 20091101

• Proteasome inhibitors in the treatment of multiple myeloma.

  Leukemia 20091101

• Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization.

  Cancer research 20091101

• Bortezomib and restoration of chemosensitivity.

  Nature reviews. Clinical oncology 20091101

• Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system.

  Molecular cancer therapeutics 20091101

• Commentary on Perrone et al.: 'vitamin C: not for breakfast anymore...if you have myeloma'.

  Leukemia 20091101

• Multiple myeloma with multiple and bulky extramedullary plasmacytomas as initial presentation.

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20091101

• [2-methoxyestradiol disrupts aggresomes induction by bortezomib and potentiates apoptosis in multiple myeloma cells.].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20091101

• Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.

  Blood 20091029

• GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib.

  Blood 20091029

• Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091020

• Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091020

• Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

  Cancer cell 20091006

• Proteasome inhibitors in cancer therapy.

  Current drug targets 20091001

• Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).

  Cancer 20091001

• Cutaneous myeloma and bortezomib.

  Annals of hematology 20091001

• Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer.

  Laboratory investigation; a journal of technical methods and pathology 20091001

• Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.

  British journal of haematology 20091001

• Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Krüppel-like transcription factors.

  Arteriosclerosis, thrombosis, and vascular biology 20091001

• Donor cell-derived acute lymphocytic leukemia after allogeneic stem cell transplantation for multiple myeloma.

  International journal of hematology 20091001

• Neurological adverse effects caused by cytotoxic and targeted therapies.

  Nature reviews. Clinical oncology 20091001

• Cord blood transplantation with a reduced-intensity conditioning regimen for patients with relapsed aggressive multiple myeloma after cytoreduction with bortezomib.

  International journal of hematology 20091001

• Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.

  American journal of hematology 20091001

• Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors.

  Bioorganic & medicinal chemistry 20091001

• Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.

  Journal of immunology (Baltimore, Md. : 1950) 20091001

• Selectively killing transformed cells through proteasome inhibition.

  Cell cycle (Georgetown, Tex.) 20091001

• [Synergistic effects of proteasome inhibitor and histone deacetylase inhibitor on apoptosis and aggresome formation in T lymphoma cells].

  Zhongguo shi yan xue ye xue za zhi 20091001

• Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment.

  Clinical lymphoma & myeloma 20091001

• Novel therapies in the treatment of multiple myeloma.

  Journal of the National Comprehensive Cancer Network : JNCCN 20091001

• [Hematopoietic stem cell transplantation for multiple myeloma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20091001

• [New treatment strategies for multiple myeloma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20091001

• [IgA pemphigus accompanying multiple myeloma].

  Vnitrni lekarstvi 20091001

• [IgA pemphigus accompanying multiple myeloma has disappeared following the treatment with bortezomib (Velcade), cyclophosphamide and dexamethasone. Case study and literature review].

  Vnitrni lekarstvi 20091001

• Frontline therapy in mantle cell lymphoma: the role of high-dose therapy and integration of new agents.

  Current hematologic malignancy reports 20091001

• Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090920

• Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions.

  Oncogene 20090910

• Therapeutic use of tea derivatives: all that glitters is not gold.

  Blood 20090910

• Initial therapy in multiple myeloma: investigating the new treatment paradigm.

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20090901

• Ascorbic acid inhibits antitumor activity of bortezomib in vivo.

  Leukemia 20090901

• Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone.

  Leukemia research 20090901

• The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor.

  British journal of haematology 20090901

• Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.

  British journal of haematology 20090901

• Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.

  British journal of haematology 20090901

• The future of small molecule inhibitors in lymphoma.

  Current oncology reports 20090901

• Nuclear factor kappaB inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish embryos.

  Molecular cancer therapeutics 20090901

• Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.

  Molecular cancer therapeutics 20090901

• [Establishment of a bortezomib-resistant myeloma cell line and differential proteins analysis by MALDI-OF-MS].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20090901

• [The effects and safety of bortezomib combined with dexamethasone in the treatment of primary systemic amyloidosis].

  Zhonghua nei ke za zhi 20090901

• Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.

  Blood 20090827

• Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.

  Journal of medicinal chemistry 20090827

• [Current treatment of follicular lymphoma].

  Revue medicale suisse 20090826

• Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.

  Blood 20090820

• Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.

  Experimental cell research 20090815

• Simultaneous proteosome inhibition and heat shock protein induction by bortezomib is beneficial in experimental pancreatitis.

  European journal of pharmacology 20090815

• Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.

  Cancer research 20090815

• Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090815

• Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090810

• Bortezomib reverses a post-translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma.

  Pediatric blood & cancer 20090801

• The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.

  Leukemia 20090801

• Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib.

  Leukemia research 20090801

• Monitoring and treating posttransplant human leukocyte antigen antibodies.

  Human immunology 20090801

• Potent anti-inflammatory effects of low-dose proteasome inhibition in the vascular system.

  Journal of molecular medicine (Berlin, Germany) 20090801

• The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury.

  American journal of physiology. Renal physiology 20090801

• Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction.

  British journal of haematology 20090801

• A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090801

• Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.

  Molecular cancer therapeutics 20090801

• An audience with...Joseph Bolen. Interview by Bethan Hughes.

  Nature reviews. Drug discovery 20090801

• Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.

  Anticancer research 20090801

• [Very good partial response and long time to progression by short-term bortezomib plus dexamethasone therapy for a patient with relapsed and refractory multiple myeloma-a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090801

• Bortezomib: the subtle line between drug-induced peripheral neuropathy and post-herpetic neuralgia.

  Clinical lymphoma & myeloma 20090801

• Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.

  Clinical lymphoma & myeloma 20090801

• [Combination of bortezomib and dexamethasone for newly diagnosed multiple myeloma].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20090801

• Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.

  Blood 20090730

• Multiple myeloma.

  Lancet (London, England) 20090725

• High levels of tRNA abundance and alteration of tRNA charging by bortezomib in multiple myeloma.

  Biochemical and biophysical research communications 20090724

• Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of alpha-amino acid boronates.

  Journal of medicinal chemistry 20090723

• Effects of the BH3-only protein human Noxa on mitochondrial dynamics.

  FEBS letters 20090721

• Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090720

• Proteasome inhibitors block HIV-1 replication by affecting both cellular and viral targets.

  Biochemical and biophysical research communications 20090717

• Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids.

  American journal of respiratory cell and molecular biology 20090701

• Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

  Leukemia 20090701

• Novel therapies for peripheral T-cell non-Hodgkin's lymphomas.

  Current opinion in hematology 20090701

• Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.

  Experimental hematology 20090701

• Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.

  Leukemia & lymphoma 20090701

• Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.

  Japanese journal of clinical oncology 20090701

• Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population.

  Haematologica 20090701

• Effect of autophagy on multiple myeloma cell viability.

  Molecular cancer therapeutics 20090701

• Rounding up apoptosis resistance targets in lung cancer.

  American journal of respiratory cell and molecular biology 20090701

• Successful mobilization of peripheral blood stem cells with bortezomib + high-dose cyclophosphamide + G-CSF in a light chain myeloma patient after failure with Total Therapy 2.

  International journal of hematology 20090701

• Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.

  Cancer research 20090701

• Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.

  Journal of the National Cancer Institute 20090701

• Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.

  Molecular cancer therapeutics 20090701

• Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy.

  Molecular cancer therapeutics 20090701

• Worsening low back pain.

  The Journal of family practice 20090701

• Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis.

  The Journal of biological chemistry 20090619

• Synthesis and biological evaluation of boron peptide analogues of Belactosin C as proteasome inhibitors.

  Bioorganic & medicinal chemistry letters 20090615

• Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.

  Cell cycle (Georgetown, Tex.) 20090615

• Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090615

• Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells.

  Blood 20090611

• Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.

  Blood 20090611

• From orbital hybridization to chemotherapeutics neutralization.

  Blood 20090611

• Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.

  Blood 20090604

• Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies.

  International journal of radiation oncology, biology, physics 20090601

• AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib.

  European journal of haematology 20090601

• Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.

  European journal of haematology 20090601

• Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells.

  Leukemia 20090601

• Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).

  Leukemia 20090601

• Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.

  European journal of haematology 20090601

• Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.

  British journal of haematology 20090601

• Effect of proteasome inhibitors on endotoxin-induced diaphragm dysfunction.

  American journal of physiology. Lung cellular and molecular physiology 20090601

• Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells.

  Leukemia & lymphoma 20090601

• Bioactive 5,6-dihydro-alpha-pyrone derivatives from Hyptis brevipes.

  Journal of natural products 20090601

• Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma.

  Leukemia & lymphoma 20090601

• Bortezomib-induced lupus erythematosus tumidus.

  The oncologist 20090601

• Bortezomib in treatment of extramedullary plasmacytoma of the pancreas.

  Hepatobiliary & pancreatic diseases international : HBPD INT 20090601

• Multiple significant bortezomib-related toxicities in one patient: case report and literature review.

  Clinical lymphoma & myeloma 20090601

• Combination effect between bortezomib and tumor necrosis factor alpha on gefitinib-resistant non-small cell lung cancer cell lines.

  Anticancer research 20090601

• [Apoptosis of Burkitt's lymphoma Raji cell line induced by bortezomib].

  Zhongguo shi yan xue ye xue za zhi 20090601

• Bortezomib for the treatment of multiple myeloma patients.

  Health technology assessment (Winchester, England) 20090601

• [Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20090601

• Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells.

  International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 20090601

• Multiple myeloma, painful neuropathy, acupuncture?

  American journal of clinical oncology 20090601

• [Effect of bortezomib on acute graft-versus-host disease in mice model and its mechanism].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20090601

• Abrogation of anti-HLA antibodies via proteasome inhibition.

  Transplantation 20090527

• PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090515

• The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.

  Cancer research 20090515

• Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

  Journal of medicinal chemistry 20090514

• Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

  Blood 20090507

• Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor.

  British journal of cancer 20090505

• Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study.

  Bone marrow transplantation 20090501

• Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines.

  European journal of nuclear medicine and molecular imaging 20090501

• Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.

  Leukemia 20090501

• ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.

  Molecular pharmacology 20090501

• Inhibitors of the ubiquitin-proteasome system are not all alike: identification of a new necrotic pathway.

  Autophagy 20090501

• Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.

  Cancer biology & therapy 20090501

• Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.

  American journal of hematology 20090501

• Does bortezomib induce de facto varicella zoster virus reactivation in patients with multiple myeloma?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090501

• Early gene expression changes induced by the bacterial superantigen staphylococcal enterotoxin B and its modulation by a proteasome inhibitor.

  Physiological genomics 20090501

• A phase II study of bortezomib in patients with MALT lymphoma.

  Haematologica 20090501

• Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.

  British journal of haematology 20090501

• A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study.

  Leukemia & lymphoma 20090501

• [Therapeutic news in multiple myeloma. Congress of the French National Society of Internal Medicine, December 2008, Bordeaux].

  La Revue de medecine interne 20090501

• Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.

  Cancer research 20090501

• Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients.

  Internal medicine journal 20090501

• Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.

  Molecular cancer therapeutics 20090501

• Hematology: Bortezomib in newly diagnosed multiple myeloma.

  Nature reviews. Clinical oncology 20090501

• Targeting the proteasome pathway.

  Expert opinion on therapeutic targets 20090501

• Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas.

  The oncologist 20090501

• [Multiple myeloma].

  Nihon rinsho. Japanese journal of clinical medicine 20090501

• [Bortezomib-induced eruption: Sweet syndrome? Two case reports].

  Annales de dermatologie et de venereologie 20090501

• [Bortezomib-induced neutrophilic dermatosis with CD30+ lymphocytic infiltration].

  Annales de dermatologie et de venereologie 20090501

• [Bortezomib-induced acute neutrophilic dermatosis].

  Annales de dermatologie et de venereologie 20090501

• Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.

  Leukemia & lymphoma 20090501

• Piling up the JNK: drug synergy through ER stress.

  Cancer biology & therapy 20090501

• [A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas].

  Zhonghua nei ke za zhi 20090501

• microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.

  Blood 20090430

• CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

  Blood 20090430

• Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.

  Blood 20090430

• Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.

  Blood 20090430

• Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.

  The Journal of biological chemistry 20090424

• Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability.

  Blood 20090423

• Synthesis of boronic acid derivatives of tyropeptin: proteasome inhibitors.

  Bioorganic & medicinal chemistry letters 20090415

• Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090415

• Bortezomib in combination with dexamethasone for a young multiple myeloma with t(8; 14).

  Leukemia research 20090401

• Bortezomib-induced neurogenic bladder in patients with multiple myeloma.

  Annals of hematology 20090401

• Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma.

  Leukemia research 20090401

• A striking response to bortezomib in a patient with pleural localization of multiple myeloma.

  Leukemia research 20090401

• Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.

  Reproductive sciences (Thousand Oaks, Calif.) 20090401

• High-content functional screen to identify proteins that correct F508del-CFTR function.

  Molecular & cellular proteomics : MCP 20090401

• 'Change can happen' by PKA: proteasomes in in vivo hearts.

  Journal of molecular and cellular cardiology 20090401

• Bortezomib-related colon mucositis in a multiple myeloma patient.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20090401

• Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias.

  British journal of haematology 20090401

• Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial.

  British journal of haematology 20090401

• Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity.

  Haematologica 20090401

• Proteasome inhibition overcomes the resistance of renal cell carcinoma cells against the PPARgamma ligand troglitazone.

  Cellular and molecular life sciences : CMLS 20090401

• A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression.

  International journal of hematology 20090401

• Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment.

  Histopathology 20090401

• Restoration of chemosensitivity by bortezomib: implications for refractory myeloma.

  Nature reviews. Clinical oncology 20090401

• Bortezomib and Waldenstrom's macroglobulinemia.

  Expert opinion on pharmacotherapy 20090401

• Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model.

  Molecular cancer therapeutics 20090401

• Bortezomib in relapsed multiple myeloma: results of a non-interventional study by office-based haematologists.

  Onkologie 20090401

• Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.

  Seminars in hematology 20090401

• Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib.

  Clinical lymphoma & myeloma 20090401

• Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model.

  Anticancer research 20090401

• [PAD regimen for relapsed or refractory patients with multiple myeloma].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20090401

• Treatment of relapsed and refractory myeloma.

  Current hematologic malignancy reports 20090401

• The Isopeptidase Inhibitor G5 Triggers a Caspase-independent Necrotic Death in Cells Resistant to Apoptosis: A COMPARATIVE STUDY WITH THE PROTEASOME INHIBITOR BORTEZOMIB.

  The Journal of biological chemistry 20090327

• Regulation of multiple myeloma survival and progression by CD1d.

  Blood 20090312

• Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma.

  Leukemia 20090301

• Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.

  Journal of cancer research and clinical oncology 20090301

• Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.

  Thrombosis research 20090301

• Treatment of newly diagnosed myeloma.

  Leukemia 20090301

• Pathogenesis of myeloma bone disease.

  Leukemia 20090301

• Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels.

  Biochimie 20090301

• Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090301

• Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.

  Biochemical pharmacology 20090301

• Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.

  British journal of haematology 20090301

• Topical analgesic combinations for bortezomib neuropathy.

  Journal of pain and symptom management 20090301

• Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.

  British journal of haematology 20090301

• Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition.

  Clinical and experimental immunology 20090301

• [Depletion of plasma cells - a novel strategy in the therapy of systemic lupus erythematosus in mice and man].

  Zeitschrift fur Rheumatologie 20090301

• Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma.

  International journal of hematology 20090301

• Bortezomib-induced histiocytoid Sweet syndrome.

  Journal of the American Academy of Dermatology 20090301

• Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression.

  Cancer research 20090301

• Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.

  Haematologica 20090301

• Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.

  Cardiovascular & hematological disorders drug targets 20090301

• Proteasome inhibition promotes functional recovery after peripheral nerve reperfusion injury.

  The Journal of trauma 20090301

• 2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma.

  Electrophoresis 20090301

• Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.

  Clinical lymphoma & myeloma 20090301

• Role of proteasome inhibition in Waldenström's macroglobulinemia.

  Clinical lymphoma & myeloma 20090301

• [Establishment of a GFP-based cellular model for screening novel proteasome inhibitors].

  Sheng wu gong cheng xue bao = Chinese journal of biotechnology 20090301

• ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells.

  Proceedings of the National Academy of Sciences of the United States of America 20090217

• Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy.

  Cancer research 20090215

• Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090215

• The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090215

• A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.

  Investigational new drugs 20090201

• Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade).

  Bone marrow transplantation 20090201

• Generalized cutis laxa and fibrillar glomerulopathy resulting from IgG Deposition in IgG-lambda Monoclonal Gammopathy: pulmonary hemorrhage during stem cell mobilization and complete hematological response with bortezomib and dexamethasone therapy.

  European journal of haematology 20090201

• Treatment of light chain deposition disease with bortezomib and dexamethasone.

  Haematologica 20090201

• Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.

  Cancer science 20090201

• The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.

  Experimental cell research 20090201

• New evidence in oncologic and cardiocirculatory medicine.

  Internal and emergency medicine 20090201

• The persisting challenge of selective and specific proteasome inhibition.

  Journal of peptide science : an official publication of the European Peptide Society 20090201

• Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.

  Molecular cancer therapeutics 20090201

• Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.

  Molecular cancer therapeutics 20090201

• Proteasome inhibition blocks ligand-induced dynamic processing and internalization of epidermal growth factor receptor via altered receptor ubiquitination and phosphorylation.

  Cancer research 20090201

• Not boring at all. Boron is the new carbon in the quest for novel drug candidates.

  EMBO reports 20090201

• MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090201

• A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090201

• Treatment of multiple myeloma in the targeted therapy era.

  The Annals of pharmacotherapy 20090201

• [Bortezomib-induced BiP expression and apoptosis in multiple myeloma cells].

  Zhongguo shi yan xue ye xue za zhi 20090201

• [Bortezomib combined with other drugs for treating 60 cases of multiple myeloma].

  Zhongguo shi yan xue ye xue za zhi 20090201

• [Development of an extramedullary plasmacytoma despite disappearing M protein in multiple myeloma by bortezomib treatment].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20090201

• A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45.

  British journal of cancer 20090127

• Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.

  Blood 20090122

• BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis.

  FEBS letters 20090122

• Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.

  Oncogene 20090115

• Novel agents in myeloma: an exciting saga.

  Cancer 20090115

• Elucidation of potential bortezomib response markers in mutliple myeloma patients.

  Journal of pharmaceutical and biomedical analysis 20090115

• Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090115

• Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090115

• Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090115

• [Current concepts and treatment advances in systemic mastocytosis].

  La Revue de medecine interne 20090101

• Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).

  Archives of gynecology and obstetrics 20090101

• Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090101

• Enhancing transduction of the liver by adeno-associated viral vectors.

  Gene therapy 20090101

• Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6.

  Leukemia research 20090101

• An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer.

  European journal of cancer (Oxford, England : 1990) 20090101

• Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20090101

• The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.

  American journal of hematology 20090101

• In vitro activity of bortezomib in cultures of patient tumour cells--potential utility in haematological malignancies.

  Medical oncology (Northwood, London, England) 20090101

• Velcade sensitizes prostate cancer cells to TRAIL induced apoptosis and suppresses tumor growth in vivo.

  Cancer biology & therapy 20090101

• Effects of bortezomib on bone disease in multiple myeloma.

  American journal of hematology 20090101

• High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.

  British journal of haematology 20090101

• Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090101

• Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience.

  International journal of hematology 20090101

• Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy.

  Cancer 20090101

• Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090101

• Combination therapy with TRAIL: Recent developments and potential pitfalls.

  Cancer biology & therapy 20090101

• The ubiquitin-proteasome system contributes to the inflammatory injury in ischemic diabetic myocardium: the role of glycemic control.

  Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 20090101

• Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells.

  BMC cancer 20090101

• Proteasome inhibition reduces donor-specific antibody levels.

  Transplantation proceedings 20090101

• Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.

  Cytotherapy 20090101

• The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients.

  Clinical and experimental rheumatology 20090101

• Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells.

  Anticancer research 20090101

• Targeted therapy and hematological malignancy.

  Targeted oncology 20090101

• GC-1 mRHBDD1 knockdown spermatogonia cells lose their spermatogenic capacity in mouse seminiferous tubules.

  BMC cell biology 20090101

• Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.

  Clinical pharmacokinetics 20090101

• Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.

  Journal of hematology & oncology 20090101

• Bortezomib: a review of its use in patients with multiple myeloma.

  Drugs 20090101

• Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.

  Cutaneous and ocular toxicology 20090101

• Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo.

  Immunobiology 20090101

• Protein kinase Cdelta stimulates proteasome-dependent degradation of C/EBPalpha during apoptosis induction of leukemic cells.

  PloS one 20090101

• [Pharmacodynamic characteristics of velcade efficacy in resistant and recurrent multiple myeloma: determination of free light chains of blood serum immunoglobulins].

  Terapevticheskii arkhiv 20090101

• Bortezomib and liposomal doxorubicin are highly effective in obtaining the best possible response before autologous transplant for multiple myeloma.

  Acta haematologica 20090101

• MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma.

  Acta haematologica 20090101

• Further progress in the treatment of multiple myeloma?

  The National medical journal of India 20090101

• BU-32: a novel proteasome inhibitor for breast cancer.

  Breast cancer research : BCR 20090101

• An NMR Study of the Bortezomib Degradation under Clinical Use Conditions.

  Advances in hematology 20090101

• Bortezomib induces erythema multiforme-like cutaneous adverse effects: report of two cases.

  Wiener klinische Wochenschrift 20090101

• How to treat a newly diagnosed young patient with multiple myeloma.

  Hematology. American Society of Hematology. Education Program 20090101

• How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.

  Hematology. American Society of Hematology. Education Program 20090101

• Novel therapies for relapsed myeloma.

  Hematology. American Society of Hematology. Education Program 20090101

• ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?

  Hematology. American Society of Hematology. Education Program 20090101

• From the guest editor: the evolving treatment paradigm in multiple myeloma.

  Cancer journal (Sudbury, Mass.) 20090101

• Risk stratification in the era of novel therapies.

  Cancer journal (Sudbury, Mass.) 20090101

• Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates.

  Cancer journal (Sudbury, Mass.) 20090101

• Integrating novel therapies in the transplant paradigm.

  Cancer journal (Sudbury, Mass.) 20090101

• Novel agents for relapsed and/or refractory multiple myeloma.

  Cancer journal (Sudbury, Mass.) 20090101

• Evolving role of novel agents for maintenance therapy in myeloma.

  Cancer journal (Sudbury, Mass.) 20090101

• Future novel single agent and combination therapies.

  Cancer journal (Sudbury, Mass.) 20090101

• [IgA multiple myeloma with adverse prognostic factors--a case report].

  Przeglad lekarski 20090101

• Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.

  mAbs 20090101

• Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.

  Clinical therapeutics 20090101

• Enhancing apoptosis and overcoming resistance of gemcitabine in pancreatic cancer with bortezomib: a role of death-associated protein kinase-related apoptosis-inducing protein kinase 1.

  Tumori 20090101

• A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy.

  Clinical neurosurgery 20090101

• High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.

  Clinical transplantation 20090101

• Removal of physiologic corticosteroid doses results in HLA antibody appearance and allograft dysfunction in patients transplanted under a clonal deletion protocol.

  Clinical transplants 20090101

• A summary of bortezomib use in transplantation across 29 centers.

  Clinical transplants 20090101

• Bortezomib in kidney transplant desensitization: a case report.

  Clinical transplants 20090101

• Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC.

  Clinical transplants 20090101

• Use of bortezomib as adjunctive therapy for densensitization in combined heart and kidney transplantation--a case report.

  Clinical transplants 20090101

• Successful desensitization in a crossmatch positive living-related kidney transplant recipient using a bortezomib-based protocol.

  Clinical transplants 20090101

• Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases.

  Clinical transplants 20090101

• Bortezomib for antibody mediated rejection treatment: experience at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City.

  Clinical transplants 20090101

• The fate of anti-HLA antibody among renal transplantation recipients treated with bortezomib.

  Clinical transplants 20090101

• Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.

  Clinical transplants 20090101

• Bortezomib affects the function of human B cells: possible implications for desensitization protocols.

  Clinical transplants 20090101

• Desensitization protocol using bortezomib for highly sensitized patients awaiting heart or lung transplants.

  Clinical transplants 20090101

• Bortezomib in kidney transplant recipients with antibody mediated rejection: three case reports.

  Clinical transplants 20090101

• Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.

  Clinical transplants 20090101

• Proteasome inhibition for recipient desensitization? A report of two sensitized kidney transplant candidates subjected to bortezomib treatment.

  Clinical transplants 20090101

• Bortezomib in lung transplantation: a promising start.

  Clinical transplants 20090101

• Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?

  Clinical transplants 20090101

• Bortezomib rescue in refractory acute humoral rejection--report of a case.

  Clinical transplants 20090101

• Bortezomib alone fails to decrease donor specific anti-HLA antibodies: 4 case reports.

  Clinical transplants 20090101

• Bortezomib successfully reduces monoclonal serum free light chain levels in a patient with recurrent myeloma and cast nephropathy in the renal transplant.

  Clinical transplants 20090101

• Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients.

  Clinical transplants 20090101

• Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases.

  Clinical transplants 20090101

• Rescue therapy for early antibody mediated rejection with a proteasome inhibitor: a case report.

  Clinical transplants 20090101

• Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation.

  Clinical transplants 20090101

• Acute rejection in a highly sensitized lung transplant recipient with pre-formed donor-directed anti-HLA class II antibodies: role of bortezomib therapy.

  Clinical transplants 20090101

• Bortezomib for refractory antibody-mediated cardiac allograft rejection.

  Clinical transplants 20090101

• Bortezomib for acute humoral rejection in two repeat transplant recipients.

  Clinical transplants 20090101

• Bortezomib as a rescue therapy for hyperacute and multi-drug resistant mixed acute rejection after kidney transplantation.

  Clinical transplants 20090101

• Bortezomib does not reduce ABO-isoagglutinin titers and may not be useful for ABO-incompatible transplant desensitization.

  Clinical transplants 20090101

• Modulation of antibody response in a sensitized patient with ongoing antibody-mediated injury.

  Clinical transplants 20090101

• Use of bortezomib for prevention and treatment of rejection in sensitized patients.

  Clinical transplants 20090101

• Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series.

  Clinical transplants 20090101

• Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

  Transplantation 20081227

• Bortezomib plus melphalan and prednisone for multiple myeloma.

  The New England journal of medicine 20081211

• Bortezomib plus melphalan and prednisone for multiple myeloma.

  The New England journal of medicine 20081211

• Bortezomib plus melphalan and prednisone for multiple myeloma.

  The New England journal of medicine 20081211

• Cooperative relationship between pharmaceutical companies, academia, and media explains sharp decrease in frequency of pulmonary complications after bortezomib in Japan.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081210

• Distinct specificities of Mycobacterium tuberculosis and mammalian proteasomes for N-acetyl tripeptide substrates.

  The Journal of biological chemistry 20081205

• A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.

  Cancer chemotherapy and pharmacology 20081201

• A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.

  Cancer chemotherapy and pharmacology 20081201

• Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followed by autologous peripheral stem cell transplantation.

  Annals of hematology 20081201

• Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20081201

• Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.

  Haematologica 20081201

• The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.

  Leukemia 20081201

• Bortezomib-induced survival signals and genes in human proximal tubular cells.

  The Journal of pharmacology and experimental therapeutics 20081201

• Proteasome inhibition: a new therapeutic option in lupus nephritis?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20081201

• S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma.

  The Journal of pathology 20081201

• Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.

  International journal of oncology 20081201

• Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.

  International journal of molecular medicine 20081201

• Delayed complete remission in a patient with multiple myeloma.

  European journal of clinical investigation 20081201

• Bortezomib-associated tumor lysis syndrome in multiple myeloma.

  Leukemia & lymphoma 20081201

• Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.

  Clinical lymphoma & myeloma 20081201

• Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells.

  Molecular cancer therapeutics 20081201

• [The influence of bortezomib on HL-60 cell function induced by all-trans retinoic acid plus bufalin and its mechanism].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20081201

• Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.

  Journal of the peripheral nervous system : JPNS 20081201

• Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.

  Journal of the peripheral nervous system : JPNS 20081201

• Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells.

  Molecular oncology 20081201

• Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081115

• Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081115

• Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways.

  Cancer research 20081115

• Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.

  Dermatology online journal 20081115

• A C-terminal fragment of Cyclin E, generated by caspase-mediated cleavage, is degraded in the absence of a recognizable phosphodegron.

  The Journal of biological chemistry 20081107

• Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.

  Leukemia research 20081101

• Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib.

  Leukemia research 20081101

• Frontline treatment of multiple myeloma in elderly patients.

  Blood reviews 20081101

• Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease.

  Leukemia research 20081101

• Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.

  Blood 20081101

• The proteasome and its role in the degradation of oxidized proteins.

  IUBMB life 20081101

• Combating endometriosis by blocking proteasome and nuclear factor-kappaB pathways.

  Human reproduction (Oxford, England) 20081101

• Dynamic effect of bortezomib on nuclear factor-kappaB activity and gene expression in tumor cells.

  Molecular pharmacology 20081101

• Response to bortezomib in refractory type I cryoglobulinemia.

  American journal of hematology 20081101

• Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.

  British journal of haematology 20081101

• Immune-mediated neuropathies in myeloma patients treated with bortezomib.

  Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 20081101

• Advances in therapy of multiple myeloma.

  Current opinion in oncology 20081101

• Novel targets for myeloma bone disease.

  Expert opinion on therapeutic targets 20081101

• Effects of combination treatment of bortezomib and dexamethasone in SCCHN cell lines depend on tumor cell specificity.

  Oncology reports 20081101

• Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts.

  Oncology reports 20081101

• Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.

  British journal of haematology 20081101

• Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma.

  International journal of hematology 20081101

• Deborah Dunsire.

  Nature biotechnology 20081101

• Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.

  Molecular cancer therapeutics 20081101

• Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response.

  Leukemia & lymphoma 20081101

• [In vitro effect of bortezomib alone or in combination with harringtonine or arsenic trioxide on proliferation and apoptosis of multidrug resistant leukemia cells].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20081101

• IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis.

  Cancer research 20081015

• [Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation].

  Orvosi hetilap 20081012

• Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081010

• Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081010

• A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma.

  Oncogene 20081009

• In vivo investigations on anti-fibrotic potential of proteasome inhibition in lung and skin fibrosis.

  American journal of respiratory cell and molecular biology 20081001

• Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20081001

• A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma.

  Blood 20081001

• Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.

  Experimental hematology 20081001

• The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.

  Blood 20081001

• Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation.

  World journal of urology 20081001

• Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.

  Leukemia 20081001

• Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA.

  Blood 20081001

• The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.

  British journal of haematology 20081001

• Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan.

  International journal of hematology 20081001

• Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.

  British journal of haematology 20081001

• Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy.

  Leukemia & lymphoma 20081001

• Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors.

  Nature medicine 20081001

• Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells.

  International journal of molecular medicine 20081001

• [Treatment for multiple myeloma: current status and future strategy in Japan].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20081001

• A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab.

  Clinical lymphoma & myeloma 20081001

• Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial.

  Clinical lymphoma & myeloma 20081001

• [Effects of proteasome inhibitor bortezomib on NF-kappaB activity and ICAM-1 mRNA expression of K562 cells].

  Zhongguo shi yan xue ye xue za zhi 20081001

• [Inducing-apoptosis effect of bortezomib on acute monocytic leukemia cell SHI-1 and its influence on expressions of Bcl2l12, Bcl-2 and Bax genes].

  Zhongguo shi yan xue ye xue za zhi 20081001

• Simultaneous inhibition of the constitutively activated nuclear factor kappaB and of the interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells.

  Cell cycle (Georgetown, Tex.) 20081001

• Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.

  Leukemia & lymphoma 20081001

• The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs.

  Leukemia & lymphoma 20081001

• Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.

  Clinical advances in hematology & oncology : H&O 20081001

• [Proteasome inhibitors sensitize ovarian cancer cells to paclitaxel induced apoptosis].

  Zhonghua fu chan ke za zhi 20081001

• Diagnosis and the current trends in multiple myeloma therapy.

  Polskie Archiwum Medycyny Wewnetrznej 20081001

• Role of bortezomib for the treatment of previously untreated multiple myeloma.

  Expert review of hematology 20081001

• Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.

  Cancer letters 20080928

• Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080920

• From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080920

• HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway.

  Biochemical and biophysical research communications 20080919

• Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.

  Blood 20080915

• Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis.

  Cancer cell 20080909

• Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.

  Journal of cellular physiology 20080901

• Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.

  Blood 20080901

• BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.

  Leukemia 20080901

• Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo.

  Cancer science 20080901

• Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib.

  International journal of hematology 20080901

• Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma.

  International journal of hematology 20080901

• Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours.

  European journal of cancer (Oxford, England : 1990) 20080901

• New drugs in multiple myeloma.

  Current opinion in supportive and palliative care 20080901

• Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.

  Anti-cancer drugs 20080901

• 20S ways to apoptosis.

  Nature chemical biology 20080901

• Infiltration of the spinal cord in a patient with multiple myeloma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080901

• Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway.

  Molecular cancer therapeutics 20080901

• The role of novel drugs in multiple myeloma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080901

• Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation.

  European journal of immunology 20080901

• Update on recent developments for patients with newly diagnosed multiple myeloma.

  Annals of the New York Academy of Sciences 20080901

• Proteasome inhibitors in pediatric cancer treatment.

  Hawaii medical journal 20080901

• Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.

  Clinical advances in hematology & oncology : H&O 20080901

• Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

  The New England journal of medicine 20080828

• Treatment of myeloma--are we making progress?

  The New England journal of medicine 20080828

• Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation.

  Blood 20080815

• Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.

  Cancer 20080815

• Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080815

• Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080815

• Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.

  Cancer research 20080815

• Bortezomib is able to reduce angiogenesis in half of patients affected by idiopathic myelofibrosis: an ex vivo study.

  Leukemia research 20080801

• Bortezomib therapy in myelofibrosis: a phase II clinical trial.

  Leukemia 20080801

• Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.

  Annals of hematology 20080801

• Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.

  The Journal of pharmacology and experimental therapeutics 20080801

• Pathogenesis and treatment of renal failure in multiple myeloma.

  Leukemia 20080801

• Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination.

  Journal of molecular medicine (Berlin, Germany) 20080801

• Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib.

  Radiology 20080801

• The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?

  Drug discovery today 20080801

• Treatment of relapsed and refractory myeloma.

  Leukemia & lymphoma 20080801

• Productively combining proteasome inhibition with the immunotherapy of cancer.

  Journal of molecular medicine (Berlin, Germany) 20080801

• Targeting TRAIL death receptors.

  Current opinion in pharmacology 20080801

• Can tumor growth be further inhibited by combining drugs such as bortezomib with image-guided interventional oncologic procedures?

  Radiology 20080801

• Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.

  Molecular cancer research : MCR 20080801

• [Synergistic effects of arsenic trioxide and proteasome inhibitor bortezomib on apoptosis induction in Raji cell line].

  Zhongguo shi yan xue ye xue za zhi 20080801

• [Clinical study of bortezomib in combination with dexamethasone for the treatment of multiple myeloma].

  Zhongguo shi yan xue ye xue za zhi 20080801

• Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells.

  Molecular cancer therapeutics 20080801

• Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma.

  Clinical lymphoma & myeloma 20080801

• Practical considerations for multiple myeloma: an overview of recent data and current options.

  Clinical lymphoma & myeloma 20080801

• A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.

  Cancer research 20080715

• A novel role for a familiar protein in apoptosis induced by proteasome inhibition.

  Cancer cell 20080708

• Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition.

  Cancer cell 20080708

• [Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study].

  Zhonghua yi xue za zhi 20080708

• Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?

  Leukemia research 20080701

• Alkylating agents induce activation of NFkappaB in multiple myeloma cells.

  Leukemia research 20080701

• VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.

  Leukemia 20080701

• Role of decorin in the antimyeloma effects of osteoblasts.

  Blood 20080701

• Treatment of plasma cell dyscrasias with lenalidomide.

  Leukemia 20080701

• The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.

  Nature medicine 20080701

• Bortezomib: a novel chemotherapeutic agent for hematologic malignancies.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080701

• Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.

  International journal of oncology 20080701

• Bortezomib in the front-line treatment of multiple myeloma.

  Expert review of anticancer therapy 20080701

• Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress.

  Cancer research 20080701

• Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080701

• New treatments in multiple myeloma: beyond optimal treatment.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080701

• Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis.

  Molecular cancer therapeutics 20080701

• Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.

  Molecular cancer therapeutics 20080701

• Targeted treatment and new agents in diffuse large B-cell lymphoma.

  Seminars in hematology 20080701

• The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib.

  Cancer research 20080615

• [Novel medical treatment modalities in hematology].

  Ugeskrift for laeger 20080609

• Asymmetric copper-catalyzed synthesis of alpha-amino boronate esters from N-tert-butanesulfinyl aldimines.

  Journal of the American Chemical Society 20080604

• Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.

  Cancer chemotherapy and pharmacology 20080601

• Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.

  Immunology 20080601

• The therapeutic potential of the proteasome in leukaemia.

  Hematological oncology 20080601

• Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080601

• The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.

  British journal of haematology 20080601

• Proteasome inhibition improves diaphragm function in congestive heart failure rats.

  American journal of physiology. Lung cellular and molecular physiology 20080601

• Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.

  Haematologica 20080601

• Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.

  Neuro-oncology 20080601

• Autophagy activation by rapamycin eliminates mouse Mallory-Denk bodies and blocks their proteasome inhibitor-mediated formation.

  Hepatology (Baltimore, Md.) 20080601

• The potential of proteasome inhibitors in cancer therapy.

  Expert opinion on investigational drugs 20080601

• Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.

  Haematologica 20080601

• Maintenance treatment in multiple myeloma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080601

• Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080601

• Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.

  Current protein & peptide science 20080601

• [Proteasome inhibitor induces apoptosis and influences the expression of Notch1 and NF-kappaB in multiple myeloma RPMI8226 cells].

  Zhongguo shi yan xue ye xue za zhi 20080601

• KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling.

  Molecular cancer therapeutics 20080601

• Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.

  Molecular cancer therapeutics 20080601

• The proteasome inhibitor bortezomib inhibits intimal hyperplasia of autologous vein grafting in rat model.

  Transplantation proceedings 20080601

• [Serum free light chains for diagnosis and follow-up of multiple myeloma].

  The Korean journal of laboratory medicine 20080601

• [Clinical implications of bortezomib in frontline treatment of newly-diagnosed multiple myeloma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080601

• An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma.

  Clinical lymphoma & myeloma 20080601

• Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.

  Clinical lymphoma & myeloma 20080601

• [Proteasome inhibitor bortezomib sensitizes Hep-2 human laryngeal squamous cell carcinoma cells to ionizing radiation in vitro and in vivo].

  Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery 20080601

• [Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20080601

• [Treatment of myeloma in the elderly].

  Bulletin du cancer 20080528

• Targeting NF-kappaB in Waldenstrom macroglobulinemia.

  Blood 20080515

• Comment on the role of FIH in the inhibitory effect of bortezomib on hypoxia-inducible factor-1.

  Blood 20080515

• Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080510

• Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.

  Journal of the National Cancer Institute 20080507

• Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.

  British journal of cancer 20080506

• Efficacy of Bortezomib followed by local irradiation in two patients with extramedullary plasmacytomas.

  Leukemia research 20080501

• Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-dependent caspases.

  International journal of cancer 20080501

• A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080501

• Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.

  European journal of haematology 20080501

• Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080501

• Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.

  Blood 20080501

• Bortezomib-induced reversible posterior leucoencephalopathy syndrome.

  British journal of haematology 20080501

• Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib.

  British journal of haematology 20080501

• Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma.

  British journal of haematology 20080501

• Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up.

  British journal of haematology 20080501

• Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets.

  Current opinion in oncology 20080501

• p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.

  British journal of haematology 20080501

• Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.

  Journal of immunology (Baltimore, Md. : 1950) 20080501

• Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B).

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080501

• Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.

  Cancer research 20080501

• Current therapy of myeloma induced renal failure.

  Leukemia & lymphoma 20080501

• Adverse events of unapproved drugs in Japan.

  The Lancet. Oncology 20080501

• Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens.

  Leukemia & lymphoma 20080501

• Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region.

  Molecular cancer therapeutics 20080501

• Bortezomib in multiple myeloma.

  Expert opinion on drug metabolism & toxicology 20080501

• Proteasome inhibitors: a therapeutic strategy for haematological malignancy.

  Frontiers in bioscience : a journal and virtual library 20080501

• [Aggravated post-herpetic neuralgia due to bortezomib].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20080501

• Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.

  Cancer chemotherapy and pharmacology 20080401

• Proteasome inhibition therapies in childhood cancer.

  Leukemia 20080401

• Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.

  Leukemia 20080401

• Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL.

  Cancer biology & therapy 20080401

• PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.

  Blood 20080401

• Persistent supravenous eruption induced by intravenous bortezomib therapy.

  The British journal of dermatology 20080401

• Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.

  Cancer 20080401

• Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.

  Haematologica 20080401

• Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma.

  European journal of cancer (Oxford, England : 1990) 20080401

• Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.

  Oncology reports 20080401

• [Bortezomib in relapsed or refractory multiple myeloma: results in a cohort of 39 patients].

  Revista clinica espanola 20080401

• Bortezomib: putting mantle cell lymphoma on death row.

  Leukemia & lymphoma 20080401

• Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways.

  Leukemia & lymphoma 20080401

• Bortezomib in mantle cell lymphoma.

  Future oncology (London, England) 20080401

• Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.

  Cell cycle (Georgetown, Tex.) 20080401

• [Efficacy of bortezomib combined dexamethasone in 24 patients with multiple myeloma].

  Ai zheng = Aizheng = Chinese journal of cancer 20080401

• [Study on the relationship of beta-catenin level and sensitivity to Bortezomib of myeloma cell lines].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20080401

• Treatment of newly diagnosed multiple myeloma.

  Current hematologic malignancy reports 20080401

• Treatment for elderly patients with multiple myeloma.

  Lancet (London, England) 20080322

• Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080320

• Multiple myeloma with testicular involvement.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080320

• Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1.

  Blood 20080315

• Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080315

• Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.

  Journal of cancer research and clinical oncology 20080301

• Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.

  The Journal of surgical research 20080301

• Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines.

  Leukemia 20080301

• alpha-Amido boronic acids: a synthetic challenge and their properties as serine protease inhibitors.

  Medicinal research reviews 20080301

• Proteasome inhibitors: poisons and remedies.

  Medicinal research reviews 20080301

• Bortezomib in combination with thalidomide and dexamethasone--a successful treatment regimen in refractory extramedullary multiple myeloma.

  Annals of hematology 20080301

• CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.

  Blood 20080301

• Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL.

  Blood 20080301

• Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.

  Cytokine 20080301

• Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.

  Cell death and differentiation 20080301

• Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction.

  American journal of physiology. Heart and circulatory physiology 20080301

• Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin.

  Laboratory investigation; a journal of technical methods and pathology 20080301

• Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines.

  The British journal of dermatology 20080301

• Dampening Ab responses using proteasome inhibitors following in vivo B cell activation.

  European journal of immunology 20080301

• High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.

  Haematologica 20080301

• Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.

  Haematologica 20080301

• Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

  British journal of haematology 20080301

• Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080301

• Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080301

• [Effect of Velcade on the gene expression profiles of K562 cells: study of its molecular mechanism].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20080301

• Systemic therapies for recurrent and/or metastatic salivary gland cancers.

  Expert review of anticancer therapy 20080301

• Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.

  Journal of medicinal chemistry 20080227

• BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.

  Oncogene 20080221

• Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide).

  Biochemical pharmacology 20080215

• Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.

  Blood 20080215

• Successful treatment of extramedullary gastric plasmacytoma with the combination of bortezomib and dexamethasone: first reported case.

  Leukemia research 20080201

• Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.

  Leukemia research 20080201

• CHOP transcription factor mediates IL-8 signaling in cystic fibrosis bronchial epithelial cells.

  American journal of respiratory cell and molecular biology 20080201

• Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.

  Blood 20080201

• Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.

  European journal of haematology 20080201

• Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.

  Blood 20080201

• Fold up or perish: unfolded protein response and chemotherapy.

  Cell death and differentiation 20080201

• Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis.

  The Prostate 20080201

• Antioxidants block proteasome inhibitor function in endometrial carcinoma cells.

  Anti-cancer drugs 20080201

• Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits.

  Cancer 20080201

• Position statement on the use of bortezomib in multiple myeloma.

  International journal of laboratory hematology 20080201

• Concurrent radiation therapy and bortezomib in myeloma patient.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20080201

• Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.

  The Journal of clinical investigation 20080201

• Bone building with bortezomib.

  The Journal of clinical investigation 20080201

• Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.

  Cancer research 20080201

• Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease.

  Haematologica 20080201

• Unusual discordant responses in two multiple myeloma patients during bortezomib treatment.

  Onkologie 20080201

• [Effect of arsenic trioxide combined with bortezomib on proliferation, apoptosis and beta-catenin level in myeloma cell lines].

  Zhongguo shi yan xue ye xue za zhi 20080201

• Controversies regarding the use of dexamethasone in patients with multiple myeloma.

  Clinical advances in hematology & oncology : H&O 20080201

• MYC-induced sensitivity of human malignant melanoma to proteasome inhibitors - a KaMYCaze effect.

  Pigment cell & melanoma research 20080201

• Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.

  American journal of clinical oncology 20080201

• [Efficiency of bortezomib and dexamethasone in relapsed multiple myeloma treatment: retrospective study in consecutive cases].

  Anales de medicina interna (Madrid, Spain : 1984) 20080201

• Multiple myeloma presenting with advanced renal failure: a case report and new treatment options.

  Clinical lymphoma & myeloma 20080201

• [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].

  Zhonghua nei ke za zhi 20080201

• [Bortezomib-based combination therapy for newly diagnosed multiple myeloma].

  Zhonghua nei ke za zhi 20080201

• A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.

  Oncogene 20080131

• High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.

  Blood 20080115

• Revealing targeted therapy for human cancer by gene module maps.

  Cancer research 20080115

• Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080115

• Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.

  Pediatric blood & cancer 20080101

• Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells.

  Breast cancer research and treatment 20080101

• Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.

  Journal of cellular biochemistry 20080101

• PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells.

  Leukemia research 20080101

• MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity.

  Cancer gene therapy 20080101

• Deafness associated with the use of Bortezomib in multiple myeloma.

  Acta oncologica (Stockholm, Sweden) 20080101

• Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.

  Leukemia 20080101

• Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer.

  Gynecologic oncology 20080101

• Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro.

  Thrombosis research 20080101

• Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma.

  Cancer science 20080101

• An update on drug combinations for treatment of myeloma.

  Expert opinion on investigational drugs 20080101

• Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition.

  Journal of immunology (Baltimore, Md. : 1950) 20080101

• The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.

  Haematologica 20080101

• The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080101

• Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.

  Cancer research 20080101

• Bortezomib-induced skin eruption.

  Dermatology (Basel, Switzerland) 20080101

• [Molecular-targeted therapy for prostate cancer].

  Hinyokika kiyo. Acta urologica Japonica 20080101

• Sensitivity of mesenchymal stem cells and their progeny to medicines used for the treatment of hematoproliferative diseases.

  Acta haematologica 20080101

• Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication.

  PloS one 20080101

• Proteasome inhibition as a novel therapy in treating rheumatoid arthritis.

  Medical hypotheses 20080101

• Expanding role of bortezomib in multiple myeloma: nursing implications.

  Cancer nursing 20080101

• Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.

  Molecular cancer 20080101

• Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines.

  Anticancer research 20080101

• Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.

  Molecular cancer 20080101

• Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema.

  American journal of clinical dermatology 20080101

• Report on platinum drug symposium.

  The West Virginia medical journal 20080101

• Targeted therapy--possible new therapeutic option for malignant mesothelioma?

  Connective tissue research 20080101

• Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia.

  Acta haematologica 20080101

• Effect of bortezomib and cetuximab in EGF-stimulated HNSCC.

  Anticancer research 20080101

• [Clinical characteristics of velcade cumulative effect in resistant and recurrent multiple myeloma].

  Terapevticheskii arkhiv 20080101

• Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.

  Journal of experimental therapeutics & oncology 20080101

• Bortezomib as a therapeutic candidate for neuroblastoma.

  Journal of experimental therapeutics & oncology 20080101

• Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation.

  Leukemia & lymphoma 20080101

• Targeting NF-kappaB: a promising molecular therapy in inflammatory arthritis.

  International reviews of immunology 20080101

• A threshold regression mixture model for assessing treatment efficacy in a multiple myeloma clinical trial.

  Journal of biopharmaceutical statistics 20080101

• Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma.

  Drugs 20080101

• From palliation to epigenetic therapy in myelofibrosis.

  Hematology. American Society of Hematology. Education Program 20080101

• Induction therapy in multiple myeloma.

  Hematology. American Society of Hematology. Education Program 20080101

• Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity?

  Current medicinal chemistry 20080101

• [Experience with velcade administration in multiple myeloma].

  Terapevticheskii arkhiv 20080101

• Newer therapeutic molecules for multiple myeloma.

  Indian journal of cancer 20080101

• [Bortezomib as an alternative in the treatment of patients with malignant gammopathy].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20080101

• [Pulmonary toxicity after bortezomib].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20080101

• Bortezomib in multiple myeloma: treatment and retreatment. A single center experience.

  Acta poloniae pharmaceutica 20080101

• Elimination of post-transplant donor-specific HLA antibodies with bortezomib.

  Clinical transplants 20080101

• Inhibitors of the Ubiquitin-Proteasome System and the cell death machinery: How many pathways are activated?

  Current molecular pharmacology 20080101

• Novel agents in the frontline management of multiple myeloma.

  Hematology/oncology and stem cell therapy 20080101

• A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement.

  Journal of the neurological sciences 20071215

• A novel bioluminescent mouse model and effective therapy for adult T-cell leukemia/lymphoma.

  Cancer research 20071215

• Severe intestinal vasculitis in a patient under treatment with bortezomib.

  Annals of hematology 20071201

• Targeted treatments to improve stem cell outcome: old and new drugs.

  Bone marrow transplantation 20071201

• Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.

  The Journal of clinical endocrinology and metabolism 20071201

• A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.

  The Journal of urology 20071201

• A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience.

  Cancer investigation 20071201

• [Therapy of multiple myeloma: indications and options].

  Der Internist 20071201

• Management of relapsed and relapsed refractory myeloma.

  Hematology/oncology clinics of North America 20071201

• Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.

  Expert opinion on therapeutic targets 20071201

• The role of bortezomib in the treatment of lymphoma.

  Cancer investigation 20071201

• Clinical updates and nursing considerations for patients with multiple myeloma.

  Clinical journal of oncology nursing 20071201

• Severe hyponatremia in a patient with mantle cell lymphoma treated with bortezomib: a case report and review of the literature.

  Onkologie 20071201

• What is the correct philosophy for the treatment of multiple myeloma?

  Leukemia & lymphoma 20071201

• Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma.

  Leukemia & lymphoma 20071201

• [Diagnosis and management guideline for multiple myeloma].

  Nihon rinsho. Japanese journal of clinical medicine 20071201

• [Chemotherapy for multiple myeloma].

  Nihon rinsho. Japanese journal of clinical medicine 20071201

• [Role of bortezomib in the treatment of multiple myeloma].

  Nihon rinsho. Japanese journal of clinical medicine 20071201

• [Role of stem cell transplantation in treatment of multiple myeloma].

  Nihon rinsho. Japanese journal of clinical medicine 20071201

• [Molecular targeting therapy for multiple myeloma].

  Nihon rinsho. Japanese journal of clinical medicine 20071201

• [Situation of translational research and development of molecular-targeted agents for multiple myeloma].

  Nihon rinsho. Japanese journal of clinical medicine 20071201

• Bortezomib in multiple myeloma.

  Best practice & research. Clinical haematology 20071201

• [Advances in therapeutic strategies for multiple myeloma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071201

• Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20071201

• Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-kappaB activation.

  Plastic and reconstructive surgery 20071201

• Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.

  Japanese journal of clinical oncology 20071201

• Multiple myeloma: novel approaches for relapsed disease.

  Clinical lymphoma & myeloma 20071201

• Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

  Blood 20071115

• Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib.

  Cancer chemotherapy and pharmacology 20071101

• Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.

  Blood 20071101

• Novel therapies in myeloma.

  Current opinion in hematology 20071101

• The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.

  British journal of haematology 20071101

• Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease.

  British journal of haematology 20071101

• Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071101

• Bortezomib sensitizes human astrocytoma cells to tumor necrosis factor related apoptosis-inducing ligand induced apoptosis.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071101

• Use of intrapleural bortezomib in myelomatous pleural effusion.

  British journal of haematology 20071101

• Bortezomib induces apoptosis in T-cell prolymphocytic leukemia (T-PLL).

  Leukemia & lymphoma 20071101

• [Pharmacological and clinical profile of Bortezomib (Velcade)].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20071101

• [STI571 enhances the effect of arsenic trioxide and Velcade on bcr/abl+-CD34+ cell proliferation and apoptosis].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20071101

• [Progress in the study of proteasome inhibitor inducing hepatic stellate cell apoptosis].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20071101

• Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.

  Oncology (Williston Park, N.Y.) 20071101

• Bortezomib inhibits osteoclast activity in patients with multiple myeloma.

  Clinical lymphoma & myeloma 20071101

• Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells.

  British journal of cancer 20071022

• Satisfaction guaranteed--'payment by results' for biologic agents.

  The New England journal of medicine 20071018

• Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice.

  Cancer research 20071015

• [New treatment of multiple myeloma].

  La Revue de medecine interne 20071001

• Bortezomib-associated cutaneous vasculitis.

  The British journal of dermatology 20071001

• Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma.

  Haematologica 20071001

• Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071001

• The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells.

  International journal of oncology 20071001

• Neutrophilic dermatitis associated with bortezomib in a patient with multiple myeloma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20071001

• M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis.

  British journal of haematology 20071001

• The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.

  Investigative ophthalmology & visual science 20071001

• Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071001

• Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.

  Leukemia & lymphoma 20071001

• Proteasome inhibitor, bortezomib, for myeloma and lymphoma.

  International journal of clinical oncology 20071001

• [Effect of bortezomib used alone or in combination with arsenic trioxide on HL-60 cell xenograft in nude mice].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20071001

• High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future.

  Seminars in hematology 20071001

• Bortezomib in the treatment of AL amyloidosis: targeted therapy?

  Haematologica 20071001

• Bortezomib-induced peripheral neurotoxicity: still far from a painless gain.

  Haematologica 20071001

• Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.

  Haematologica 20071001

• Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070920

• Gene mutation revelation points to new target for myeloma treatment, studies say.

  Journal of the National Cancer Institute 20070919

• Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.

  Cancer research 20070915

• Bortezomib for the treatment of mantle cell lymphoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070915

• Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070915

• Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.

  World journal of gastroenterology 20070907

• Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.

  Blood 20070901

• Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.

  Cell death and differentiation 20070901

• Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins.

  Cell death and differentiation 20070901

• Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.

  American journal of hematology 20070901

• Bortezomib inhibits human osteoclastogenesis.

  Leukemia 20070901

• The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma.

  Leukemia 20070901

• Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.

  Journal of virology 20070901

• Choline induces transcriptional repression and proteasomal degradation of the malarial phosphoethanolamine methyltransferase.

  Eukaryotic cell 20070901

• Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.

  Cancer 20070901

• First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma.

  European journal of haematology 20070901

• Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070901

• Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.

  British journal of haematology 20070901

• Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines.

  British journal of haematology 20070901

• Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation.

  Haematologica 20070901

• The role of proteasome in malignant diseases.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20070901

• New therapies in multiple myeloma.

  Clinical and experimental medicine 20070901

• Myeloma bone disease and proteasome inhibition therapies.

  Blood 20070815

• Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells.

  Cell cycle (Georgetown, Tex.) 20070815

• TIEG1 induces apoptosis through mitochondrial apoptotic pathway and promotes apoptosis induced by homoharringtonine and velcade.

  FEBS letters 20070807

• Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.

  Leukemia research 20070801

• High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.

  Blood 20070801

• Unexpected cardiotoxicity in haematological bortezomib treated patients.

  British journal of haematology 20070801

• PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells.

  Leukemia 20070801

• Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.

  British journal of haematology 20070801

• Possible mechanism(s) of action of bortezomib in a patient with bronchioloalveolar carcinoma.

  Lung cancer (Amsterdam, Netherlands) 20070801

• Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.

  European journal of haematology 20070801

• Hsp72 controls bortezomib-induced HepG2 cell death via interaction with pro-apoptotic factors.

  Oncology reports 20070801

• Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.

  British journal of haematology 20070801

• The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone.

  Haematologica 20070801

• Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070801

• Incorporating bortezomib into the treatment of lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070801

• Proteasome function is required for DNA damage response and fanconi anemia pathway activation.

  Cancer research 20070801

• [Recent progress in rituximab therapy and its resistance--how do we overcome?].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070801

• Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma.

  Surgery 20070801

• [Effects of proteasome inhibitors on leukemias].

  Zhongguo shi yan xue ye xue za zhi 20070801

• Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070801

• Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma.

  The oncologist 20070801

• Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma.

  International journal of hematology 20070801

• Use of novel proteosome inhibitors as a therapeutic strategy in lymphomas current experience and emerging concepts.

  Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 20070801

• Combination treatment approaches and novel therapies for lymphoma.

  Clinical advances in hematology & oncology : H&O 20070801

• Drug pricing: No cure, no cost.

  BMJ (Clinical research ed.) 20070721

• TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.

  International journal of cancer 20070715

• Bortezomib inhibits T-cell function versus infective antigenic stimuli in a dose-dependent manner in vitro.

  Leukemia research 20070701

• Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.

  Cancer chemotherapy and pharmacology 20070701

• Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?

  Leukemia research 20070701

• Community experience with bortezomib in patients with multiple myeloma.

  American journal of hematology 20070701

• SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.

  Apoptosis : an international journal on programmed cell death 20070701

• The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.

  Blood 20070701

• Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.

  Blood 20070701

• Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.

  Leukemia 20070701

• Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells.

  Leukemia 20070701

• Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth.

  British journal of haematology 20070701

• Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor.

  European journal of gastroenterology & hepatology 20070701

• Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation.

  Blood 20070701

• Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.

  British journal of haematology 20070701

• Looking beyond the headlines.

  The Lancet. Oncology 20070701

• Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

  Leukemia & lymphoma 20070701

• Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia.

  Leukemia & lymphoma 20070701

• Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

  Cancer research 20070701

• TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.

  Molecular cancer therapeutics 20070701

• [HL-60 cell apoptosis induced by bortezomib alone or in combination with arsenic trioxide in vitro].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20070701

• Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.

  Anti-cancer drugs 20070701

• [New targeted therapies in hormone-refractory prostate cancer].

  Bulletin du cancer 20070701

• [Breast cancer and Her-2].

  Nihon rinsho. Japanese journal of clinical medicine 20070628

• Allografting or autografting for myeloma.

  The New England journal of medicine 20070621

• A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070615

• Drugs 'refund' scheme proposed for England and Wales.

  BMJ (Clinical research ed.) 20070609

• Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland.

  Swiss medical weekly 20070602

• Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.

  Leukemia research 20070601

• Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.

  Blood 20070601

• Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug.

  American journal of hematology 20070601

• Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer.

  Molecular pharmacology 20070601

• Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.

  British journal of haematology 20070601

• Efficacy and safety of bortezomib in patients with plasma cell leukemia.

  Cancer 20070601

• Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070601

• Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070601

• Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.

  Cancer research 20070601

• Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.

  Hematology (Amsterdam, Netherlands) 20070601

• 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.

  Molecular cancer therapeutics 20070601

• New drugs for myeloma.

  The oncologist 20070601

• Proteasome inhibition and multiple myeloma.

  Current opinion in investigational drugs (London, England : 2000) 20070601

• [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20070601

• Novel therapeutic avenues in myeloma: changing the treatment paradigm.

  Oncology (Williston Park, N.Y.) 20070601

• [Multiple myeloma and intravenous immunoglobulins].

  La Revue de medecine interne 20070601

• The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.

  Blood 20070515

• Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice.

  Cell cycle (Georgetown, Tex.) 20070515

• Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070515

• The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.

  Cancer research 20070515

• Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.

  Leukemia research 20070501

• The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.

  American journal of hematology 20070501

• NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs.

  Blood 20070501

• Targeting aurora kinases as therapy in multiple myeloma.

  Blood 20070501

• Medical management update: multiple myeloma.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20070501

• Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.

  The Journal of clinical endocrinology and metabolism 20070501

• Proteasomal inhibition in intracerebral hemorrhage: neuroprotective and anti-inflammatory effects of bortezomib.

  Neuroscience research 20070501

• The proteasome: a worthwhile target for the treatment of solid tumours?

  European journal of cancer (Oxford, England : 1990) 20070501

• Assessment of apoptosis-inducing effects of docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells.

  Cancer biology & therapy 20070501

• Immune-modulatory effects of bortezomib in GVHD.

  Leukemia & lymphoma 20070501

• Inhibition of chronic graft-vs-host disease with retention of anti-myeloma effects by the proteasome inhibitor bortezomib.

  Leukemia & lymphoma 20070501

• Targeting the ubiquitin-proteasome pathway in cancer therapy.

  Anti-cancer agents in medicinal chemistry 20070501

• Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.

  Japanese journal of clinical oncology 20070501

• Role of autologous stem cell transplantation in multiple myeloma.

  Current hematologic malignancy reports 20070501

• Current status of bortezomib in the treatment of multiple myeloma.

  Current hematologic malignancy reports 20070501

• Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070420

• Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.

  Blood 20070415

• Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events.

  Blood 20070415

• A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.

  Oncogene 20070405

• Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis.

  Leukemia research 20070401

• A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.

  Investigational new drugs 20070401

• Late onset of bortezomib-associated cutaneous reaction following herpes zoster.

  Annals of hematology 20070401

• Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.

  Blood 20070401

• Quantitative sensory findings in patients with bortezomib-induced pain.

  The journal of pain : official journal of the American Pain Society 20070401

• The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells.

  Cancer gene therapy 20070401

• Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.

  Apoptosis : an international journal on programmed cell death 20070401

• Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma.

  Leukemia 20070401

• Bortezomib-associated rash: a new recognizable and avoidable side-effect.

  The British journal of dermatology 20070401

• Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide.

  Leukemia 20070401

• Proteasome inhibition specifically sensitizes leukemic cells to anthracyclin-induced apoptosis through the accumulation of Bim and Bax pro-apoptotic proteins.

  Cancer biology & therapy 20070401

• Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20070401

• Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation.

  Onkologie 20070401

• Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.

  Cancer research 20070401

• Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents.

  Haematologica 20070401

• Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018).

  Haematologica 20070401

• [Induction of apoptosis in HL-60 cells by bortezomib alone or in combination with harringtonine in vitro].

  Zhongguo shi yan xue ye xue za zhi 20070401

• Proteasome inhibitors.

  Oncology (Williston Park, N.Y.) 20070401

• Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma.

  Clinical lymphoma & myeloma 20070401

• Initial Therapy of Multiple Myeloma in Patients who are Candidates for Stem Cell Transplantation.

  Current treatment options in oncology 20070401

• Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib.

  Blood 20070315

• Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

  Blood 20070315

• Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.

  Blood 20070315

• A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070315

• The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.

  Cancer research 20070315

• Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis.

  Cancer immunology, immunotherapy : CII 20070301

• Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin.

  Annals of hematology 20070301

• Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.

  Experimental neurology 20070301

• Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.

  Leukemia 20070301

• p27 degradation by an ellipticinium series of compound via ubiquitin-proteasome pathway.

  Cancer biology & therapy 20070301

• TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window.

  Hepatology (Baltimore, Md.) 20070301

• NICE: friend and foe.

  Nature clinical practice. Oncology 20070301

• Virus-associated tumor imaging by induction of viral gene expression.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070301

• A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070301

• Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells.

  Haematologica 20070301

• The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.

  British journal of haematology 20070301

• Use of systemic proteasome inhibition as an immune-modulating agent in disease.

  Endocrine, metabolic & immune disorders drug targets 20070301

• Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.

  Human immunology 20070301

• Emerging drugs in multiple myeloma.

  Expert opinion on emerging drugs 20070301

• Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460.

  Molecular cancer therapeutics 20070301

• A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells.

  Molecular cancer therapeutics 20070301

• A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.

  Journal of drugs in dermatology : JDD 20070301

• Multiple myeloma therapies.

  Nature reviews. Drug discovery 20070301

• The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.

  The oncologist 20070301

• Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.

  Clinical genitourinary cancer 20070301

• Repeated complete responses with bortezomib in a heavily pretreated primary refractory patient with light chain multiple myeloma.

  Clinical lymphoma & myeloma 20070301

• Multiple myeloma involving the cavernous sinus: a report of 3 cases and response to bortezomib.

  Clinical lymphoma & myeloma 20070301

• Impact of differential recovery in bioanalysis: the example of bortezomib in whole blood.

  Analytical chemistry 20070215

• Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.

  Cancer research 20070215

• Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.

  Cancer research 20070215

• Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.

  Cancer research 20070215

• Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070215

• A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.

  Cancer chemotherapy and pharmacology 20070201

• Dual alterations in casein kinase I-epsilon and GSK-3beta modulate beta-catenin stability in hyperproliferating colonic epithelia.

  American journal of physiology. Gastrointestinal and liver physiology 20070201

• Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.

  International journal of cancer 20070201

• BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.

  British journal of haematology 20070201

• Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation.

  Cancer biology & therapy 20070201

• American Society of Hematology--48th Annual Meeting and Exposition. Updates on hematological therapies. 9-12 December 2006 Orlando, FL, USA.

  IDrugs : the investigational drugs journal 20070201

• The emerging role of novel therapies for the treatment of relapsed myeloma.

  Journal of the National Comprehensive Cancer Network : JNCCN 20070201

• [Recent progress in the treatment of multiple myeloma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20070201

• [Proteasome inhibitors for multiple myeloma].

  Nihon rinsho. Japanese journal of clinical medicine 20070128

• Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer.

  Cancer research 20070115

• Burn-induced increase in atrogin-1 and MuRF-1 in skeletal muscle is glucocorticoid independent but downregulated by IGF-I.

  American journal of physiology. Regulatory, integrative and comparative physiology 20070101

• A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070101

• Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.

  Leukemia 20070101

• Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells.

  Immunology 20070101

• Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.

  Leukemia 20070101

• Proteasome inhibitors: antitumor effects and beyond.

  Leukemia 20070101

• Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.

  Leukemia 20070101

• EGF receptor activity modulates apoptosis induced by inhibition of the proteasome of vascular smooth muscle cells.

  Journal of the American Society of Nephrology : JASN 20070101

• An internationally recognized uniform cytogenetic classification system is needed for multiple myeloma.

  Leukemia 20070101

• Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia.

  Nature medicine 20070101

• Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications.

  British journal of haematology 20070101

• Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.

  Molecular cancer therapeutics 20070101

• Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.

  Molecular cancer therapeutics 20070101

• Pseudomembranous colitis following bortezomib therapy in a myeloma patient.

  Acta haematologica 20070101

• Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.

  Drugs in R&D 20070101

• 48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.

  Clinical lymphoma & myeloma 20070101

• Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma.

  Clinical lymphoma & myeloma 20070101

• Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone.

  Leukemia & lymphoma 20070101

• The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells.

  Anticancer research 20070101

• Review. Clinical pharmacokinetics of bortezomib.

  In vivo (Athens, Greece) 20070101

• Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement.

  Acta oncologica (Stockholm, Sweden) 20070101

• Severe epidermal necrolysis after bortezomib treatment for multiple myeloma.

  Acta haematologica 20070101

• Bortezomib and lenalidomide effective in myeloma.

  Cancer biology & therapy 20070101

• Bortezomib plus doxorubicin combination slows progression of multiple myeloma.

  Cancer biology & therapy 20070101

• Sensitizing tumor cells to immune-mediated cytotoxicity.

  Advances in experimental medicine and biology 20070101

• [Velcade in multiple myeloma].

  Terapevticheskii arkhiv 20070101

• Management of novel therapeutics' side effects: a nurse-centric model.

  ONS connect 20070101

• Advances in the treatment of MDS, multiple myeloma, and CLL.

  ONS connect 20070101

• Managing patients with multiple myeloma and mantle cell lymphoma: where are we now?

  ONS connect 20070101

• Multiple myeloma patient care: treatment options and nursing considerations.

  ONS connect 20070101

• Multiple myeloma: charging toward a bright future.

  CA: a cancer journal for clinicians 20070101

• Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B.

  BMC clinical pharmacology 20070101

• Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib.

  Acta haematologica 20070101

• The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells.

  Molecular cancer 20070101

• The treatment of relapsed and refractory multiple myeloma.

  Hematology. American Society of Hematology. Education Program 20070101

• Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial.

  BMC cancer 20070101

• Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia.

  Anticancer research 20070101

• Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells.

  Leukemia research 20061201

• VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia.

  American journal of hematology 20061201

• Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.

  European journal of haematology 20061201

• A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.

  Cancer 20061201

• Targeting ubiquitin in cancers.

  European journal of cancer (Oxford, England : 1990) 20061201

• Current status of new drugs for the treatment of patients with multiple myeloma.

  Internal medicine journal 20061201

• Investigational treatments for multiple myeloma.

  Expert opinion on investigational drugs 20061201

• Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.

  British journal of haematology 20061201

• Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner.

  Molecular cancer therapeutics 20061201

• Novel agents for multiple myeloma treatment.

  Current pharmaceutical biotechnology 20061201

• Bortezomib as an antitumor agent.

  Current pharmaceutical biotechnology 20061201

• Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells.

  Molecular cancer therapeutics 20061201

• Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib.

  Molecular cancer therapeutics 20061201

• Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the 'lung injury by bortezomib' joint committee of the Japanese society of hematology and the Japanese society of clinical hematology.

  International journal of hematology 20061201

• The proteasome as a potential target for novel anticancer drugs and chemosensitizers.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20061201

• [Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].

  Zhongguo shi yan xue ye xue za zhi 20061201

• [Clinical and hematological characteristics of adult T-cell leukemia/lymphoma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20061201

• [Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the 'Lung Injury by Bortezomib' Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20061201

• Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.

  Blood 20061115

• Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.

  Cancer 20061115

• NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20061115

• Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.

  Breast cancer research and treatment 20061101

• Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma.

  European journal of haematology 20061101

• Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.

  Current opinion in oncology 20061101

• Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

  Haematologica 20061101

• Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma.

  Journal of the American Academy of Dermatology 20061101

• Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061101

• Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.

  The Lancet. Oncology 20061101

• Can survivin expression predict the response to bortezomib in cases with mantle cell lymphoma?

  Leukemia & lymphoma 20061101

• Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition.

  Molecular cancer therapeutics 20061101

• Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20061101

• Management of toxicities associated with bortezomib.

  Oncology (Williston Park, N.Y.) 20061101

• [Follicular keratosis and multiple myeloma].

  Actas dermo-sifiliograficas 20061101

• Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.

  Clinical lymphoma & myeloma 20061101

• Bortezomib-induced tumor lysis syndrome in multiple myeloma.

  Clinical lymphoma & myeloma 20061101

• Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20061101

• Bortezomib in the treatment of cancer.

  Recent patents on anti-cancer drug discovery 20061101

• Can NF-kappaB be a target for novel and efficient anti-cancer agents?

  Biochemical pharmacology 20061030

• Are the Scots getting a better deal on prescribed drugs than the English?

  BMJ (Clinical research ed.) 20061028

• Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa.

  The Journal of biological chemistry 20061020

• Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061020

• Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells.

  Biochemical and biophysical research communications 20061006

• Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl.

  Leukemia research 20061001

• Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.

  Blood 20061001

• Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse.

  American journal of physiology. Gastrointestinal and liver physiology 20061001

• Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.

  The Journal of clinical endocrinology and metabolism 20061001

• Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.

  Cancer research 20061001

• [Bortezomib in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20061001

• [Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor].

  Zhonghua yi xue za zhi 20060912

• [Recent progress in diagnosis of and therapy for multiple myeloma].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20060910

• Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.

  Journal of the National Cancer Institute 20060906

• Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.

  International journal of cancer 20060901

• Inhibition of bortezomib-induced apoptosis by red blood cell uptake.

  Leukemia 20060901

• Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.

  Cancer 20060901

• Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease.

  British journal of haematology 20060901

• Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.

  European journal of haematology 20060901

• Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade.

  Molecular cancer research : MCR 20060901

• [A cure for multiple myeloma?].

  Presse medicale (Paris, France : 1983) 20060901

• [New drugs for myeloma].

  Presse medicale (Paris, France : 1983) 20060901

• Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.

  Molecular cancer therapeutics 20060901

• Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.

  Molecular cancer therapeutics 20060901

• Bortezomib dosing in relapsed multiple myeloma.

  Clinical lymphoma & myeloma 20060901

• Response to bortezomib and activation of osteoblasts in multiple myeloma.

  Clinical lymphoma & myeloma 20060901

• Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma.

  Clinical lymphoma & myeloma 20060901

• Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.

  Journal of the National Cancer Institute 20060816

• Proteasome inhibitor drugs on the rise.

  Cancer research 20060815

• Ariad Pharmaceuticals wins first round over Eli Lilly, patents on methods can be far-reaching.

  Journal of the National Cancer Institute 20060802

• Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation.

  Annals of hematology 20060801

• Proteasome inhibition as novel treatment strategy in leukaemia.

  British journal of haematology 20060801

• Proteasome inhibitor bortezomib for the treatment of multiple myeloma.

  Leukemia 20060801

• Severe pulmonary complication after bortezomib treatment for multiple myeloma.

  Blood 20060801

• Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma.

  Pharmacotherapy 20060801

• Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?

  British journal of haematology 20060801

• Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas.

  Clinical and laboratory haematology 20060801

• Estrogen-triggered delays in mammary gland gene expression during the estrous cycle: evidence for a novel timing system.

  The Journal of endocrinology 20060801

• [Proteasome inhibitor bortezomib as an anticancer drug].

  Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme 20060801

• [Multiple myeloma cell line U266 apoptosis induced by velcade].

  Zhongguo shi yan xue ye xue za zhi 20060801

• Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells.

  Molecular cancer therapeutics 20060801

• Bortezomib is effective in primary plasma cell leukemia.

  Leukemia & lymphoma 20060801

• [Bortezomib-induced tumor lysis syndrome with a remarkable elevation of LDH in a case of relapsed and therapy-resistant multiple myeloma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20060801

• New drugs for multiple myeloma.

  Clinical advances in hematology & oncology : H&O 20060801

• Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation.

  Blood 20060715

• Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.

  Cancer research 20060715

• Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.

  Cancer chemotherapy and pharmacology 20060701

• The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.

  Apoptosis : an international journal on programmed cell death 20060701

• Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies).

  Current opinion in oncology 20060701

• Bortezomib induces in HepG2 cells IkappaBalpha degradation mediated by caspase-8.

  Molecular and cellular biochemistry 20060701

• Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060701

• Life-threatening motor neurotoxicity in association with bortezomib.

  Haematologica 20060701

• Bortezomib for multiple myeloma.

  Expert opinion on pharmacotherapy 20060701

• Additional dexamethasone improves the response rate among patients with multiple myeloma treated with single agent bortezomib.

  Haematologica 20060701

• Perspective on the current use of bortezomib in multiple myeloma.

  Haematologica 20060701

• Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.

  Haematologica 20060701

• Proteasome inhibition in multiple myeloma.

  European journal of cancer (Oxford, England : 1990) 20060701

• Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.

  Nature clinical practice. Oncology 20060701

• Use of bortezomib in B-cell non-Hodgkin's lymphoma.

  Expert review of anticancer therapy 20060701

• Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.

  British journal of haematology 20060701

• Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress.

  Cancer biology & therapy 20060701

• Dexamethasone reduces the risk of bortezomib-induced pulmonary complications in Japanese myeloma patients.

  International journal of hematology 20060701

• Emerging role of novel combinations for induction therapy in multiple myeloma.

  Clinical lymphoma & myeloma 20060701

• The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.

  Molecular cancer therapeutics 20060701

• Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.

  Blood 20060615

• Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells.

  Cancer research 20060615

• Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.

  Cancer research 20060615

• Systemic therapy in the palliative management of advanced salivary gland cancers.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060610

• Proteasome inhibitors in lung cancer.

  Critical reviews in oncology/hematology 20060601

• Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.

  Leukemia 20060601

• Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.

  Experimental hematology 20060601

• The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

  Cancer research 20060601

• Differential regulation of eotaxin-1/CCL11 and eotaxin-3/CCL26 production by the TNF-alpha and IL-4 stimulated human lung fibroblast.

  Biological & pharmaceutical bulletin 20060601

• Apoptosis: a relevant tool for anticancer therapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060601

• Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.

  Haematologica 20060601

• An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20060601

• [Molecular-targeted therapy for hormone-refractory prostate cancer].

  Hinyokika kiyo. Acta urologica Japonica 20060601

• Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.

  Current cancer drug targets 20060601

• Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.

  Clinical therapeutics 20060601

• Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma.

  Blood 20060515

• Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors.

  Journal of immunology (Baltimore, Md. : 1950) 20060515

• United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060515

• The proteasome inhibitor VELCADE reduces infarction in rat models of focal cerebral ischemia.

  Neuroscience letters 20060508

• Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines.

  Blood 20060501

• Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060501

• Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.

  Blood 20060501

• Cell cycle-dependent cytotoxic and cytostatic effects of bortezomib on colon carcinoma cells.

  Cell death and differentiation 20060501

• Bortezomib: an effective agent in extramedullary disease in multiple myeloma.

  European journal of haematology 20060501

• Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060501

• The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060501

• A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma.

  International journal of hematology 20060501

• The proteasome: a novel target for anticancer therapy.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20060501

• Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation.

  Oncology (Williston Park, N.Y.) 20060501

• Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.

  Clinical lymphoma & myeloma 20060501

• [Recurrent varicella in a woman with mantle cell lymphoma].

  Actas dermo-sifiliograficas 20060501

• Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.

  Clinical advances in hematology & oncology : H&O 20060501

• The safety and efficacy of bortezomib in relapsed multiple myeloma.

  Clinical advances in hematology & oncology : H&O 20060501

• Optimizing bortezomib treatment in patients with relapsed multiple myeloma.

  Clinical advances in hematology & oncology : H&O 20060501

• Enhancing care and managing side effects in patients receiving bortezomib.

  Clinical advances in hematology & oncology : H&O 20060501

• PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells.

  The Journal of biological chemistry 20060428

• Fourth biannual report of the Cochrane Haematological Malignancies Group.

  Journal of the National Cancer Institute 20060419

• Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).

  Journal of immunology (Baltimore, Md. : 1950) 20060415

• Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.

  Blood 20060415

• Modulation of uridine phosphorylase gene expression by tumor necrosis factor-alpha enhances the antiproliferative activity of the capecitabine intermediate 5'-deoxy-5-fluorouridine in breast cancer cells.

  Molecular pharmacology 20060401

• Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes.

  Drug metabolism and disposition: the biological fate of chemicals 20060401

• JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.

  Apoptosis : an international journal on programmed cell death 20060401

• Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells.

  Anti-cancer drugs 20060401

• Pharmacotherapy of multiple myeloma.

  Expert opinion on pharmacotherapy 20060401

• Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.

  Cancer research 20060401

• Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

  Cancer research 20060401

• Hematologic malignancies: from clinical science to clinical practice - 2nd European Congress.

  IDrugs : the investigational drugs journal 20060401

• Proteasome inhibition: novel therapy for multiple myeloma.

  Onkologie 20060401

• Oxidative deboronation of the peptide boronic acid proteasome inhibitor bortezomib: contributions from reactive oxygen species in this novel cytochrome P450 reaction.

  Chemical research in toxicology 20060401

• [New treatment strategy of multiple myeloma for cure].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060401

• [The plasma cell myeloma--molecular pathogenesis and target therapies].

  Therapeutische Umschau. Revue therapeutique 20060401

• Medullary renal cell carcinoma and response to therapy with bortezomib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060320

• Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram.

  International journal of cancer 20060315

• Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis.

  Blood 20060315

• Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.

  Cancer 20060315

• Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.

  Leukemia research 20060301

• Successful treatment of lymph node extramedullary plasmacytoma with bortezomib.

  Annals of hematology 20060301

• Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20060301

• Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines.

  European journal of haematology 20060301

• New developments in chemotherapy for advanced non-small cell lung cancer.

  Current opinion in oncology 20060301

• Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate.

  Molecular microbiology 20060301

• Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation.

  Experimental biology and medicine (Maywood, N.J.) 20060301

• Ubiquitin and cancer: from molecular targets and mechanisms to the clinic -- AACR Special Conference.

  IDrugs : the investigational drugs journal 20060301

• Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.

  Structure (London, England : 1993) 20060301

• SUMOylation plays a role in gemcitabine- and bortezomib-induced cytotoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone.

  Molecular cancer therapeutics 20060301

• Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells.

  Molecular cancer therapeutics 20060301

• Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060220

• Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060220

• Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.

  Blood 20060215

• Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060215

• [Bortezomib].

  Deutsche medizinische Wochenschrift (1946) 20060203

• No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.

  Leukemia research 20060201

• Antimyeloma activity of heat shock protein-90 inhibition.

  Blood 20060201

• Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib.

  Annals of hematology 20060201

• Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach.

  Leukemia & lymphoma 20060201

• Response to bortezomib (velcade) in a case of advanced bronchiolo-alveolar carcinoma (BAC). A case report.

  Lung cancer (Amsterdam, Netherlands) 20060201

• Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.

  International journal of oncology 20060201

• Targeting the proteasome as a therapeutic strategy against haematological malignancies.

  Expert opinion on investigational drugs 20060201

• Proteasome inhibition induces hepatic stellate cell apoptosis.

  Hepatology (Baltimore, Md.) 20060201

• Success in translational research: lessons from the development of bortezomib.

  Nature reviews. Drug discovery 20060201

• Closing the gap.

  Nature reviews. Drug discovery 20060201

• Targeting the ubiquitin-proteasome pathway in breast cancer therapy.

  Future oncology (London, England) 20060201

• [Effects of proteasome inhibitor PS-341 on the multiple cytokine expressions of mesenchymal stem cells from bone marrow in patients with multiple myeloma].

  Zhongguo shi yan xue ye xue za zhi 20060201

• [Promising targeted molecular therapies for the future years in non-small-cell lung cancer].

  Revue de pneumologie clinique 20060201

• Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060201

• NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145.

  Blood 20060115

• Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060115

• [Prognostic factors and new treatments of multiple myeloma].

  La Revue du praticien 20060115

• Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death.

  The Journal of biological chemistry 20060113

• Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.

  Cancer immunology, immunotherapy : CII 20060101

• The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.

  Blood 20060101

• Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients.

  Leukemia & lymphoma 20060101

• Velcade and vitamin C: too much of a good thing?

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060101

• Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060101

• Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.

  Cancer research 20060101

• A practical update on the use of bortezomib in the management of multiple myeloma.

  The oncologist 20060101

• The proteasome and proteasome inhibitors in cancer therapy.

  Annual review of pharmacology and toxicology 20060101

• Bortezomib: proteasome inhibition as an effective anticancer therapy.

  Annual review of medicine 20060101

• Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.

  Acta haematologica 20060101

• Allosteric regulators of the proteasome: potential drugs and a novel approach for drug design.

  Current medicinal chemistry 20060101

• Novel treatment approaches for patients with multiple myeloma.

  Clinical lymphoma & myeloma 20060101

• Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator.

  Thrombosis and haemostasis 20060101

• Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas.

  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20060101

• Treatment of multiple myeloma: an emphasis on new developments.

  Annals of medicine 20060101

• Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.

  BMC cancer 20060101

• The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.

  Acta haematologica 20060101

• Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.

  Anticancer research 20060101

• Longitudinally quantitative 2-deoxy-2-[18F]fluoro-D-glucose micro positron emission tomography imaging for efficacy of new anticancer drugs: a case study with bortezomib in prostate cancer murine model.

  Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 20060101

• Advancing access to myeloma treatment: administration, side effects, and implications for survival.

  ONS news 20060101

• Advances in the treatment of multiple myeloma: a nursing perspective.

  ONS news 20060101

• Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria.

  Pathology oncology research : POR 20060101

• [Inappropriate commercial presentation of selected drugs and associated overcost].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20060101

• Bortezomib-induced rhabdomyolysis in multiple myeloma.

  Acta haematologica 20060101

• Bortezomib-induced skin lesion.

  Acta haematologica 20060101

• Multiple myeloma associated with porphyria cutanea tarda: a possible role of bortezomib?

  Dermatology (Basel, Switzerland) 20060101

• Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure.

  Acta haematologica 20060101

• Severe pulmonary complications in African-American patient after bortezomib therapy.

  American journal of therapeutics 20060101

• Detection of a proteasome in Pneumocystis carinii and its modulation by specific proteasome inhibitors.

  The Journal of eukaryotic microbiology 20060101

• [Use of proteasome inhibitors in the treatment of patients with multiple myeloma].

  Terapevticheskii arkhiv 20060101

• Activity of bortezomib in glioblastoma.

  Anticancer research 20060101

• Management of multiple myeloma with bortezomib: experts review the data and debate the issues.

  Oncology 20060101

• The proteasome and its inhibitors in immune regulation and immune disorders.

  Critical reviews in immunology 20060101

• The efficacy and safety of bortezomib (velcade) in the treatment of relapsed multiple mye.

  Acta poloniae pharmaceutica 20060101

• The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.

  Blood 20051215

• Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.

  Cancer research 20051215

• Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.

  Cancer research 20051215

• Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib.

  Leukemia research 20051201

• Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.

  International journal of radiation oncology, biology, physics 20051201

• Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

  Blood 20051201

• Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.

  Cancer treatment reviews 20051201

• Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.

  Pharmacotherapy 20051201

• Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibition.

  Hematology (Amsterdam, Netherlands) 20051201

• Waldenström's macroglobulinemia and bortezomib.

  Haematologica 20051201

• Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.

  Haematologica 20051201

• Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin.

  Molecular cancer therapeutics 20051201

• New treatment approaches in multiple myeloma.

  The Israel Medical Association journal : IMAJ 20051201

• Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20051201

• [New strategy for the treatment of multiple myeloma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20051201

• Other compounds and targets in non-small cell lung cancer.

  Seminars in oncology 20051201

• Bulbar palsy in multiple myeloma.

  Haematologica 20051201

• Bortezomib-induced Sweet's syndrome.

  Haematologica 20051201

• Skin lesions induced by bortezomib.

  Haematologica 20051201

• New treatments for multiple myeloma.

  Oncology (Williston Park, N.Y.) 20051201

• Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.

  Clinical advances in hematology & oncology : H&O 20051201

• Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

  Cancer 20051115

• Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity.

  Blood 20051101

• Proteasome degradation of GRK2 during ischemia and ventricular tachyarrhythmias in a canine model of myocardial infarction.

  American journal of physiology. Heart and circulatory physiology 20051101

• Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.

  Blood 20051101

• Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.

  Drug metabolism and disposition: the biological fate of chemicals 20051101

• Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.

  Cancer 20051101

• Proteasome inhibitors in non-Hodgkin's lymphoma.

  Journal of the National Comprehensive Cancer Network : JNCCN 20051101

• A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.

  Cancer cell 20051101

• Anti-angiogenic and anti-tumor properties of proteasome inhibitors.

  Current cancer drug targets 20051101

• Proteasome inhibition: a new approach for the treatment of malignancies.

  Bulletin du cancer 20051101

• Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.

  Clinical lymphoma & myeloma 20051101

• The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis.

  Annals of the New York Academy of Sciences 20051101

• Mantle cell lymphomas.

  Clinical advances in hematology & oncology : H&O 20051101

• N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products.

  Cancer research 20051015

• Control of ASPP2/(53BP2L) protein levels by proteasomal degradation modulates p53 apoptotic function.

  The Journal of biological chemistry 20051014

• Multiple myeloma: the present and the future.

  The Medical journal of Australia 20051003

• PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20051001

• [Proteasome inhibitors].

  La Revue de medecine interne 20051001

• Development of effective new treatments for multiple myeloma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051001

• Toxic neuropathy.

  Current opinion in neurology 20051001

• Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.

  British journal of haematology 20051001

• Bortezomib-induced Sweet syndrome.

  British journal of haematology 20051001

• Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.

  Molecular cancer therapeutics 20051001

• Preclinical data with bortezomib in lung cancer.

  Clinical lung cancer 20051001

• Sequencing bortezomib with chemotherapy and targeted agents.

  Clinical lung cancer 20051001

• Bortezomib-based combinations in the treatment of non-small-cell lung cancer.

  Clinical lung cancer 20051001

• The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer.

  Clinical lung cancer 20051001

• Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.

  Clinical lung cancer 20051001

• Drug Discovery Technology and Development 2005 - IBC's Tenth World Congress. Cancer mouse models and other techniques for improved prediction of efficacy.

  IDrugs : the investigational drugs journal 20051001

• Treatment paradigms for the newly diagnosed patient with multiple myeloma.

  Seminars in hematology 20051001

• Lenalidomide and thalidomide: mechanisms of action--similarities and differences.

  Seminars in hematology 20051001

• [Current therapy for multiple myeloma].

  Polskie Archiwum Medycyny Wewnetrznej 20051001

• Bortezomib in multiple myeloma.

  The New England journal of medicine 20050922

• Bortezomib in multiple myeloma.

  The New England journal of medicine 20050922

• Intracellular protein degradation: from a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting (Nobel lecture).

  Angewandte Chemie (International ed. in English) 20050919

• A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.

  Cancer research 20050915

• The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis.

  Blood 20050901

• Stability of bortezomib 1-mg/mL solution in plastic syringe and glass vial.

  The Annals of pharmacotherapy 20050901

• Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect.

  Leukemia 20050901

• Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.

  Hepatology (Baltimore, Md.) 20050901

• Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050901

• Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050901

• Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.

  Cancer research 20050901

• [Bortezomib in second-line therapy].

  Medizinische Monatsschrift fur Pharmazeuten 20050901

• Bortezomib increases survival of patients with relapsed multiple myeloma.

  Health news (Waltham, Mass.) 20050901

• Emerging trends in the clinical use of bortezomib in multiple myeloma.

  Clinical lymphoma & myeloma 20050901

• Evolving role of stem cell transplantation in multiple myeloma.

  Clinical lymphoma & myeloma 20050901

• Induction therapy before transplantation in multiple myeloma: new strategies to achieve complete response.

  Clinical lymphoma & myeloma 20050901

• [A new therapy with bortezomib, an oncologic medicinal product of the year 2004].

  Annales pharmaceutiques francaises 20050901

• Overview of drug therapy for multiple myeloma.

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20050901

• Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050815

• Perspectives for combination therapy to overcome drug-resistant multiple myeloma.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20050801

• Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20050801

• Lysosomes and endoplasmic reticulum: targets for improved, selective anticancer therapy.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20050801

• A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050801

• Proteasome inhibitor for treatment of multiple myeloma.

  The Lancet. Oncology 20050801

• Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.

  British journal of haematology 20050801

• A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.

  Journal of Korean medical science 20050801

• Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.

  Oncogene 20050721

• Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.

  Cancer research 20050715

• Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.

  Cancer research 20050715

• Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050715

• Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.

  Cancer chemotherapy and pharmacology 20050701

• PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis.

  Experimental hematology 20050701

• Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice.

  Haematologica 20050701

• Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma.

  Leukemia & lymphoma 20050701

• Phosphorylation of AML1/RUNX1 regulates its degradation and nuclear matrix association.

  Molecular cancer research : MCR 20050701

• Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation.

  Cancer biology & therapy 20050701

• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  The New England journal of medicine 20050616

• Images in clinical Medicine. Bortezomib-induced skin lesions.

  The New England journal of medicine 20050616

• Bortezomib for myeloma -- much ado about something.

  The New England journal of medicine 20050616

• [Therapeutic outcomes in systemic lymphatic diseases and plasmacytoma. New hope for palliative patients].

  MMW Fortschritte der Medizin 20050616

• A phase II study of bortezomib in the treatment of metastatic malignant melanoma.

  Cancer 20050615

• Serum amyloid A-luciferase transgenic mice: response to sepsis, acute arthritis, and contact hypersensitivity and the effects of proteasome inhibition.

  Journal of immunology (Baltimore, Md. : 1950) 20050615

• NF-kappaB and not the MAPK signaling pathway regulates GADD45beta expression during acute inflammation.

  The Journal of biological chemistry 20050603

• A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival.

  Blood 20050601

• Multifunctional role of Erk5 in multiple myeloma.

  Blood 20050601

• Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20050601

• Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.

  Drug metabolism and disposition: the biological fate of chemicals 20050601

• High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation.

  Leukemia 20050601

• Proteasome: an emerging target for cancer therapy.

  Anti-cancer drugs 20050601

• Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.

  Cancer research 20050601

• Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050601

• Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse.

  Haematologica 20050601

• PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.

  British journal of haematology 20050601

• Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.

  British journal of haematology 20050601

• Current treatment options for myeloma.

  Expert opinion on pharmacotherapy 20050601

• [New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050601

• Proteasome inhibition as a therapeutic strategy for hematologic malignancies.

  Expert review of anticancer therapy 20050601

• Treatment of mantle cell lymphoma: targeting the microenvironment.

  Expert review of anticancer therapy 20050601

• Severe acute enteritis in a multiple myeloma patient receiving bortezomib and spinal radiotherapy: case report.

  Journal of chemotherapy (Florence, Italy) 20050601

• New biological agents in the treatment of advanced non-small cell lung cancer.

  Seminars in respiratory and critical care medicine 20050601

• Bortezomib in combination with dexamethasone for relapsed multiple myeloma.

  Leukemia research 20050501

• Severe irreversible bilateral hearing loss after bortezomib (VELCADE) therapy in a multiple myeloma (MM) patient.

  Leukemia 20050501

• In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells.

  European journal of haematology 20050501

• Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.

  Nature methods 20050501

• A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050501

• Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines.

  Cancer research 20050501

• Treatment of myeloma in patients not eligible for transplantation.

  Current treatment options in oncology 20050501

• Lung cancer - Second Annual Winter Conference.

  IDrugs : the investigational drugs journal 20050501

• Future therapies in hormone-refractory prostate cancer.

  Urology 20050501

• Genotypic guidance for chemotherapy choices.

  Drug discovery today 20050501

• Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.

  Drugs of today (Barcelona, Spain : 1998) 20050501

• New therapies for the treatment of multiple myeloma.

  Clinical advances in hematology & oncology : H&O 20050501

• Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.

  Oncogene 20050428

• Bortezomib is an efficient agent in plasma cell leukemias.

  International journal of cancer 20050420

• Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.

  Blood 20050415

• A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.

  Cancer 20050401

• Side effects and good effects from new chemotherapeutic agents. Case 3. Bortezomib in primary refractory plasmacytoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050401

• Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab.

  The oncologist 20050401

• Proteasome inhibitor therapy in multiple myeloma.

  Molecular cancer therapeutics 20050401

• Targeted therapy in multiple myeloma.

  Cancer control : journal of the Moffitt Cancer Center 20050401

• Velcade displays promising activity in primary effusion lymphoma cells.

  Cancer biology & therapy 20050401

• Novel approaches to the management of myeloma.

  Oncology (Williston Park, N.Y.) 20050401

• Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.

  Leukemia & lymphoma 20050401

• [Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20050401

• Bortezomib: proteasome inhibition as an effective anticancer therapy.

  Future oncology (London, England) 20050401

• Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.

  Cancer 20050315

• Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.

  Cancer research 20050315

• Select forms of tumor cell apoptosis induce dendritic cell maturation.

  Journal of leukocyte biology 20050301

• Innovations in antineoplastic therapy.

  The Nursing clinics of North America 20050301

• Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy.

  Cancer cell 20050301

• The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.

  Molecular cancer therapeutics 20050301

• [Multiple myeloma--recent advances in diagnosis and treatment].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050301

• Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway.

  Molecular cancer research : MCR 20050301

• Bortezomib-induced severe hepatitis in multiple myeloma: a case report.

  Archives of internal medicine 20050227

• VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism.

  Oncogene 20050224

• Multiple myeloma.

  The New England journal of medicine 20050224

• [Multiple myeloma -- therapy].

  Deutsche medizinische Wochenschrift (1946) 20050211

• Missing the target: ubiquitin ligase drugs stall.

  Journal of the National Cancer Institute 20050202

• Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2.

  Leukemia 20050201

• Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050201

• Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050201

• Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050201

• Proteasome inhibition in the treatment of cancer.

  Cell cycle (Georgetown, Tex.) 20050201

• Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.

  Haematologica 20050201

• Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.

  Southern medical journal 20050201

• Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.

  Neoplasia (New York, N.Y.) 20050201

• Evolving treatment strategies for myeloma.

  British journal of cancer 20050131

• Proteasome inhibition as a novel therapeutic target in human cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050120

• Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).

  Oncogene 20050113

• Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma.

  Oncogene 20050113

• The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells.

  Cancer biology & therapy 20050101

• Bortezomib therapy following first relapse.

  Oncology (Williston Park, N.Y.) 20050101

• Intracellular inhibitory effects of Velcade correlate with morphoproteomic expression of phosphorylated-nuclear factor-kappaB and p53 in breast cancer cell lines.

  Annals of clinical and laboratory science 20050101

• Measuring ubiquitin conjugation in cells.

  Methods in molecular biology (Clifton, N.J.) 20050101

• Proteasome inhibitors in cancer therapy.

  Methods in molecular biology (Clifton, N.J.) 20050101

• Novel biological therapies for the treatment of multiple myeloma.

  Best practice & research. Clinical haematology 20050101

• Nuclear factor-kappaB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-kappaB.

  Annals of clinical and laboratory science 20050101

• Proteasome inhibition in cancer therapy.

  Journal of infusion nursing : the official publication of the Infusion Nurses Society 20050101

• Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.

  Acta oncologica (Stockholm, Sweden) 20050101

• Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases.

  Prostate cancer and prostatic diseases 20050101

• The current status of thalidomide in the management of multiple myeloma.

  Acta haematologica 20050101

• [Bortezomib (Velcade) in relapsed/refractory multiple myeloma--the first experience in the Czech Republic].

  Casopis lekaru ceskych 20050101

• [About treatment of multiple myelomas. A report at the 10th International Workshop in Sydney].

  Recenti progressi in medicina 20050101

• Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus.

  Antiviral therapy 20050101

• Anti-angiogenic effect of bortezomib in patients with multiple myeloma.

  Acta haematologica 20050101

• Proteasome inhibitors as therapeutics.

  Essays in biochemistry 20050101

• The ubiquitin proteasome pathway from bench to bedside.

  Hematology. American Society of Hematology. Education Program 20050101

• New agents for the treatment of ovarian cancer: the next generation.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20050101

• Bortezomib (Velcade)--a new therapeutic strategy for patients with refractory multiple myeloma.

  Folia medica 20050101

• Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells.

  Cancer research 20041215

• Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041215

• Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role.

  Molecular pharmacology 20041201

• Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041201

• Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.

  Cancer research 20041201

• Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20041201

• Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.

  Clinical prostate cancer 20041201

• Emerging advances in the management of lung cancer.

  Clinical lung cancer 20041201

• Use of proteasome inhibition in the treatment of lung cancer.

  Clinical lung cancer 20041201

• Targeting multiple myeloma cells and their bone marrow microenvironment.

  Annals of the New York Academy of Sciences 20041201

• Discovery, Development, and clinical applications of bortezomib.

  Oncology (Williston Park, N.Y.) 20041201

• Pharmacology, pharmacokinetics, and practical applications of bortezomib.

  Oncology (Williston Park, N.Y.) 20041201

• The proteasome.

  Seminars in oncology 20041201

• Clinical update: novel targets in gynecologic malignancies.

  Seminars in oncology 20041201

• Clinical update: novel targets in multiple myeloma.

  Seminars in oncology 20041201

• p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.

  Oncogene 20041118

• Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.

  Molecular and cellular biology 20041101

• Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.

  The Journal of thoracic and cardiovascular surgery 20041101

• [Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer].

  Aktuelle Urologie 20041101

• Activity of bortezomib in advanced non-small-cell lung cancer.

  Clinical lung cancer 20041101

• Characteristics, pathogenesis, and novel treatments for multiple myeloma.

  Journal of the National Comprehensive Cancer Network : JNCCN 20041101

• Proteasome inhibition: mechanism of action.

  Journal of the National Comprehensive Cancer Network : JNCCN 20041101

• Bortezomib in combination with other therapies for the treatment of multiple myeloma.

  Journal of the National Comprehensive Cancer Network : JNCCN 20041101

• Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.

  Journal of the National Comprehensive Cancer Network : JNCCN 20041101

• Proteasome inhibition for treatment of multiple myeloma: clinical update.

  Journal of the National Comprehensive Cancer Network : JNCCN 20041101

• Molecular profiles of proteasome inhibition in plasma cell dyscrasias.

  Journal of the National Comprehensive Cancer Network : JNCCN 20041101

• Multiple myeloma.

  The New England journal of medicine 20041028

• Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.

  Blood 20041015

• Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.

  Cancer research 20041015

• Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.

  Cancer chemotherapy and pharmacology 20041001

• Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas.

  Leukemia 20041001

• Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.

  Journal of cancer research and clinical oncology 20041001

• A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

  British journal of haematology 20041001

• Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.

  The Annals of thoracic surgery 20041001

• Bortezomib rapidly suppresses ubiquitin thiolesterification to ubiquitin-conjugating enzymes and inhibits ubiquitination of histones and type I inositol 1,4,5-trisphosphate receptor.

  Molecular cancer therapeutics 20041001

• Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications.

  Clinical journal of oncology nursing 20041001

• Identification of a potent and rapidly reversible inhibitor of the 20S-proteasome.

  Bioorganic & medicinal chemistry letters 20040920

• Phase II trial of bortezomib for patients with advanced renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040915

• Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040915

• The bortezomib-induced mitochondrial damage is mediated by accumulation of active protein kinase C-delta.

  Biochemical and biophysical research communications 20040903

• New drugs 04. Part III.

  Nursing 20040901

• Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma.

  Managed care interface 20040901

• Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants.

  Blood 20040801

• Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.

  Leukemia 20040801

• Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis.

  Leukemia research 20040801

• The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas.

  Current treatment options in oncology 20040801

• Bortezomib as a potential treatment for prostate cancer.

  Cancer research 20040801

• Bortezomib data show improved survival in patients with relapsed multiple myeloma.

  Oncology (Williston Park, N.Y.) 20040801

• Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.

  Blood 20040715

• Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.

  Cancer research 20040715

• [Proteasome inhibitors].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040701

• [Proteasome inhibitor, bortezomib (Vercade), potently inhibits the growth of adult T-cell leukemia cells].

  Nihon rinsho. Japanese journal of clinical medicine 20040701

• Approval summary for bortezomib for injection in the treatment of multiple myeloma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040615

• The potential role of proteasome inhibitors in the treatment of lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040615

• A review of the proteasome inhibitor bortezomib in multiple myeloma.

  Expert opinion on pharmacotherapy 20040601

• Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040601

• Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040601

• Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040601

• Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.

  Molecular cancer therapeutics 20040601

• New oncology strategy: molecular targeting of cancer cells.

  Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses 20040601

• Targeting the ubiquitin-proteasome pathway in breast cancer.

  Clinical breast cancer 20040601

• Phase I study of bortezomib in refractory or relapsed acute leukemias.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040515

• The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.

  Experimental cell research 20040501

• The proteasome: a suitable antineoplastic target.

  Nature reviews. Cancer 20040501

• Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein.

  Cancer research 20040501

• Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040501

• Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity.

  Molecular cancer therapeutics 20040501

• The development of proteasome inhibitors as anticancer drugs.

  Cancer cell 20040501

• Tandem transplants in the treatment of multiple myeloma. Pro.

  Clinical advances in hematology & oncology : H&O 20040501

• Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341.

  Oncogene 20040429

• The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.

  Blood 20040415

• Proteasome inhibition induces cytokeratin accumulation in vivo.

  Experimental and molecular pathology 20040401

• Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.

  The Journal of thoracic and cardiovascular surgery 20040401

• Bortezomib and its role in the management of patients with multiple myeloma.

  Expert review of anticancer therapy 20040401

• Multiple myeloma: the role of transplant and novel treatment strategies.

  Seminars in oncology 20040401

• 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.

  Apoptosis : an international journal on programmed cell death 20040301

• Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells.

  Cancer science 20040301

• The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.

  Molecular cancer therapeutics 20040301

• New developments with bortezomib in treating multiple myeloma.

  Clinical lymphoma 20040301

• Update on the proteasome inhibitor bortezomib in hematologic malignancies.

  Clinical lymphoma 20040301

• The proteasome inhibitor, PS-341, causes cytokeratin aggresome formation.

  Experimental and molecular pathology 20040201

• Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.

  Seminars in oncology 20040201

• [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20040201

• Proteinase inhibitors - IBC's Third International Conference. New approaches, new discoveries, new targets.

  IDrugs : the investigational drugs journal 20040201

• [Targeted in therapies multiple myeloma].

  Zhonghua nei ke za zhi 20040201

• [Proteasome inhibition: a new therapeutic approach for the treatment of multiple myeloma].

  Orvosi hetilap 20040111

• Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040101

• The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.

  Molecular cancer therapeutics 20040101

• Development of the proteasome inhibitor Velcade (Bortezomib).

  Cancer investigation 20040101

• 'Development of the proteasome inhibitor Velcade (Bortezomib)' by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D.

  Cancer investigation 20040101

• The role of proteasome inhibitors in solid tumors.

  Annals of medicine 20040101

• Proteasome inhibition in hematologic malignancies.

  Annals of medicine 20040101

• Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia.

  Annals of clinical and laboratory science 20040101

• Proteasome inhibition therapy: assessing the clinical implications in hematologic diseases.

  ONS news 20040101

• Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy.

  Annals of clinical and laboratory science 20040101

• [Proteasome inhibitors--new option in the treatment of tumor diseases].

  Casopis lekaru ceskych 20040101

• [The role of proteasome in pathophysiology of cancer cachexia].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20040101

• The proteasome as a target for cancer therapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031215

• New therapeutic strategies for soft tissue sarcomas.

  Current treatment options in oncology 20031201

• Bortezomib treatment for multiple myeloma.

  The Annals of pharmacotherapy 20031201

• Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.

  Oncogene 20031120

• Combinations of targeted therapies take aim at multiple pathways.

  Journal of the National Cancer Institute 20031119

• The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

  Blood 20031115

• The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells.

  Cancer research 20031101

• [Current screening for molecular target therapy of cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031101

• Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.

  Oncogene 20031016

• The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells.

  Leukemia 20031001

• Promoting proteasomes: trash to treasure.

  Drug discovery today 20031001

• Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031001

• Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031001

• Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.

  Cancer research 20031001

• Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.

  Seminars in hematology 20031001

• Bortezomib: a novel therapy approved for multiple myeloma.

  Clinical advances in hematology & oncology : H&O 20031001

• Bortezomib in multiple myeloma.

  The New England journal of medicine 20030925

• Bortezomib in multiple myeloma.

  The New England journal of medicine 20030925

• Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.

  The Journal of biological chemistry 20030905

• Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts.

  Molecular cancer therapeutics 20030901

• A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma.

  Clinical lymphoma 20030901

• Therapy strategies for multiple myeloma: current status.

  Wiener klinische Wochenschrift 20030814

• Innovative strategies in lymphoma therapy.

  Wiener klinische Wochenschrift 20030814

• The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells.

  Oncogene 20030807

• Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20030801

• Bortezomib.

  Nature reviews. Drug discovery 20030801

• The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.

  Haematologica 20030801

• Can smart bombs win the war on cancer? By pinpointing abnormalities specific to tumor cells, a novel generation of cancer drugs may usher in a whole new era of cancer treatment.

  Harvard health letter 20030801

• Bortezomib (velcade) for multiple myeloma.

  The Medical letter on drugs and therapeutics 20030721

• The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

  Blood 20030701

• Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis.

  Journal of immunology (Baltimore, Md. : 1950) 20030701

• Imaging 26S proteasome activity and inhibition in living mice.

  Nature medicine 20030701

• Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.

  The Journal of surgical research 20030701

• The proteasome--an emerging therapeutic target in cancer.

  The New England journal of medicine 20030626

• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  The New England journal of medicine 20030626

• First proteasome inhibitor approved for multiple myeloma.

  Journal of the National Cancer Institute 20030618

• Molecule of the month. Bortezomib.

  Drug news & perspectives 20030601

• [Gene expression profile changes in human multiple myeloma].

  Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University 20030601

• Apoptosis meets proteasome, an invaluable therapeutic target of anticancer drugs.

  The Italian journal of biochemistry 20030601

• Targeting proteasome inhibition in hematologic malignancies.

  Reviews in clinical and experimental hematology 20030601

• Management of multiple myeloma: a systematic review and critical appraisal of published studies.

  The Lancet. Oncology 20030501

• The proteasome: structure, function, and role in the cell.

  Cancer treatment reviews 20030501

• Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.

  Cancer treatment reviews 20030501

• Clinical update: proteasome inhibitors in hematologic malignancies.

  Cancer treatment reviews 20030501

• Clinical update: proteasome inhibitors in solid tumors.

  Cancer treatment reviews 20030501

• Clinical trials referral resource. Current clinical trials of bortezomib.

  Oncology (Williston Park, N.Y.) 20030501

• [Thalidomide treatment in multiple myeloma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20030501

• Potential for proteasome inhibition in the treatment of cancer.

  Drug discovery today 20030401

• Proteasome inhibition: a new anti-inflammatory strategy.

  Journal of molecular medicine (Berlin, Germany) 20030401

• Novel biologically based therapies for Waldenstrom's macroglobulinemia.

  Seminars in oncology 20030401

• Novel therapies in multiple myeloma.

  International journal of hematology 20030401

• The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

  Blood 20030315

• The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030301

• Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030301

• New agents and approaches in the treatment of multiple myeloma.

  Clinical advances in hematology & oncology : H&O 20030301

• APEX (Assessment of Proteasome inhibition for Extending remissions) trial: phase III randomized, multicenter, placebo-controlled trial to evaluate the efficacy and safety of bortezomib versus dexamethasone in patients with recurrent or treatment-resistant multiple myeloma.

  Clinical advances in hematology & oncology : H&O 20030301

• Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

  Blood 20030215

• Moving disease biology from the lab to the clinic.

  Cancer 20030201

• Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.

  Cancer 20030201

• Function of nuclear factor kappaB in pancreatic cancer metastasis.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030101

• The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer.

  Breast cancer research : BCR 20030101

• [Perspectives on the oncologist pharmacopoeia].

  Bulletin du cancer 20030101

• [Bortezomib (Velcade). Laboratory: Millenium Pharmaceuticals Inc].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20030101

• Speedy approvals for new cancer treatments.

  FDA consumer 20030101

• Multiple myeloma: increasing our treatment options.

  Cancer control : journal of the Moffitt Cancer Center 20030101

• Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.

  Cancer control : journal of the Moffitt Cancer Center 20030101

• Understanding novel therapeutic agents for multiple myeloma.

  Clinical journal of oncology nursing 20030101

• Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.

  The oncologist 20030101

• Recent advances of molecular targeted agents: opportunities for imaging.

  Cancer biology & therapy 20030101

• Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.

  Cancer biology & therapy 20030101

• Human somatic cell knockouts reveal determinants of sensitivity and resistance to proteasome inhibitor PS-341.

  Cancer biology & therapy 20030101

• Bortezomib.

  Clinical journal of oncology nursing 20030101

• Advances in the biology and treatment of myeloma bone disease.

  Seminars in oncology 20021201

• Moving disease biology from the laboratory to the clinic.

  Seminars in oncology 20021201

• High-dose therapy and immunomodulatory drugs in multiple myeloma.

  Seminars in oncology 20021201

• Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20021115

• Proteasome inhibitors as new anticancer drugs.

  Current opinion in oncology 20021101

• Role of the bone marrow microenvironment in multiple myeloma.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20021101

• The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.

  Oncogene 20020919

• New drugs in acute myeloid leukemia.

  Current oncology reports 20020901

• Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

  Cancer research 20020901

• Hematologic malignancies: new developments and future treatments.

  Seminars in oncology 20020801

• A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020801

• PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis.

  Molecular cancer therapeutics 20020801

• Proteasome inhibitors in the treatment of B-cell malignancies.

  Clinical lymphoma 20020601

• NF-kappa B as a therapeutic target in multiple myeloma.

  The Journal of biological chemistry 20020510

• Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.

  Cancer research 20020215

• Cancer research. Taking garbage in, tossing cancer out?

  Science (New York, N.Y.) 20020125

• Ethanol withdrawal induced CYP2E1 degradation in vivo, blocked by proteasomal inhibitor PS-341.

  Free radical biology & medicine 20020101

• [Update on . . . the proteasome inhibitor PS341].

  Bulletin du cancer 20020101

• Development of the proteasome inhibitor PS-341.

  The oncologist 20020101

• Proteasome inhibition: a novel approach to cancer therapy.

  Trends in molecular medicine 20020101

• Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma.

  The oncologist 20020101

• Aggresome formation in liver cells in response to different toxic mechanisms: role of the ubiquitin-proteasome pathway and the frameshift mutant of ubiquitin.

  Experimental and molecular pathology 20011201

• Proteasome inhibition in cancer: development of PS-341.

  Seminars in oncology 20011201

• The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.

  Seminars in oncology 20011201

• Proteasome inhibitor holds promise for patients with refractory multiple myeloma.

  Expert review of anticancer therapy 20011201

• The proteasome: a new target for novel drug therapies.

  American journal of clinical pathology 20011101

• Molecular pathways that modify tumor radiation response.

  American journal of clinical oncology 20011001

• Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.

  The Journal of surgical research 20010901

• The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.

  Oncogene 20010727

• Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells.

  Leukemia 20010601

• Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

  International journal of radiation oncology, biology, physics 20010501

• Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

  Cancer research 20010501

• Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010501

• The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

  Cancer research 20010401

• 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.

  Journal of cellular biochemistry 20010401

• New drugs in gynecologic cancer.

  Current treatment options in oncology 20010401

• Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20000901

• Proteasome inhibitors: a novel class of potent and effective antitumor agents.

  Cancer research 19990601

• Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis.

  Proceedings of the National Academy of Sciences of the United States of America 19981222

• Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.

  Bioorganic & medicinal chemistry letters 19980217